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1. Chapter 1: Literature review 
1.1. Introduction 
Haematological malignancies (HMs) include cancer and related disorders of the cells 
of the blood, bone marrow or lymphatic systems. Currently the most widely used 
classification system is the World Health Organization classification system of 
HMs(1). This classification system classifies HMs into 12 broad categories based 
upon clinical, morphological, immunophenotypic and genetic characteristics of the 
tumour cells. Approximately 250 new cases of HMs are diagnosed in Tasmania each 
year(2). 
Familial aggregation of HMs has been repeatedly described in the literature(3-24), 
but the genetic contributors to this disease in most families remains unknown. The 
only germline mutation found to date is a DAPK1 mutation which was found in a 
family with chronic lymphocytic leukaemia (CLL)(25). In this family additional 
down-regulation of DAPK1 was still needed before CLL developed(25).  
Mature haematological cells originate from a common precursor cell (haematopoietic 
stem cell (HSC)) that has the capacity to differentiate to any of the mature cell types 
and to self renew(26). It has been established that for a cell to become malignant 
multiple genetic mutations must occur in the same cell. In familial cancer families it 
is reported that the first hit is the germline mutation that is inherited in these 
families(27). A two-hit theory for cancer (Knudsen’s two hit hypothesis) for 
retinoblastoma was first published in 1971, where in the dominantly inherited form 
of retinoblastoma one mutation is inherited through the germ-cells and a second 
mutation occurs in somatic cells; in the non-inherited (sporadic) form both mutations 
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occur in somatic cells(28). It is now clear that many more than two hits are required 
for a cancer to develop(29) and this is now referred to as the progressive multi-hit 
model of gene mutation(30); and that initial gene mutations promote genetic 
instability and therefore promote the occurrence of further abnormalities. This theory 
also encompasses that the same gene can be involved in a familial cancer as well as 
in a sporadic form of the disease. 
Acquired cytogenetic abnormalities characteristically feature in many types of HMs. 
These abnormalities can be classified as numerical or structural chromosomal 
abnormalities. Of the numerical abnormalities, there is a specific pattern as to which 
chromosomes are lost or gained regardless of the type of HM. Also, for the structural 
abnormalities that occur, certain genes are frequently involved regardless of the type 
of HM. It should be noted that people born with constitutional disorders of these 
genes or chromosomes that are commonly mutated in HMs are also at an increased 
risk of developing a HM(31). The classic example is trisomy 21; people born with 
this have a substantially increased risk of developing leukaemia and trisomy 21 is 
commonly found in HMs. 
A known predisposing factor for the development of a HM is a family history of a 
HM(3-5, 32-34), suggesting a genetic risk for these types of disorders. There are 
many reports of familial HMs(4-15, 17-24, 33, 34), particularly for one subtype of 
HM, chronic lymphocytic leukaemia (CLL)(4, 6-8, 11, 15, 18, 22, 24, 34). The 
relative risk for relatives of people with CLL has been reported to be 7.52, and 1.45 
for non-Hodgkin lymphoma (NHL) and 2.35 for Hodgkin lymphoma (HL)(6). An 
interesting aspect of CLL is that it is the most common leukaemia in western 
countries(6) but rarely seen in Asian countries(35), and if a person of Asian ethnicity 
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moves to a western country they keep their low risk(35).This supports a genetic 
rather than an environmental risk with exposure of all family members to the same 
environmental risk factors(35). There is also a reported increased risk (double) for 
identical twins if one twin develops a HM by the age of 15(36). This strongly 
supports a role for genetic factors this disease.  
It is hypothesized that in these HM families there is a predisposition allele and if 
additional acquired mutations occur then a HM develops. The type of HM depends 
upon which cell receives a second, third or fourth hit(37-39).  
1.2. Haematopoietic stem cell development 
HSC are derived from cells in the aortic endothelium(40). During embryogenesis 
production of HSC occurs in the yolk sac, the aorta-gonad mesonephros, the 
placenta, the fetal liver, the thymus and by the time of birth, from the bone 
marrow(41). In adult life they are found only in the bone marrow of healthy 
individuals(41). There are different types of HSC, mostly classified as long term 
HSC or short term HSC (refer to Figure 1.2.1). 
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Figure 1.2.1: Development of mature haematopoietic cells from HSC (26). 
 
Multipotential stem cells are self-generating and also produce precursor cells with increasing 
restriction of their lineage and proliferation potential. (CFU-s Colony forming units, CMP common 
myeloid progenitors, CLP common lymphoid progenitors, MEP megakaryocyte-erythroid progenitors, 
GMP Granulocyte macrophage progenitors, BFU blast forming unit, E Erythrocyte, Meg 
Megakaryocyte, Eo Eosinophil, GM Granulocyte macrophage, M macrophage, G granulocyte). 
 
1.2.1. Types of HSCs 
Long term HSC: This is a pluripotent stem cell that is capable of self-renewal as well 
as maturing to short term HSC. Transcription factors that regulate this type of HSC 
are RUNX1, SCL/TAL1, LMO1, MLL, TEL(ETV6), BMI-1, GFI-1 and GATA-2(41). 
Not surprisingly many of these same genes are involved in many of the leukaemia-
associated translocations(41). 
Short term HSC: These are referred to as multipotent progenitors, as they can 
differentiate down any cell line and produce the following common myeloid 
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progenitor and common lymphoid progenitor. The common myeloid progenitor 
differentiates into either a megakaryocyte/erythroid progenitor (committed to either 
the erythroid or megakaryocytic cell lines) or a granulocyte/macrophage progenitor 
(committed to the myeloid lineage, but can differentiate into a mast cell, eosinophil, 
neutrophil or a monocyte). The common lymphoid progenitors are committed to the 
lymphoid cell line, but can still mature into either a T or B lymphocyte. 
1.2.2. Reprogramming of committed HSC 
It used to be considered that once committed to a specific lineage, the programming 
of a HSC was unidirectional; this has now been found not to be the case(41). For 
example, the common lymphoid progenitor can be reprogrammed by expression of 
C/EBP to become a granulocyte/macrophage progenitor and a precursor T cell can be 
reprogrammed with the expression of GATA3 to become a mast cell(41). This 
highlights how related these morphologically distinct haematopoietic cells really are. 
1.3. Classification of HMs 
The classification of HMs has changed over the years and the current accepted 
classification system is the WHO classification of HM which was first published in 
2001(42) and updated in 2008(1). This classification system takes into account 
clinical, morphological, immunophenotypic and genetic changes to determine the 
subtype of HM. The WHO classification system recognises that previous 
classification systems that relied purely on morphology were insufficient and that 
some subtypes could not be distinguished by morphology alone(42).  Even today the 
sub-classification of HMs can be difficult and is limited by what tests are available in 
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a routine diagnostic laboratory. There are 12 broad categories of HMs (see Table 
1.3.1) with over 100 subtypes.  
Table 1.3.1: Overview of the types of HMs. 
Broad category Number of major subtypes 
Myelodysplastic syndromes 7 
Myeloid and Lymphoid neoplasms with 
eosinophilia and abnormalities of PDGFRA, 
PDGFRB or FGFR1 
3 
Myelodysplastic/myeloproliferative neoplasms 4 
Myeloproliferative Neoplasms 8 
Acute myeloid leukaemia 7 
Acute leukaemia of ambiguous lineage 7 
Precursor lymphoid neoplasms 9 
Mature B cell neoplasms 28 
Mature T and NK cell neoplasm 17 
Hodgkin lymphoma 5 
Immunodeficiency-associated lymphoproliferative 
disorders 
4 
Histiocytic and dendritic cell neoplasms 7 
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1.3.1. World Health Organization Classification of HMs 
1.3.1.1. Myelodysplastic syndromes 
Myelodysplastic syndromes (MDS) are acquired bone marrow failure disorders and 
are often considered to be “pre-leukaemic” conditions(1) with a risk of transforming 
to AML. They most commonly present in the 8th decade of life with a predominance 
of males(1). There are known environmental factors such as benzene exposure and a 
history of previous chemotherapy or radiotherapy that can cause MDS, however such 
a predisposing factors account for only 2% of cases of MDS(42). There are 7 types 
of de novo MDS 
 Refractory cytopenia with unilineage dysplasia.  
 Refractory anaemia with ring sideroblasts. 
 Refractory cytopenia with multilineage dysplasia.  
 Refractory anaemia with excess blasts. 
 MDS with isolated del(5q).  
 MDS unclassifiable. 
 Childhood MDS.  
Classic cytogenetic changes found in MDS include deletions/monosomies of 
chromosomes 3, 5, 7 and gains of chromosomes 8, 11, 21.  All of these abnormalities 
are also observed in other types of HMs(1).  
It has also emerged that epigenetic alterations play a major role in the acquired 
changes that occur in MDS(43). These changes consist of DNA methylation and 
histone modification and are capable of changing gene expression(44). A common 
finding in MDS is hypermethylation of genes involved in cell cycle control and cell 
adhesion(44). This is of great clinical interest as epigenetic changes are amenable to 
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reversal with pharmacological drugs, several of which (histone deacetylase inhibitors 
and DNA methyltransferase inhibitors) are approved for use in MDS(43).  
1.3.1.2. Myeloid and Lymphoid neoplasms with eosinophilia and 
abnormalities of PDGFRA, PDGFRB or FGR1 
There are three disorders in this category  
 Myeloid and lymphoid neoplasms with PDGFRA rearrangements. 
 Myeloid and lymphoid neoplasms with PDGFRB rearrangements. 
 Myeloid and lymphoid neoplasms with FGR1 rearrangements. 
This new category reflects the fact that one genetic mutation that usually results in a 
myeloproliferative neoplasm can sometimes manifest as a lymphoid neoplasm.  The 
underlying factor in this category is a genetic defect that results in aberrant tyrosine 
kinase activity. It highlights that one genetic mutation that can result in different 
types of clinical diseases.                                                                
1.3.1.3. Myelodysplastic/Myeloproliferative disorders 
This was a new category to this classification syndrome in 2001. The inclusion of 
this category highlights the clinical heterogeneity of HMs, in that they can represent 
a spectrum of disease features rather than a specific disease(1). There are 4 subtypes 
in this category. 
 Chronic myelomonocytic leukaemia. 
 Atypical chronic myeloid leukaemia BCR-ABL1 negative. 
 Juvenile myelomonocytic leukaemia. 
 MDS/MPD unclassifiable.  
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Chronic myelomonocytic leukaemia has features of both MDS and MPD with the 
degree of dysplasia/proliferation different in each patient. However the common 
acquired cytogenetic findings are not unique to this disorder and overlap with MDS, 
MPD and AML abnormalities(1).  
1.3.1.4. Myeloproliferative Neoplasms (MPD) 
According to the WHO classification syndrome there are 8 MPDs 
 Chronic myeloid leukaemia. 
 Chronic neutrophilic leukaemia. 
 Chronic eosinophilic leukaemia NOS. 
 Essential thrombocytosis. 
 Polycythaemia vera. 
 Myelofibrosis. 
 Mastocytosis. 
 Myeloproliferative neoplasm unclassifiable. 
These disorders are associated with an increase (proliferation) in circulating 
haematological cells: platelets, granulocytes or red cells(1). However many patients 
have more than one cell type increased. Intriguingly, it was postulated in 1951 that a 
group of disorders (chronic granulocytic leukemia, polycythemia vera, idiopathic 
myeloid metaplasia of the spleen, thrombocythemia, megakaryocytic leukemia and 
erythroleukemia) should be classified together because of their overlapping clinical 
features (45). These disorders still form the basis of this category and this concept 
still appears valid even with today’s knowledge. 
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Chronic myeloid leukaemia (CML) is defined by a specific translocation 
(t(9;22)(q34;q11.2)), which results in the fusion of the BCR and ABL1 genes and 
produces an abnormal tyrosine kinase with deregulated activity(46). This disorder is 
associated in the literature with a series of firsts; it was the first type of leukaemia to 
recognised as a distinct clinical entity (46), the first HM to be defined by its 
cytogenetic cause(47, 48), the first HM to have the genes identified and the first HM 
to be treated with a targeted therapy against the specific acquired genetic 
mutation(49). More recently, mutations in another tyrosine kinase receptor (JAK2) 
have been found in MPDs(50). This mutation in JAK2 (V617F) is not specific to a 
particular type of MPD, but can be found in many. It has been reported that the type 
of HM that develops is dependant upon the allelic burden, however this dosage effect 
does not explain fully the phenotypic heterogeneity of MPDs(51). This once again 
highlights how the same genetic mutation is associated with different types of HMs.  
1.3.1.5. Acute myeloid leukaemia and related precursor neoplasms 
There are approximately 7 major subtypes of AML 
 AML with recurrent genetic abnormalities. 
 AML with myelodysplasia-related changes. 
 Therapy related AML. 
 AML NOS. 
 Myeloid sarcoma. 
 Myeloid proliferations related to Down syndrome. 
 Blastic plasmacytoid dendritic cell neoplasm.  
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AML used to be defined as having a blast cell count greater than 30% in the bone 
marrow, however with the new classification system(1) the minimum blast count is 
reduced to 20%. In a few specific cytogenetic subtypes  [t(8;21)(q22;q22), 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22), t(15;17)(q22;q12), t(9;11)(p22;q23), 
t(6;9)(p23;q34), inv(3)(q21q26.2), t(3;3)(q21;q26.2) and t(1;22)(p13;q13)] the blast 
cell count is irrelevant and in these types it is classified as AML, whereas previously 
they would have been classified as a MDS. Under the subtype of AML with recurrent 
genetic abnormalities, a new subtype emerged in the current classification, AML 
with gene mutations  (fms-related tyrosine kinase 3; nucleophosmin; CEBPA; KIT; 
MLL; WT1; NRAS; KRAS). Mutations in these genes can occur in any subtype of 
AML(1). There have been several reports of familial AML(52) in the literature, 
mostly with mutations involving RUNX1(53) or CEBPA(21, 52), the same genes that 
are involved in mutations in non-familial AML. Many of the classic secondary 
changes (such as del3q, del5q, del7q, monosomy 7, trisomy 8) that are seen in AML 
are seen in other types of HM(1), also many of the genes (MLL, RUNX1) 
translocated in AML are also translocated in other types of HMs.  
1.3.1.6. Acute leukaemia of ambiguous lineage 
There are 7 major groups of acute leukaemia with ambiguous lineage(1) 
 Acute undifferentiated leukaemia. 
 Mixed phenotype acute leukaemia with BCR-ABL1. 
 Mixed phenotype acute leukaemia with MLL rearrangement. 
 Mixed phenotype acute leukaemia B/Myeloid NOS. 
 Mixed phenotype acute leukaemia T/Myeloid NOS.  
 Mixed phenotype acute leukaemia NOS. 
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 Natural killer cell lymphoblastic leukaemia/lymphoma.  
This category of leukaemia again highlights the overlap that can occur between the 
different cell lineages and it occurs because the leukaemogenic event occurred in a 
primitive HSC that still had the ability to either develop into a granulocyte, B 
lymphocyte, T lymphocyte or NK cell. This again shows that there is an overlap in 
the genetic events that can cause different HMs. 
1.3.1.7. Precursor lymphoid neoplasms  
There are two major categories of precursor lymphoid neoplasms, either B 
lymphoblastic leukaemia/lymphoma or T lymphoblastic leukaemia/lymphoma(1). 
The B lymphoblastic leukaemia/lymphomas are further classified according to the 
genetic abnormalities found. Their names show the arbitrary divide between 
lymphoma and leukaemia, in that the same disease is called one or the other 
depending on the predominant site of disease, either in the lymph nodes or solid 
tissue (lymphoma) or bone marrow or blood (leukaemia).  
B lymphoblastic leukaemia/lymphoma  
These disorders are seen in both adults and children, with a peak incidence in 
children between the age of 2-5 years(1). There are 8 types of B lymphoblastic 
leukaemia/lymphoma mostly based on genetic changes 
 B lymphoblastic leukaemia/lymphoma NOS. 
 B lymphoblastic leukaemia/lymphoma with 
t(9;22)(q34;q11.2). 
 B lymphoblastic leukaemia/lymphoma with MLL 
rearrangement. 
 B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22). 
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 B lymphoblastic leukaemia/lymphoma with hyperdiploidy. 
 B lymphoblastic leukaemia/lymphoma with hypodiploidy. 
 B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32). 
 B lymphoblastic leukaemia/lymphoma with 
t(1;19)(q23;p13.3). 
These genetic subtypes each have a different prognosis and treatment options, but 
morphologically the lymphoblasts are indistinguishable. They also overlap with other 
HMs in that the genes (BCR/ABL1, MLL, RUNX1) that are involved in defining 
subtypes of ALL are also commonly involved in causing other types of HMs.  
T lymphoblastic leukaemia/lymphoma 
This disorder is common in adolescent males and often presents with a mediastinal 
mass(1). Approximately 50-70% of cases will have an abnormal karyotype and they 
typically involve recurrent rearrangements of the T cell receptor loci (14q11.2 and 
7q35)(1). The distinction between lymphoma and leukaemia in this disorder is 
arbitrary; the term ‘lymphoma’ if there is purely nodal disease and ‘leukaemia’ if 
blood or bone marrow is predominantly involved. This highlights how cells of the 
same phenotype can give rise to differing clinical manifestations. This disorder 
generally has a poorer prognosis than B-ALL and as yet is not classified based upon 
the specific genetic subtypes. 
1.3.1.8. Mature B cell neoplasms 
There are 28 major types of mature B cell neoplasms according to the WHO(1) 
 Chronic lymphocytic leukaemia/small lymphocytic lymphoma 
 B-cell prolymphocytic leukaemia. 
 Splenic marginal zone lymphoma. 
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 Hairy cell leukaemia. 
 Splenic lymphoma/leukaemia unclassifiable. 
 Lymphoplasmacytic lymphoma. 
 Heavy chain disease. 
 Plasma cell neoplasms. 
 Extranodal marginal zone lymphoma of mucosa-associated tissue. 
 Nodal marginal zone lymphoma. 
 Follicular lymphoma. 
 Primary cutaneous follicle centre lymphoma. 
 Mantle cell lymphoma. 
 Diffuse large B cell lymphoma (DLBCL), NOS. 
 T cell/histiocyte rich large B-cell lymphoma. 
 Primary DLBCL of the CNS. 
 EBV positive DLBCL of the elderly. 
 DLBCL associated with chronic inflammation. 
 Lymphomatoid granulomatosis. 
 Primary mediastinal large B cell lymphoma. 
 Intravascular large B cell lymphoma. 
 ALK positive large B cell lymphoma. 
 Plasmablastic lymphoma. 
 Large B cell lymphoma arising in HHV8-associated multicentric 
Castleman disease. 
 Primary effusion lymphoma. 
 Burkitt lymphoma. 
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 B cell lymphoma unclassifiable with features intermediate 
between DLBCL and Burkitt lymphoma. 
 B cell lymphoma unclassifiable with features intermediate 
between DLBCL and classical Hodgkin lymphoma.  
They consist of diseases that affect mature B cells and group together what used to 
be called the lymphoproliferative disorders (chronic leukaemia) and the non-Hodgkin 
lymphomas (NHL). In fact the divide between these phenotypic groups is non-
existent, in that CLL can also be called small lymphocytic lymphoma (SLL) 
depending upon where the bulk of the disease presents (either in the lymph nodes 
(SLL) or circulating in the blood (CLL) or even from where the diagnostic material 
is taken: in other words a lymph node biopsy from a CLL patient will be reported as 
showing SLL if the pathologist is unaware of the blood findings. This once again 
highlights the overlap that exists between the different types of HMs.  
The majority of mature B cell neoplasms typically present in the 7th decade of life 
with a male predominance although they are found in all ages(1).  Several of the 
major subtypes are defined by specific chromosomal translocations: Mantle cell 
lymphoma by the t(11;14)(q13;q32) involving the CCND1 and IGH@ genes 
however this translocation is also seen in multiple myeloma (MM) and plasma cell 
leukaemia(54); Follicular lymphoma  by the t(14;18)(q32;q21) involving the IGH@ 
and BCL2 genes which can also be seen in DLBCL and Burkitt lymphoma(55, 56); 
Burkitt lymphoma by an 8q24 (MYC) rearrangement which can also be seen in 
DLBCL(57), CLL and  MM.  This shows how one genetic abnormality can give rise 
to many different types of HMs, which supports the hypothesis that a germline 
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mutation can give rise to different types of HMs depending upon which HSC the 
next hit arises in.  
1.3.1.9. Mature T cell neoplasms 
This group of HMs links disorders that used to be separated as T cell lymphomas and 
T cell lymphoproliferative disorders(1). Mature T cell neoplasms are less frequent 
than mature B cell neoplasms, but in the WHO classification there are 17 major types 
of mature T cell neoplasms(1) 
 T-cell prolymphocytic leukaemia. 
 T-cell large granular lymphocytic leukaemia. 
 Chronic lymphoproliferative disorders of NK cells. 
 Aggressive NK cell leukaemia. 
 Epstein –Barr virus positive T cell LPD of childhood. 
 Adult T-cell leukaemia/lymphoma. 
 Extranodal NK/T cell lymphoma nasal type. 
 Enteropathy associated T cell lymphoma. 
 Hepatosplenic panniculitits like T cell lymphoma. 
 Mycosis fungoides. 
 Sezary syndrome. 
 Primary cutaneous CD30 positive T cell LPDs. 
 Primary cutaneous peripheral T cell lymphoma rare subtypes. 
 Peripheral T cell lymphoma NOS. 
 Angioimmunoblastic T cell lymphoma. 
 Anaplastic large cell lymphoma ALK positive. 
 Anaplastic large cell lymphoma ALK negative. 
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1.3.1.10. Hodgkin lymphoma 
Hodgkin lymphoma was first described in 1832, but only in the last 10 years have the 
malignant cells (Hodgkin and Reed–Sternberg cells) been recognised as B 
lymphocytes(1). There are two major types of HL 
 Nodular lymphocyte predominant HL. 
 Classical HL (CHL). 
CHL is subdivided into 4 types: Nodular sclerosis CHL, Mixed cellularity CHL, 
Lymphocyte-rich CHL and Lymphocyte depleted CHL.  
1.3.1.11. Others 
Both of the two other major subtypes of HMs, immunodeficiency associated LPDs 
and histiocytic and dendritic cell neoplasms are very rare(1).  
1.4. Recurrent acquired cytogenetic abnormalities observed in more than one 
type of HM. 
The acquired cytogenetic changes that occur in HMs have been widely studied for 
many years, and in fact most of the reported cytogenetic changes associated with 
cancers were first reported in HMs(58). Despite the fact that there are over 100 
different subtypes of HMs(1), many of the acquired genetic changes that occur are 
not unique to one subtype of HM, but are seen in many different subtypes. This is 
true for both specific genes and classic chromosome abnormalities. 
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1.4.1. Specific genes 
1.4.1.1. RUNX1 translocations 
The RUNX1 gene is located on the long arm of chromosome 21 at region 2 band 2 
(chr21q22). This gene was originally called AML1 due to its translocation with 
RUNX1T1 [t(8;21)(q22;q22)] in the leukaemic cells of patients with AML. This 
translocation results in a specific type of AML (AML with maturation), now 
classified as AML with t(8;21)(q22;q22)(1). However this gene (RUNX1) is also the 
most commonly translocated gene in childhood ALL [t(12;21)(p13;q22)](1). The 
normal function of RUNX1 involves it forming a heterodimer with core-binding 
factor beta.  A rearrangement of core-binding factor beta is associated with a specific 
subtype of AML, AML with eosinophilia with inversion (16)(p13.1q22)(1). 
Acquired point mutations in RUNX1 have also been found in AML and ALL(1). 
1.4.1.2. BCR/ABL1 fusions 
The translocation that results in the fusion of the BCR gene on the long arm of 
chromosome 22 with the ABL1 gene on the long arm of chromosome 9 defines 
CML(59). It is interesting to note that this translocation (t(9;22)(q34;q11.2)) is also 
seen in 5% of children with ALL, 15-30% of adults with ALL and 2% of patients 
with de novo AML(60). Even when the molecular breakpoints of the translocation 
are analysed, they are not specific for CML(60). There are 3 main breakpoints in the 
BCR gene, namely minor BCR, major BCR and micro BCR. Depending upon where 
the breakpoint is, a different sized fusion protein is transcribed. The minor BCR 
(a1a2 breakpoints) results in a p190BCR-ABL, whereas the major BCR (either b2a2 or 
b3a2) results in a p210BCR-ABL, and the micro BCR (e19a2) results in a p230BCR-ABL(60). 
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These discoveries show that the same genetic mutation can give rise to different 
types of HMs. 
1.4.1.3. Mixed Lineage Leukaemia (MLL) translocations 
Translocations involving this gene (MLL) are seen in both myeloid and lymphoid 
disorders (61) and has over 60 partner genes that have been reported in HMs(62). 
However each different translocation partner is not specific for a particular type of 
HM(61), and the same translocation can be seen in different types of HMs(61). The 
classic example would be the translocation between MLL and AF4 
[t(4;11)(q21;q23)], which is seen in infant acute ALL, but can also be seen in 
AML(63). 
1.4.1.4. IGH@ translocations 
The IGH@ locus is rearranged in most B lymphoid malignancies and is involved 
with many other partner genes(1). However a few specific IGH@ translocations are 
regarded as hallmarks of a particular subtype of HM, in particular the IGH@/CCND1 
translocation that defines MCL although this translocation can also be seen in 
MM(54). Similarly, the IGH@/MYC translocation that defines Burkitt lymphoma is 
not specific to Burkitt lymphoma but can also be seen in other types of 
lymphoproliferative disorders(56). The IGH@/BCL2 translocation that defines 
follicular lymphoma is also not specific and can also be seen in DLBCL(56).  
1.4.2. Common chromosomal abnormalities 
Many of the common chromosomal changes that are seen in HMs are also not 
specific to one subtype of HM. 
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1.4.2.1. Trisomy 8 
Trisomy 8 is observed in both myeloid and lymphoid disorders and both chronic and 
acute types of HMs and is one of the most common secondary chromosomal gains 
seen in HMs(1). It should also be noted that patients with Warkany syndrome, which 
is defined as a mosaic trisomy 8 constitutional disorder, are at increased risk of 
developing a HM(64). It has also been reported that up to 15-20% of cases of HMs 
that have trisomy 8 as the sole abnormality, are due to an underlying Warkany 
Syndrome rather than an acquired gain(64). 
1.4.2.2. Sex chromosome abnormalities 
Sex chromosome abnormalities (monosomies or trisomies) are very common 
secondary changes and are found in both myeloid and lymphoid malignancies(65).  
1.4.2.3. Trisomy 21 
Trisomy 21 as an acquired gain is frequently seen in ALL(66) and is the second most 
common trisomy  in myeloid disorders(67).  
1.5. Constitutional disorders predisposing to develop a haematological 
malignancy 
Constitutional cytogenetic disorders are generally classified as an aneuploidy 
(monosomy or trisomy) or structural disorders (translocations, deletions, duplications 
or inversions) of chromosomes that a person is born with. Many of these disorders 
also have an increased risk of developing a HM(68-70). It seems that the underlying 
genetic abnormality acts as the first hit and provides an environment that makes the 
cells prone to acquiring more genetic abnormalities. 
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1.5.1. Aneuploidy disorders 
1.5.1.1. Trisomy 21 
This is the most common autosomal trisomy and is observed in 1 in every 600-1000 
live-born births(71). Children born with this disorder are at a 100 times increased 
risk of developing a HM, in particular acute megakaryoblastic leukaemia, which is 
otherwise an extremely rare subtype of acute myeloid leukaemia(72). They can also 
develop transient abnormal myelopoiesis (TAM), which morphologically looks like 
AML, but has a high rate of spontaneous remission(73). Approximately 20% of these 
TAM patients will then go on to develop acute megakaryoblastic leukaemia by the 
age of 4 years(69) with acquired GATA1 mutations. In the current classification 
system, the myeloid proliferations related to Down syndrome are grouped together in 
their own category(1). 
1.5.1.2. Other autosomal trisomies 
Only a few other autosomal trisomies are compatible with life. These are trisomy 18, 
trisomy 15, trisomy 13, trisomy 22 and mosaic trisomy 8(71). Patients with these 
disorders are also at an increased risk of developing a HM(68). Furthermore these 
trisomies may also be seen as secondary gains in many different types of HMs(67). 
Trisomy 8 is seen in approximately 1 in 25000 livebirths(69), but is the most 
common trisomy seen in HMs. Interestingly a study found that in approximately 15-
20% of cases, a sole trisomy 8 in a HM is actually a constitutional finding rather than 
an acquired gain(74). Trisomy 22 is the most common secondary finding in AML 
with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)(75).  
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1.5.1.3. Numerical sex chromosome abnormalities 
Turner syndrome 
Turner syndrome is seen in approximately 1 in 2000 livebirths(76) and is defined as 
45,X. A non-significant increase in leukaemia is seen in people with Turner 
syndrome(76). A loss of an X chromosome as a secondary cytogenetic event is seen 
as a frequent event in HMs(77). 
Other disorders 
Loss of the Y chromosome is also a common acquired finding in HMs(78). It is 
unclear whether this loss is purely age related, as the incidence of –Y increases with 
age, or specifically disease associated(78). If over 75% of cells have a –Y, then it is 
thought to be disease related(79). 
1.5.2. Structural chromosomal abnormalities 
Beckwith-Weidemann syndrome (11p11-15.1) 
Beckwith-Weidemann Syndrome (BWS) is a fetal overgrowth syndrome with an 
increased incidence of childhood cancers, in particular Wilms tumours(80). The 
genetics of BWS are complex and can arise by duplication, uniparental disomy 
(UPD), inversion or translocation of chromosome 11p11-15, however what is 
common is that BWS arises if there is no maternal contribution to 11p15(80). 
Patients with this disorder have been shown to have a significant excess of cancer 
deaths(81). In Wilms tumours it is noted that there is loss of the maternal 
chromosome 11 in the tumour cells(80). Acquired UPD for many regions of the 
genome is now being found in many types of HMs(82). 
Prader-Willi/Angelmen Syndrome 
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Both of these disorders can be caused by the same genetic deletion of chromosome 
15q11-13(83), but they have completely different disease phenotypes. This shows 
that even in constitutional disorders the same genetic defect can result in different 
disorders. Prader-Willi syndrome (PWS) is caused by a deletion of chromosome 
15q11-13 in approximately 60% of cases(83) and  is seen in approximately 1 in 1600 
births(84). The phenotype consists of a floppy baby, developmental delay, 
intellectual impairment and severe childhood obesity (80). A deletion of 
chromosome 15q11-13 is also seen in 60% of cases of Angelmen syndrome(83). 
Patients with Angelmen syndrome are often described as a “happy puppet”, due to 
their happy nature, jerky limb movements and severe mental impairment(83). The 
chromosome deletion in these two syndromes can be at the exact same breakpoints, 
but if the deletion occurs on the chromosome 15 inherited from the father then the 
patient has PWS, whereas if the deletion is in the chromosome 15 inherited from the 
mother then it results in Angelmen syndrome, this is due to differential expression of 
imprinted genes which have different maternal or paternal methylation patterns(85). 
Acquired changes in methylation is seen as a common event in HMs(86). Changes in 
methylation of DAPK1 resulting in down regulation of DAPK1 expression have been 
implicated in both sporadic and familial CLL(25). Thus the same mechanism 
(changes in methylation) can result in different types of disorders, both constitutional 
and malignant(87) and the same chromosomal genetic disorder can result in 
completely different diseases (phenotypes). 
Miller Dieker Syndrome 
This is a contiguous gene deletion syndrome that is associated with lissencephaly, 
severe mental retardation and deletions of chromosome 17p13.3(88). Deletions of 
chromosome 17p are one of the commonest abnormalities seen in all types of 
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cancers(89) and TP53 (located at 17p13.1) is sometimes, but not always implicated 
as the gene involved(90). Two other tumour suppressor genes are in this region 
(HIC1 and OVCA1) and case reports of cancers occurring in patients with Miller 
Dieker syndrome are emerging in the literature(90). It is now recommended that 
surveillance for malignancies be part of the long term management of these 
patients(91). Such observations highlight the fact that structural genetic disorders can 
result in an increased susceptibility to developing a malignancy. A case report of a 
girl with Miller Dieker syndrome developing ALL has been reported in the 
literature(92) and  has recommended that surveillance for malignancies be a part of 
management for these patients. 
1.6. Specific single-gene disorders with a known increased risk of a HM 
1.6.1. TP53 Li-Fraumeni syndrome 
This syndrome was first described by both Li and Fraumeni in 1969(93). It is now 
defined as a proband aged under 45 years with any childhood tumour, or a sarcoma, 
brain tumour, or adrenocortical tumour plus a first or second degree relative in the 
same lineage with a typical Li-Fraumeni tumour at any age and an additional first or 
second degree relative in the same lineage with any cancer under the age of 60(94).  
Over 200 different germline mutations in this gene have been described(94), 
however the five most common germline mutations in TP53 are also the most 
common mutations found in sporadic cases of these tumours(94). TP53 mutations are 
frequently seen in HM and are associated with a poorer outcome(95).  
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1.6.2. Dyskeratosis congenita 
This disease can be caused by several different mutations. The X-linked recessive 
form of this disease has been shown to be due to mutations in DKC1(96). This gene 
encodes dyskerin, which is a key component in stabilising the telomerase 
complex(96). In contrast, the autosomal dominant form of this disease has been 
shown to be due to mutations in TERC or TERT(96). Both of the genetic causes (X-
linked or autosomal) result in a bone marrow failure syndrome and increased 
malignancy risk(96).  
1.7. Familial Haematological disorders 
1.7.1. Fanconi anaemia 
This disorder was first described in 1927 by Guido Fanconi(97) as a syndrome of 
bone marrow failure, short stature and radial bone abnormalities. This disease can be 
either autosomal or X linked and mutations have been described in at least thirteen 
different genes (FANCA, FANCB, FANCC, BRCA2, FANCD2, FANCE, FANCF, 
FANCG, FANCI, FANCJ, FANCL, FANCM, PALB2)(98). The genes involved in 
causing Fanconi anaemia are associated with cell cycle checkpoint control or DNA 
repair pathways(99). Patients with Fanconi anaemia are at a high risk of both HMs 
and solid malignancies(98).  
1.7.2. Familial platelet disorder 
This is an autosomal dominant familial platelet disorder characterised by 
thrombocytopenia and a tendency to develop AML(53), which has been shown to be 
due to point mutations in RUNX1(53). For the AML to develop, a second mutation 
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has to occur, either in RUNX1 or another gene(53). This supports the hypothesis that 
a germline mutation in these families is the first hit in a series of hits that must occur 
for a HM to develop. Other types of leukaemia (lymphoid) have also been reported in 
carriers of the RUNX1 mutations(100). 
1.7.3. Congenital Neutropenia 
This is a heterogeneous condition characterised by bone marrow arrest of 
myelopoiesis at the promyelocyte/myelocyte stage with an absolute neutrophil count 
of <0.5x109/L(101). One particular type of congenital neutropenia is Kostmann 
syndrome, which was first described by Rolf Kostmann as a recessive lethal disease; 
prior to this it was thought to be an acquired disorder(102). It has been found that 
approximately 80% of patients with congenital neutropenia develop acquired 
mutations in the G-CSFR gene(101) and go on to develop AML, once again 
supporting the hypothesis that germline mutations are the first hit in a series of hits 
required to develop a HM and that disorders that were thought to be sporadic can be 
due to germline mutations.  
1.8. Known causes of malignancy 
It is known that DNA damage can cause cancer (103). Cells are under constant attack 
from DNA damaging agents such as UV radiation; both DNA repair pathways and 
cell cycle checkpoint pathways have evolved to limit this damage(103). How a cell 
responds to this damage is critical to the risk of a person developing a malignancy. It 
is known that multiple genetic changes are needed for a cell to undergo a cancerous 
change(104). Genetic changes occur in genes that control how cells progress through 
the cell cycle or apoptosis pathways(104) and these pathways are 
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interconnected(105). Classically genes involved in causing cancer have been 
classified as either tumour suppressor genes or oncogenes; however it is now known 
that individual genes can in fact be both(106). Furthermore it is now emerging from 
whole genome sequencing that mutations are present in genes that were previously 
not thought to be involved in the pathogenesis of cancer(107). 
1.9. Use of families to find genetic causes of diseases 
Genetic studies using families have been successful in identifying the causative 
genetic mutation in many diseases and familial cancer syndromes(108). It has been 
found that the many genes identified in causing familial cancers are also the same 
genes mutated in sporadic forms of the same cancers. Thus the study of familial 
cancers can led to insight into disease development in the general population. It 
establishes a justification for using families as a means to finding genetic 
mutations(109). Familial studies compare the genetic makeup of affected individuals 
to see what regions they share (linkage). This was originally done using 
microsatellites, but now is being done with single nucleotide polymorphisms (SNPs). 
This identifies regions of the genome that can then be sequenced for mutations.  
1.9.1. Genetic mutations discovered using Tasmanian families  
Tasmanian families have been used in many genetic studies(33, 110-115). Tasmania 
is a unique resource for genetic studies as it is an island state with a relatively stable 
population, 65% being descendants of colonial settlement, a centralized cancer 
registry and centralized specialised pathology testing. 
Tasmanian families were used in genetic linkage studies investigating the genetic 
basis of multiple endocrine neoplasia type 1 (MEN1) which is an autosomal 
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dominant disorder(116). This lead to the identification of a gene on chromosome 
11(117). This disorder is another example of a germ line mutation in a gene (MEN1) 
giving rise to multiple different tumours of the endocrine tumours and tumours of the 
skin and central nervous system (gastrinomas, insulinoma, glucagonoma, pituitary 
ademoma, adrenocortical carcinoma, angiofibromas, collagenomas, lentiginosis, 
rhabdomyosarcoma, leiomyosarcoma, renal carcinomas and thyroid 
carcinomas)(108). Studies on Tasmanian families with prostate cancer have led to 
the identification of a locus on chromosome 5(111). 
Tasmanian families with increased incidence of non-malignant medical diseases have 
been used to identify the underling genetic causes of their disease, with a locus 
involved in glaucoma, identified on chromosome 10q22(110).  
1.9.2. Familial cancer syndromes  
The concept that cancer could be inherited has been postulated for over 100 
years(118). The identification of the specific mutations that cause familial cancer has 
had a direct benefit on the affected families in enabling genetic testing and 
counselling. The most common familial cancers that have diagnostic testing available 
include breast cancer, bowel cancer, ovarian cancer and thyroid cancer(119). There 
are now approximately 100 genes that have been identified that cause Mendelian 
inherited cancer syndromes(118). It is only with the knowledge of the specific 
genetic mutations that appropriate surveillance, counselling and treatment can be 
implemented for these families. 
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1.9.2.1. Breast Cancer 
Linkage studies of families with early onset breast cancer lead to the identification of 
a disease locus, located on chromosome 17q21(120), subsequently sequencing of this 
region found mutations in the breast cancer 1, early onset gene (BRCA1)(120). 
Subsequently the BRCA2 gene was identified on chromosome 13(121). These 
discoveries have changed the management of BRCA-positive familial breast cancer, 
including more intensive screening in those possessing the mutated genes. From 
these studies three classes of predisposition risk for breast cancer have emerged: 
firstly people with BRCA1 and BRCA2 mutations have high-penetrance 
predisposition alleles; secondly people with mutations in CHEK2, ATM, BRIP1 or 
PALB2, which are genes functionally related to BRAC1 and BRAC2, who have an 
intermediate risk; and thirdly genome-wide association studies have identified 8 
variants that have a low penetrance risk of breast cancer(122). Mutations in BRCA1 
and BRCA2 are reported to account for 20% of the heritable risk; mutations in 
CHEK2, ATM, BRIP1 or PALB2 account for approximately 5% of the heritable 
risk(123).  
1.9.2.2. Colorectal Cancer 
Approximately 30% of patients with colorectal cancer have a familial component to 
their disease(124). Single gene germline mutations have been have been found in 
approximately 5-6% of cases of colorectal cancer(125). 
Familial adenomatous polyposis 
This is an autosomal dominant disease with a 100% risk of developing colorectal 
cancer by the age of 39 years and is due to mutations in the APC gene on 
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chromosome 5q21(125).  Diagnostic testing for mutations in APC has been available 
since 1994 and knowledge of the carrier status with annual colonoscopy/endoscopy 
and eventually prophylactic total colectomy can dramatically reduce the risk of 
developing colorectal cancer(125). 
Hereditary non-polyposis colon cancer (Lynch syndrome) 
This syndrome was first described by Dr Lynch in 1966(126) in two large kindred’s 
which had an aggregation of colorectal and endometrial cancers that were inherited 
as an autosomal dominant disorder. Lynch syndrome accounts for approximately 3-
5% of colorectal cancers and is caused by mutations in one of four DNA mismatch 
repair genes (MSH2, MLH1, MSH6 or PMS2)(125). Knowledge and testing for 
carrier status has dramatically improved survival in these patients. 
1.9.2.3. Von Hippel-Lindau syndrome 
Von Hippel-Lindau syndrome results from mutations in the VHL tumour suppressor 
gene and shows marked clinical variation with age dependent penetrance(127). The 
most common clinical manifestations are retinal and central nervous system 
hemangioblastomas, renal cell carcinomas, pheochromocytoma, pancreatic endocrine 
tumours and endolymphatic sac tumours(128). Recognition of this syndrome and the 
understanding of the underlying heritable risk has improved patient outcomes by 
implementation of screening programs in carriers and genetic testing of 
relatives(129). 
1.10. Familial haematological studies in the literature 
In the literature there are 8 major epidemiological studies on the incidence of HM in 
families that have been reported(130). Three were cohort studies and 5 were case-
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controls. The familial relative risk calculated in these 8 studies ranged from 2.4 to 
8.5(6, 32, 33, 131-135).  One of these studies was conducted in Tasmania(33, 112, 
113). 
1.10.1. The 1970s Tasmanian cohort study 
In the 1970s a cohort of all patients that were diagnosed with a HM in Tasmania was 
surveyed with publications in the 1970s and two publications in the 1980s (33, 112, 
113). At the time it was appreciated that a number of the people affected with a HM 
were related. These initial studies are the basis for the current families in this study. 
These studies were focused on documenting the residential and occupational history 
of the patients; however it became apparent that families with two or more closely 
related individuals with a MPD or LPD were not uncommon(112) and thus from 
1975 formal questioning about relatives was undertaken, and confirmation of disease 
status and subtype was obtained from clinical colleagues around Australia. A total of 
866 people in Tasmania were diagnosed with either a myeloproliferative or a 
lymphoproliferative disorder between 1 of January 1972 to the 31st of December 
1980 and 100% were enrolled in these studies(33, 113). Adult controls were 
randomly selected from the electoral roll (The Australian Electoral Commission 
maintains and updates the Commonwealth electoral roll - a list of eligible persons 
who are registered to vote in Australian election) and matched for age and gender. 
Paediatric controls were randomly selected from the records of the Child and School 
Health Services of the Department of Health.  
Giles et al. 1984 reported that the overall lymphoproliferative risk for relatives of 
male patients was 3.61 compared to the risk for relatives of female patients of 3.15. 
The myeloproliferative risk was 5.17 and 5.21 respectively(33). This is a similar 
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relative risk when compared to other studies of the relative risk of HM. Goldin et al. 
2006, found that the relative risk for relatives of people with CLL was 7.52(6)  but it 
has been reported by Pottern et al. 1991(135), to be as low as 2.3. 
1.10.2. Familial studies of CLL 
A review article by Yuille et al. in 2000 reported that there were 81 families with 
CLL in the literature(24). It was also noted that in five of these families other family 
members were affected with other subtypes HMs(24). Mauro et al. 2006, reported 
that approximately 12.5% of cases of CLL have a positive family history of 
CLL(15). There have been several recent genome-wide linkage studies on familial 
CLL(18, 136-138) to try and identify the underlying genetic predisposition in this 
disease. 
Sellick et al. 2007, reported the linkage analysis from an international consortium 
that enrolled 206 familial CLL families, with maximum nonparametric linkage found 
on chromosome 2q21.2 and a further two chromosomal regions (6p22.1 and 
18q21.1) which had significant LOD scores(18). The authors of this report, Sellick et 
al. 2007, attest that these findings provide direct evidence for Mendelian 
predisposition to CLL and that more than one gene is responsible for the genetic risk. 
Fuller et al. 2008, found maximum nonparametric linkage to 2q37, 4q35, 11p15 and 
14q24. Ng et al. 2007, identified a region on 13q21.33-q22.2 as harbouring a CLL 
predisposition gene(137). Of all these families with CLL, only one mutation in one 
family has been published to date: this was a mutation in an enhancer region of 
DAPK1. This mutation resulted in decreased expression of DAPK1(25). Decreased 
expression of DAPK1 is common in sporadic and familial CLL, but the mutation has 
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not been found in other families with familial CLL or as an acquired change in 
sporadic CLL(25). 
1.10.3. Anticipation in familial HM. 
In a number of HM families, the phenomenon of ‘anticipation’ has been described(5, 
7, 10, 20, 22, 23, 139). Anticipation is defined as the onset of the disease in question 
at an earlier age or increased disease severity in successive generations, and has 
implications for the nature of the genetic condition that underpins it. 
Anticipation in CLL families has been reported with a reduction in the age at 
diagnosis by 15 years(7). It has also been observed in AML families, with the mean 
age at diagnosis in the first generation being 57 years, second generation 32 years 
and third generation 13 years(10). Anticipation has also been observed in lymphoma 
families(17), families with plasma cell dyscrasia(5) and for Hodgkin lymphoma(20) 
with a total of 140 families with HMs being documented as showing 
anticipation(17), although this phenomenon is not universally observed(140). It is 
often argued that this phenomenon is due to selection bias, however if this was the 
case, then it would be present in all families. 
Anticipation is reported to be consistent with a dominantly acting mutation; however 
causative mutations in HMs have not been identified. In other disorders where 
anticipation has been reported, it has been found to be due to an unstable dynamic 
mutation that expands with each generation(141). This type of mutation has been 
implicated in over 40 diseases. Triplet repeats have been studied in familial CLL, 
however no causative repeat was identified(142). 
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1.10.4. Genome-wide association studies (GWAS) 
The number of reported GWAS has increased dramatically over the last few years 
with the advances in genotyping technology.  These studies investigate genomic 
variation across the entire genome in order to identify genetic alleles that are 
associated with a measurable trait/disease. These types of studies have become the 
standard method in recent years to identify genetic causes of common disease(143). 
GWAS have found that common polymorphisms do contribute to common 
diseases(143). Several GWAS have been undertaken in the field of HMs(144-148). 
1.10.4.1. Genome-wide association studies in CLL 
A recent GWAS by Di Bernardo et al. 2008, identified six susceptibility loci in 
CLL(149). These loci were identified using 299,983 tagging SNPs in 1529 cases and 
3115 controls(149). The loci identified are 2q13 (rs17483466; P = 2.36 x 10-10), 
2q37.1 (rs13397985, SP140; P = 5.40 x 10-10), 6p25.3 (rs872071, IRF4; P = 1.91 x 
10-20), 11q24.1 (rs735665; P = 3.78 x 10-12), 15q23 (rs7176508; P = 4.54x10-12) and 
19q13.32 (rs11083846, PRKD2; P = 3.96 x 10-9)(149). These results suggest that 
more than one gene is contributing to the risk of developing CLL, but the authors 
state that these loci only account for approximately 3% of the excess familial risk of 
CLL(149). A study by Rudd et al. 2006, investigated SNPs in the ATM-BRCA2-
CHEK2 pathway and identified 49 SNPs that are significantly associated with an 
increased risk of developing CLL(150).  
Slager et al. 2010, reported a replication study of seven SNPs previously identified in 
a GWAS study and validated them in a further 438 CLL cases and 328 controls(147). 
Six of those previously identified SNP continued to show a significant association, 
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however they concluded that further study is needed to identify the causative 
mutation and to determine how these SNPs contribute to the pathogenesis of 
CLL(147).  
Crowther-Swanepoel et al. 2010, undertook a GWAS with validation in four datasets 
in a total of 2503 CLL cases and 2503 controls(144). They identified four new 
susceptibility loci for CLL at 2q37.3, 8q24.21, 15q21.3 and 16q24.1(144) and for 
two previously reported loci.. Therefore, in total 10 loci for CLL have been reported 
for CLL; however these are reported to account for only 10% of the heritable risk, 
with many more additional risk variants yet to be discovered(144). These GWAS in 
CLL continue to provide evidence of multiple genetic predisposition alleles for 
familial CLL 
1.10.4.2. Genome-wide association studies in ALL 
A GWAS in childhood ALL reported by Papaemmanuil et al. 2009, identified three 
risk alleles for childhood ALL, 7p12.2 (IKZF1, rs4132601), 10q21.2 (ARID5B, 
rs7089424) and 14q11.2 (CEBPE, rs2239633)(145). These authors also found that 
the 10q21.2 risk allele was specific for PBALL with hyperdiploidy and their data 
supports the hypothesis that common low-penetrance susceptibility alleles contribute 
to the risk of developing ALL(145). Trevino et al. 2009, also investigated two SNPs 
in ARID5B (rs10821936 and rs10994982) and found that these two SNPs were 
significantly associated with ALL. They concluded that germline variants contribute 
to the genetic susceptibility to ALL and to the cytogenetic subtype of ALL that 
develops(151). There is a well established ethnic difference in ALL between 
African-Americans and Caucasians which can be explained by the higher frequency 
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of the risk allele of rs10821936 in Caucasians compared to African-Americans (152).  
Healy et al. 2010, have replicated these SNPs in a French-Canadian cohort of 284 
childhood ALL cases and 207 controls and confirmed five SNPs [rs7073837 
(p=4.2 x 10–4), rs10994982 (p=3.8 x 10–4), rs10740055 (p=1.6 x 10–5), 
rs10821936 (p=1.7 x 10–7) and rs7089424 (p=3.6 x 10–7)] in the ARID5B gene with 
an increased susceptibility to childhood ALL. 
1.10.4.3. Genome-wide association studies in therapy related AML 
A side effect of cytotoxic therapy to treat a HM or other cancer is the risk of 
developing a HM as a result of the cytotoxic therapy effect on healthy cells.  Therapy 
associated HM accounts for approximately 10-30% of cases of AML(153). Certain 
therapies are higher risk than others; however only a small proportion of patients will 
develop a therapy related AML, suggesting host factors also contribute to the risk of 
developing a therapy related HM. A recent GWAS found evidence of association of 
3 SNPs for therapy related AML in patients with acquired loss of chromosome 5 or 7 
or both(154). 
1.10.4.4. Genome-wide association studies in mature B cell neoplasms 
Skibola et al. 2009, undertook a GWAS of patients with NHL using the Illumina 
HumanHap550 beadchip in the hope of identifying specific SNP associations for the 
different subtypes of mature B cell neoplasms, in particular, follicular lymphoma, 
DLBCL and CLL(146). They found that one SNP (rs6457327) located on 6p21.33 
was associated with susceptibility to follicular lymphoma(146). They concluded that 
further work is required to identify the causal variant(146) 
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1.11. Whole genome sequencing in HMs 
With the publication of the human genome sequence by two groups in 2001 and the 
subsequent advancement of sequencing technology(155-159), whole genome 
sequencing of affected families’ members and cancer genome is now possible at a 
reasonable price and timeframe. In a comparison of the genome sequence of 
leukaemic and skin cells from a patient with cytogenetically normal AML(160), ten 
acquired mutations were found in the leukemic cells. Two were in genes that have 
been implicated in leukaemia previously (FLT3 and NPM1), but 8 were in novel 
genes(160), CDH24, PCLKC, GPR123, EB12, PTPRT, KNDC1, SLC15A1 and 
GRINL1B(160).  
1.12. Discussion and Conclusion 
There is clear evidence that an inherited genetic abnormality can predispose to 
development of a HM, and that using families with multiple cases is a useful method 
for detecting genetic mutations. Due to the maturation process of haematological 
cells, a germline mutation is present in all the different types of HSC; then, if 
additional mutations occur, a different type of HM may develop depending upon how 
committed that HSC is. This has been shown with germline mutations in RUNX1 and 
CEBPA, that different types of HMS can develop in these families. This is also 
supported by other acquired genetic changes in leukaemic cells that are not specific 
for any type of HM, but are seen in many different subtypes of HMs. 
Mutations responsible for the familial risk for many other types of cancers (prostate 
cancer, breast cancer, colorectal cancer) have been identified by the use of familial 
studies; however, only one mutation in one familial CLL family has been found to 
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date. This has caused experts in the field to question the mode of inheritance in this 
condition and postulate that rather than of a Mendelian predisposition, a polygenic 
model is more likely(130). However it is clearly recognised in the literature that there 
is a genetic basis for the familial risk of HMs although genome-wide association 
studies of CLL(149) childhood ALL(145, 148) and NHL(146) have identified 
genetic variants accounting for only a small percentage of the heritable risk. 
Collections of large pedigrees with a range of HMs are rare but it is likely that the 
genetic study of such families will provide important insights into the genetic risk of 
familial HMs.  
The hypothesis is that there is a genetic mutation that is segregating in some 
Tasmanian families resulting in an increased risk for developing a HM. The aims of 
this study are firstly to identify and recruit families with multiple affected members, 
secondly to confirm and classify the type of HM and locate pathology samples from 
the affected individuals and thirdly to identify the mutation in these families. 
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2. Chapter 2: Materials and Methods 
2.1. Patient recruitment from the 13 Tasmanian families and ethics approval 
This study has ethics approval by the Human Research Ethics Committee (Tasmania) 
network (H8551 from November 2005 for 4 years and has been extended for a 
further 4 years subject to annual progress reports being submitted). Ceri Flowers, a 
research assistant with the Menzies Research Institute, was responsible for contacting 
potential study participants. A survey and consent form (Appendix A) was sent to all 
adult living relatives of deceased individuals and affected individuals in the 13 
families, when their doctor gave permission and a current address could be found. 
They were requested to provide information on a family history of a HM and consent 
to provide a peripheral blood or saliva sample.  All participants provided written 
informed consent. 
 
2.2. DNA isolation 
DNA was extracted from ethylenediaminetetraacetic acid (EDTA) whole blood or 
from saliva using the Nucleon Bacc3 (Amersham Biosciences) and PureGene DNA 
isolation kits (Gentra Systems) respectively. Formalin fixed paraffin embedded tissue 
(FFPET) was collected from pathology laboratories (Royal Hobart Hospital, Hobart 
Pathology, North-West Pathology, Launceston Pathology, Bendigo Pathology and 
Newcastle Pathology) and the DNA extracted using the Pico PureTM DNA Extraction 
Kit (Arcturus Bioscience). Giemsa stained bone marrow slides were also collected 
from pathology laboratories (Royal Hobart Hospital, Hobart Pathology, North-West 
Pathology, Launceston Pathology) and the DNA extracted using the Pico PureTM 
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DNA Extraction Kit (Arcturus Bioscience). DNA from microdissected chromosomes 
was isolated using the Pico PureTM DNA Extraction Kit (Arcturus Bioscience).  
 
2.3. DNA purification 
DNA from FFPET, Giemsa stained bone marrow aspirate smears or micro-dissected 
chromosomes were isolated as per 2.1. The DNA was then purified with the 
following method. The sample was made up to 200µl with water, then 100µl of 
phenol and 100µl of chloroform were added and the sample vortexed on high for 15 
seconds. Supernatant was removed and put into a new tube. 1µl of glycogen, 10% of 
volume of sodium acetate (pH 5.2) and 2x volumes of 100% ethanol were added. 
The sample was mixed by inversion and put on ice for two hours. This was then 
centrifuged for 5 minutes at 250 RCF and the supernatant discarded. The pellet was 
washed in 400µl of 70% ethanol and centrifuged for 15 minutes at 250 RCF. The 
supernatant was discarded and the DNA air-dried and resuspended in water or TE 
buffer. Some samples were also put onto Whatman FTA cards (Interpath) and 
extracted as per manufacturers instructions. 
 
2.4. DNA whole genome amplification 
DNA from pathology samples and micro dissected chromosomes was amplified 
using genomiphi (GE Healthcare), Repli-g® whole genome amplification (Qiagen) 
and GenomePlex® (Sigma-Aldrich). The sample was then purified using Agencourt 
AMPure (Beckman Coulter genomics). 
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2.5. Assessing DNA amount and quality 
The amount and molecular weight of the DNA extracted was assessed on a 2% 
agarose gel. The concentration was also assessed using a Nanodrop (Thermo 
Scientific) and the concentration of DNA and the 260/280 and 230/260 ratios were 
recorded.  
 
2.6. Microsatellites 
Microsatellites were selected using the UCSC genome browser 
(http://genome.ucsc.edu). The region of interest was inserted into the genome 
browser and the microsatellites within the region of interest were assessed for their 
suitability (ie size, heterozygosity score). The recommended forward and reverse 
primer sequences were recorded and also submitted to “BLAT” 
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) to ensure their uniqueness. 
Primers were order from Geneworks. The forward primer was labelled with a 
fluorchrom (Hex or Fam). Each primer was made up to 100µM concentration with 
water. A working solution of both the forward and reverse primer was made up to a 
concentration of 10µM by adding 5µl of the forward primer and 5ul of the reverse 
primer to 90µl of water. Each set of primers was optimised for an annealing 
temperature. The size of the microsatellite in each person was assessed using an ABI 
PRISM 310 Genetic Analyzer (Applied Biosystems). Raw traces were formatted in 
GeneScan (Applied Biosystems) and then imported into Genotyper (Applied 
Biosystems) for analysis. Microsatellite allele frequencies were estimated from 25 
unrelated Tasmanian people who did not have a haematological malignancy. Primer 
sequences are listed in Appendix B. 
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2.7. Single Nucleotide Polymorphisms (SNPs) 
SNPs were chosen from the UCSC genome browser (http://genome.ucsc.edu) or 
from the affymetrix SNP array. SNP’s were chosen where LK16-1 was homozygous 
for the rare allele. The DNA sequence for 200bp either side of the SNP was obtained 
from the UCSC genome browser and primers were designed for this region using 
Primer3 (http://frodo.wi.mit.edu/primer3/input.htm). The primer sequence were put 
through “BLAT” (http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) to ensure 
their uniqueness and ordered from Geneworks. Each primer was made up to 200µM 
concentration with water. A working solution of both the left and right primer was 
made up to a concentration of 5µM by adding 5µl of the left primer and 5ul of the 
right primer to 90µl of water. Each set of primers was optimised for an annealing 
temperature. PCR products were cleaned with Ampure (Beckman Coulter Genomics) 
as per manufactures instructions and the sequencing reaction run using Big Dye 
Terminator (BDT) 3.1 sequencing enzyme (Applied Biosystems) in the following 
concentration: DNA 1µl per 100bp to be sequenced, 0.25µl BDT sequencing enzyme 
(Applied Biosystems), 1.75µl of Sequencing Buffer (Applied Biosystems), 1µl of 
forward or reverse primer and water to make up to 10µl. Samples underwent 25 
cycles at 96oC for 10 seconds, 50 oC for 5 seconds and 60oC for 4 minutes. The 
sequencing reaction was then purified using CLEANSEQ (Beckman-Coulter) as per 
manufactures instructions and 30µl per sample run on an ABI PRISM 310 Genetic 
Analyzer (Applied Biosystems) and analysis of the raw traces complied and analysed 
with Sequencer 4.10.1 (Gene codes Corporation). Primer sequences are listed in 
Appendix B. 
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2.8. Sequencing of genes 
The DNA sequences of genes to be sequence were obtained from the UCSC genome 
browser (http://genome.ucsc.edu). Primers were then designed using the ExonPrimer 
for the entire cDNA, 5’UTR, 3’UTR, splice sites and 500bps upstream and 
downstream of the gene. The primers generated by this program were checked in 
“BLAT” for uniqueness and ordered from Geneworks. These primers were treated in 
the same manner as the primers used in sequencing the SNPs (Chapter 2.7). Primer 
sequences are listed in Appendix B. 
 
2.9. Conventional Cytogenetics 
Whole peripheral blood was collected into a 9ml Lithium heparin peripheral blood 
tube.  0.5mls of peripheral blood was then added to 7ml of RPMI 1640 media 
(Sigma-Aldrich) supplemented with 0.8% glutamax (Gibco, Invitrogen) and 13% 
fetal calf serum (FCS) (Gibco, Invitrogen). 0.4mls of phytohaemagglutin (PHA) 
(Roche) and 0.1ml of antibiotics (Gibco, Invitrogen) were added and the culture was 
incubated for 48 hours at 37oC. 100µl of thymidine (Sigma-Aldrich) was added and 
18 hours later this block was released with 0.1ml of 2-deoxycytidine hydrochloride 
(Sigma-Aldrich). The culture was then incubated at 37oC for 3 hours and forty-five 
minutes then 0.1µg/ml of colcemid (Gibco, Invitrogen) was added and incubated at 
37oC for 20 minutes. The culture was then centrifuged at 250 RCF for 6 minutes. The 
supernatant is discarded and the pellet was resuspend in 8ml of 0.038mol/L 
potassium chloride and incubated for 27 minutes at room temperature. Then 1ml of 
fixative was added, mixed and centrifuge at 250 RCF for 6 minutes. The supernatant 
is discarded and the pellet resuspend in 6mls of fixative and centrifuge at 250 RCF 
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for 6 minutes this step repeated. The slides were made, aged for 2 days and the 
chromosomes giemsa trypsin leishman (GTL) banded and analysed using IKAROS 
software (Metasystems, Germany) and the results were reported according to 
international system of cytogenetic nomenclature (ISCN)(161). 
 
2.10. Molecular cytogenetics 
FISH probes were ordered from The Hospital for Sick Children, Canada to cover the 
microsatellite regions on chromosome 15 and a region on chromosome 4q13. FISH 
probes were ordered from Vysis (Abbott Molecular, Australia) for IGH@, 13q14 
(D13S319), 13q34, CEP(12), TP53 and ATM and used according to product insert. 
Pretreatment of FFPET samples was with the Vysis paraffin pre-treatment reagent kit 
III (Vysis Abbott Molecular). FISH was analysed using an Axioskop 2plus 
microscope using ISIS software (Metasystems, Germany) and results reported 
according to ISCN(161). 
 
2.11. Cell Lines 
Epstein barr virus (EBV) containing supernatant was obtained from culturing 
monkey B95-8 cells. The lymphocytes from subjects were purified with a ficoll-
PaqueTM (GE Healthcare) gradient, washed in RPMI (Sigma-Aldrich) and 
resuspended in 8mls of medium (RPMI with 13% FCS and 0.8% glutamax) with 
2ug/ml cyclosporine (Sigma-Aldrich). This was split into two T25 falcon flasks, 
4ml/flask and 1ml EBV supernatant was then added to each flask. The cultures were 
fed weekly for the first two weeks and then bi-weekly and checked for cell growth 
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(clump formation). The cultures were split when there was sufficient cell growth 
(mostly after 4 weeks). RNA was then extracted using PureLink™ (Invitrogen) and 
some cultures were stored for DNA extraction on Whatman FTA cards (Interpath). 
The remaining cultures were frozen at 10 x 10-6 cells in 2ml RPMI supplemented 
with 15% FCS and 5% DMSO. 
 
2.12. Laser Dissection of chromosomes 
Chromosome preparations were made as described in Chapter 2.9. Several slides 
were made on each sample. Slides were aged for 2 days at 60OC and then GTL 
banded. The chromosome region of interest was laser micro-dissected using a PALM 
MicroBeam (Carl Zeiss) as per the manufactures instructions into a cap tube 
containing buffer from the Pico PureTM DNA Extraction Kit (Arcturus Bioscience).  
 
2.13. Standard PCR conditions 
The PCR mix consisted of 5ul of Gotaq® Green (Promega), 0.4µl of primer set, 
3.6µl of water and 1µl of DNA at 10ng/µl. The standard PCR cycling conditions 
were denaturation at 94OC for 5 minutes, followed by 30 cycles at 94OC for 30 
seconds, specific annealing temperature 60OC for 30 seconds and 72OC for 30 
seconds. The reaction was cooled to 10OC for 10 minutes. The annealing temperature 
for each PCR was optimised on a gradient cycle. 30 cycles was standard for all 
PCRs, except when the source of the DNA was from FFPET or giemsa bone marrow 
aspirate smears, then 35 cycles were performed.   
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3. Chapter 3: The clinical aspects of the 13 families with HMs. 
3.1. Introduction 
A positive family history is a well-documented risk factor for HMs. Reported 
collections of large families with multiple cases of varied types of HM are relatively 
rare(19), with most families in the literature having the same disease, mostly CLL(6-
8, 15, 18, 19, 24), however other subtypes (myeloma, AML, MPN and lymphomas) 
have been described(5, 9, 10, 13, 14, 17, 23). Many of the families in the literature 
are not complete and details are missing in terms of confirmation of disease, clinical 
features or age at diagnosis.  
A collection of 13 families featuring a dense aggregation of HM cases, was 
ascertained from a population based case control study conducted between 1972-
1980 in Tasmania(33, 112, 113) as described in Chapter 1.10.1. The original records 
of this study have been retained (by Jean Panton) and were available for review by 
myself. They noted that the “risk for children of parents is higher than the risk to 
siblings and that the risk of siblings is higher than that to parents” (33). 
3.2. Materials and Methods 
3.2.1. Updating of the families from the original 1970’s Tasmanian study 
The families from the original study(33, 112, 113) were reviewed and current 
generations included and cross-referenced with the Tasmanian Cancer Registry 
(TCR) and the genealogical databases of the Menzies Research Institute. The TCR 
was commenced in 1982 with mandatory reporting for doctors, including HMs. 
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Formerly, not all HMs were recorded by the TCR. Waldenstroms 
macroglobulinaemia, some MPNs and MDS were not recorded as they were 
considered to be “pre-malignant” conditions not cancers; however with the current 
WHO classification system(1) these disorders are now registered. The families 
prioritised for further study were selected based upon the number of cases affected, 
multiple generations affected, or sibling pairs affected.  
3.2.2. Survey of living patients from the TCR 
Ceri Flowers, a research assistant with the Menzies Research Institute, conducted 
this. A list of patients who were registered with the TCR as having a HM and living 
as of the 1st of June 2006 was generated by the TCR. An information and consent 
form (Appendix A) was sent to all living affected cases with a HM when their doctor 
gave permission and a current address could be found. They were requested to 
provide information on a family history of a HM.   
3.2.3. Confirmation of diagnosis 
Medical records from the Royal Hobart Hospital (RHH), pathology records from the 
Pathology Department of the RHH, flow cytometry records from the University of 
Tasmania’s Oncology and Immunology Laboratory, files from the 1970’s study (33, 
112, 113) and records of the TCR were obtained and pathology samples located and 
reviewed by myself to reconfirm the type of HM. If one or more of a pathology 
sample, report, doctors’ correspondence or death certificate was found and confirmed 
the HM, then that person was counted as a reconfirmed case. If records no longer 
existed or they had a HM that was not recorded by the TCR (such as Waldenstroms 
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macroglobulinaemia, MPN or MDS), but was recorded as affected in the original 
study (33, 112, 113), then that person would be considered as a confirmed case.  
3.2.4. Statistical analysis 
Graphs were drawn with Microsoft® Excel® (Mircosoft Corporation). Pedigrees 
were generated using Smartdraw (Smartdraw Software LLC). Student T-tests were 
generated with Microsoft® Excel® (Mircosoft Corporation). Age at diagnosis was 
calculated using Microsoft® Excel® (Mircosoft Corporation), ((Date of diagnosis –
Date of birth)/365) and rounded to the next full year. Test for trend was generated 
using GraphPad Prism software version 5. 
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3.3. Results: Clinical features of the 13 families  
3.3.1. Leukaemia Family 1 (LK1) 
There are 9 cases in this family. The disease characteristics are given in Table 
3.3.1.1. All cases in this family could be reconfirmed. An abbreviated pedigree 
showing the relationship of the affected persons is given in Figure 3.3.1.1. It should 
be noted that only 3 of these cases were in the original study(33, 112, 113), and that a 
further 6 subjects in this family have been diagnosed since then. All pathology 
records could be traced for this family. The male to female ratio was 5:4. The median 
age at diagnosis was 63 years (range 47-81years). There were two cases of early 
onset disease, notably CLL in a 47 year old and MDS in a 50 year old. There was 
one case of therapy-related MDS developing in a patient who originally had DLBCL 
(LK1-40). The MDS developed 14 months after the diagnosis of DLBCL. The two 
cases of primary MDS transformed to AML within one year of diagnosis. One 
patient who had HL was found at post mortem to also have an adenocarcinoma of his 
right upper lobe of his lung. There was also a cluster of cases of CLL, with a mother 
(LK1-38) and two of her children affected with CLL (LK1-34 and LK1-33). 
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Table 3.3.1.1: The disease characteristics of LK1. 
ID Gender DOB Date of 
Diagnosis 
Date of 
Death 
Diagnosis* Age at 
diagnosis 
001 M 07/12/1926 01/05/1999 15/02/2007 MALT 72 
003 M 13/12/1936 01/12/1994 05/02/1995 HL MC 58 
025 F 13/04/1906 01/11/1972 03/01/1973 
AML 
Monocytic 67 
033 M 09/08/1928 01/09/1975 04/02/1979 CLL 47 
038 F 21/11/1907 01/02/1971 28/12/1976 CLL 63 
040 M 01/01/1912 01/08/1987 09/11/1988 DLBCL 76 
058 M 01/10/1910 01/04/1991 27/04/1991 
RAEB  
 AML 81 
034 F 14/11/1930 01/01/1991 Alive CLL 61 
100 F 05/06/1956 01/01/2006 27/12/2006 
RAEBII 
AML 50 
*are defined in the abbreviation section
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Figure 3.3.1.1 Pedigree of LK1 
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3.3.2. Leukaemia Family 2 (LK2) 
There are 12 cases in this family (Figure 3.3.2.1). The disease characteristics are 
given in Table 3.3.2.1. Eight cases in this family could be reconfirmed and one case 
was excluded. Six cases were from the original study(33, 112, 113). The median age 
at diagnosis in this family was 65 years (range 39-83 years). The male to female ratio 
was 10 to 4. One patient also developed breast cancer 31 years after the diagnosis 
and successful treatment of a lymphoma. LK2-33 transformed from CMML to AML 
13 months after diagnosis.  
Figure 3.3.2.1 Pedigree of LK2 
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          


 
 Page 53 
Table 3.3.2.1: The disease characteristics of LK2. 
 
ID Gender DOB Date of 
Diagnosis 
Date Of 
Death 
Diagnosis* Age at 
Diagnosis 
001 M 12/12/1907 01/01/1968 08/08/1968 NHL  60 
007 M 29/12/1882 01/05/1954 19/01/1955 **NHL 73 
009 M 1 /12/1939 01/01/1985 10/01/1993 **NHL  46 
021 M 8 /06/1913 01/12/1985 20/04/1993 **MDS  72 
030 M 15/08/1915 01/05/1979 10/03/1979 HCL 64 
032 F 1 /12/1903 01/07/1980 23/12/1986 MM 77 
033 M 9 /02/1928 01/07/1994 10/03/1996 CMML 
AML  
66 
042 F 1 /10/1915 01/10/1968 14/03/1974 HL 53 
056 F 6 /01/1900 01/01/1983 25/06/1984  **WM 83 
063 M 29/07/1931 01/07/1995 24/07/2001 DLBCL 64 
067 M 18/09/1910 01/01/1972 10/06/1973 HL  62 
099 F 17/07/1936 01/06/1975 Alive  NHL 39 
*are defined in the abbreviation section 
** confirmed cases 
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3.3.3. Leukaemia Family 4 (LK4) 
There are 5 cases in this family (shown in Figure 3.3.3.1). The disease characteristics 
are given in Table 3.3.3.1. All cases could be reconfirmed in this family. Four cases 
were from the original study(33, 112, 113). All cases in this family are male and the 
majority of cases were Hodgkin lymphoma (3 cases). The other two cases were 
DLBCL. The median age at diagnosis was 53 years (range 23-73 years). LK4-25 was 
also diagnosed with non-invasive papillary transitional cell carcinoma grade 1 of the 
bladder, 12 years after the diagnosis of DLBCL.  
Table 3.3.3.1: The disease characteristics of LK4 family 
ID Gender DOB Date of 
Diagnosis 
Date Of 
Death 
Diagnosis* Age at 
diagnosis 
1 M 6 /09/1941 12/04/1970 Alive  HL NS 29 
12 M 14/01/1947 01/04/1970 Alive  HL stage IIIB 23 
21 M 3 /10/1906 01/07/1979 28/11/1980 DLBCL 73 
25 M 31/10/1914 01/10/1987 17/10/2001 DLBCL 73 
39 M 12/01/1912 1965 25/06/1965 HL  53 
*are defined in the abbreviation section 
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Figure 3.3.3.1 Pedigree of LK4 
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3.3.4. Leukaemia Family 16 (LK16) 
There are 12 cases in this family. An abbreviated pedigree is shown in Figure 3.3.4.1. 
The disease characteristics are given in Table 3.3.4.1. All 12 cases in this family 
could be reconfirmed. An additional case was excluded, as review of his medical 
records was not in keeping with a HM; his pancytopenia was due to chemotherapy 
for his bowel cancer. Only 4 cases were from the original study(33, 112, 113). The 
male to female ratio is 10 to 2. The median age at diagnosis was 65 years (range 35-
80 years). This is an unusual family in that it has a small cluster of five siblings out 
of seven affected with a HM. Four of the siblings had CLL and the fifth had DLBCL. 
Also, the mother of these siblings was reported to have died from CML. Her death 
certificate has been traced and the cause of death was listed as CML in 1943. There 
are also 7 other affected subjects in this family with the most recent being diagnosed 
in January 2008 with MM. Two of the affected also had another type of cancer; 
LK16-14 was diagnosed with melanoma and LK16-108 with prostate cancer. LK16-
101 developed AML 12 years after treatment for DLBCL. 
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Figure 3.3.4.1 Pedigree of LK16 
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Table 3.3.4.1: Disease characteristics of LK16 family 
ID Gender DOB Date of 
Diagnosis 
Date Of 
Death 
Diagnosis* Age at 
diagnosis 
001 M 05/03/1921 01/05/1997 17/08/2006 CLL 76 
002 M 11/11/1922 13/02/1980 19/01/1986 CLL 57 
009 M 23/02/1919 01/07/1982 6 /01/1995 DLBCL 63 
012 F 07/06/1914 01/07/1980 23/01/1999 CLL 66 
014 M 02/05/1910 25/01/1978 1 /02/1982 CLL 68 
018 F 17/10/1880 13/9/1943 13/09/1943 CML  63 
028 M 01/10/1937 01/05/1972 14/09/1972 ALL 35 
050 M 04/09/1915 01/10/1986 18/03/1987 DLBCL 71 
077 M 04/12/1911 29/09/1975 29/09/1975 AML M1 64 
087 M 05/11/1906 01/05/1986 13/07/1986 CLL 80 
101 M 02/11/1930 01/09/1980 17/06/1998 DLBCL 
AML 
50 
108 M 15/09/1935 3/01/2008 Alive MM 73 
*are defined in the abbreviation section 
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3.3.5. Leukaemia Family 26 (LK26) 
There are 5 cases in this family. An abbreviated pedigree in shown in Figure 3.3.5.1. 
The disease characteristics are given in Table 3.3.5.1. All cases could be reconfirmed 
in this family. The male to female ratio was 3 to 2. The median age at diagnosis was 
69.4 years (range 57-80). Since the original study(33, 112, 113), two more cases 
have been diagnosed in this family. The one case of a MDS (LK26-21) transformed 
to AML within one year of diagnosis.  
Table 3.3.5.1: Disease characteristics of LK26 family 
ID Gender DOB 
Date of 
Diagnosis  
Date Of 
Death Diagnosis* 
Age at 
diagnosis 
001 M 1 /06/1904 21/11/1960 20/09/1972 PV 56 
006 M 16/04/1908 01/06/1981 7 /03/1996 FL 73 
008 F 27/06/1911 01/07/1972 6 /04/1979 PV  61 
018 F 13/12/1897 01/06/1973 22/10/1974 DLBCL 76 
021 M 20/11/1910 01/11/1990 8 /12/1990 
MDS 
AML 80 
*are defined in the abbreviation section 
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Figure 3.3.5.1 Pedigree of LK26 
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3.3.6. Leukaemia Family 51 (LK51) 
There are 15 cases in this family. An abbreviated pedigree is shown in Figure 3.3.6.1. 
The disease characteristics are given in Table 3.3.6.1. Ten cases could be 
reconfirmed in this family. Seven cases were from the original study(33, 112, 113). 
The male to female ratio was 10 to 5. The median age at diagnosis was 56 years 
(range 6-81 years). There were 2 cases of childhood onset in this family. 
Interestingly neither had ALL; one had Burkitt lymphoma and the second had AML. 
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Figure 3.3.6.1 Pedigree of LK51 
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Table 3.3.6.1: The disease characteristics of LK51 
ID Gender DOB Date of 
diagnosis 
Date of 
Death 
Diagnosis* Age at 
diagnosis 
001 M 01/06/1967 01/04/1998 Alive  TNHL 31 
017 M 24/08/1959 01/05/1973 01/07/1973 AML 14 
044 M 25/11/1910 01/05/1977 04/06/1977 MM 67 
063 F 01/08/1921 01/03/1972 30/05/1972 **AML 51 
065 M 18/07/1942 01/08/1984 30/09/1985 DLBCL 42 
070 M 19/01/1905 01/03/1976 02/10/1977 **HL 71 
078 M 31/07/1899 01/05/1980 01/06/1980 **AL 81 
090 F 17/01/1927 01/04/1972 24/01/1984 HL 45 
097 M 15/04/1948 01/11/1983 14/11/1988 NHL 35 
106 F 28/01/1904 01/10/1971 18/07/1995 **NHL 67 
128 M 30/01/1996 19/11/2002 Alive  BL 6 
135 F 01/03/1906 01/06/1970 24/10/1980 CML 64 
150 M 26/02/1932 01/12/1988 18/05/1989 AML (M1) 56 
159 F 15/04/1938 07/01/1997 Alive  DLBCL 59 
184 M 15/07/1935 01/09/1992 25/08/1993 **MM 57 
*are defined in the abbreviation section 
** confirmed cases 
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3.3.7. Leukaemia Family 65 (LK65) 
There are 8 cases in this family. An abbreviated pedigree is shown in Figure 3.3.7.1. 
The disease characteristics are given in Table 3.3.7.1. Five cases could be 
reconfirmed in this family. Five cases were from the original study(33, 112, 113). 
There is a reversed male to female ratio in this family (3 to 5). The median age at 
diagnosis was 59 years (range 14-79 years).  Also of note in this family, is that the 
child (LK65-39) that was affected had AML not ALL, as ALL is more common in 
childhood then AML. 
 
Figure 3.3.7.1 Pedigree of LK65 
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Table 3.3.7.1: The patient characteristic of LK65. 
ID Gender DOB 
Date of 
diagnosis 
Date Of 
Death Diagnosis* 
Age at 
diagnosis 
001 F 01/01/1932 01/02/1976 25/10/1976 PBALL 44 
021 F 06/03/1907 01/03/1977 15/04/1977 MM 70 
022 M 14/12/1934 01/03/1983 6 /11/1983 DLBCL 48 
039 F 27/08/1951 01/03/1965 10/02/1966 AML M0 14 
046 M 27/08/1946 01/04/1978 28/12/1995 PV** 32 
058 F 22/05/1900 01/11/1979 11/03/1981 DLBCL 79 
061 M 12/09/1909 01/06/1983 26/09/1992 WM**  74 
070 F 11/03/1921 01/02/1963 03/07/1972 PV** 42 
*are defined in the abbreviation section 
** confirmed cases 
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3.3.8. Leukaemia Family 124 (LK124) 
There are 18 cases in this family. An abbreviated pedigree is shown in Figure 3.3.8.1. 
The disease characteristics are given in Table 3.3.8.1. All cases in this family could 
be reconfirmed. Only 3 cases were from the original study(33, 112, 113). The male 
to female ratio was 15 to 3. The median age at diagnosis was 70 years (range 30-84 
years). While confirming the diagnosis and classification, of the diagnosis in this 
family, some unusual clinical features emerged, namely, that several of the patients 
had disease at unusual anatomical sites. There were three cases of primary central 
nervous system (CNS) lymphoma (all DLBCL), two involved brain, and one spinal 
cord. One of these cases also developed a bone lesion in their rib 6 months after 
diagnosis. A fourth case of DLBCL also had an unusual site of presentation with 
primary bone lymphoma. There was also a case of rapid progression of a solitary soft 
tissue plasmacytoma progressing to multiple myeloma within 11 months of 
diagnosis.  This family also had two cases of primary DLBCL presenting as gastric 
lymphoma. Three of the affected also had other cancers (LK124-1 and LK124-194 
both with lung carcinoma and LK124-202 with testicular carcinoma). 
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Figure 3.3.8.1 Pedigree of LK124 
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Table 3.3.8.1: The disease characteristics of LK124 
ID Gender DOB 
Date of 
Diagnosis Date of Death 
Diagnosis
* 
Age at 
diagnosis 
1 M 08/08/1923 01/02/1997 17/04/2000 DLBCL 74 
10 M 25/05/1914 01/02/1981 07/03/1981 AML M6 67 
14 M 6 /03/1931 01/12/1979 01/02/1982 AML M1 49 
25 M 21/02/1901 01/01/1974 06/12/1974 MM 73 
35 M 20/02/1929 27/08/1998 26/10/2000 CMML 70 
57 F 7 /11/1922 01/05/1992 19/05/1993 DLBCL 70 
62 M 13/11/1923 01/09/1994 29/10/1996 MM 71 
82 M 11/04/1931 01/07/1994 20/03/1995 DLBCL 63 
93 M 29/12/1916 01/12/2000 12/12/2000 AML NOS 84 
108 M 01/12/1917 01/08/1986 03/09/1986 DLBCL 69 
117 M 08/07/1951 01/09/1995 Alive AML 44 
134 M 22/06/1959 01/09/1999 Alive DLBCL 40 
145 M 27/02/1920 01/05/2000 30/12/2000 DLBCL 80 
161 F 14/02/1926 01/08/1998 22/09/1998 DLBCL 73 
179 M 19/08/1919 02/06/2004 Alive DLBCL 85 
187 F 14/12/1943 01/01/2003 17/10/2006 DLBCL 59 
194 M 10/07/1903 01/10/1969 04/03/1977 
Plasma 
-cytoma 
MM 
66 
202 M 19/01/1972 25/02/2002 Alive APML 30 
*are defined in the abbreviation section 
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3.3.9. Leukaemia Family 132 (LK132) 
There are 5 cases in this family. An abbreviated pedigree is shown in Figure 3.3.9.1. 
The disease characteristics are given in Table 3.3.9.1. Only 2 cases could be 
reconfirmed in this family. Only 1 case was from the original study(33, 112, 113). 
This is a smaller family with a cluster of affected subjects. The male to female ratio 
was 4 to 1. The median age at diagnosis was 59 years (range 49 to 72 years).  
Figure 3.3.9.1 Pedigree of LK132 
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
      
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Table 3.3.9.1: The disease characteristics of LK132 
ID Gender DOB 
Date of 
Diagnosis 
Date of 
Death Diagnosis* 
Age at 
diagnosis 
001 M 13/07/1936 01/1/2002 24/03/2004 NHL 66 
014 M 08/06/1925 01/06/1984 24/07/2004 **CLL 59 
024 M 10/10/1930 01/08/1979 19/09/1979 **AML 49 
027 F 10/11/1910 01/01/1982 10/06/1986 **NHL 72 
031 M 19/10/1939 07/04/1998 15/07/1999 MM 59 
*are defined in the abbreviation section 
** confirmed cases 
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3.3.10. Leukaemia Family 153 (LK153) 
There are 7 cases in this family. An abbreviated pedigree is shown in Figure 3.3.10.1. 
The disease characteristics are given in Table 3.3.10.1. Only three cases could be 
reconfirmed in this family. Two cases were from the original study(33, 112, 113). 
The male to female ratio was 5 to 2. The median age at diagnosis was 57 years 
(range 34 to 81 years). This family has one sib-pair affected, both of whom are still 
alive.  
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Figure 3.3.10.1 Pedigree of LK153 
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Table 3.3.10.1: The disease characteristics of LK153 
ID Gender DOB Date of 
Diagnosis 
Date of 
Death 
Diagnosis* Age at 
Diagnosis 
1 M 30/09/1956 01/04/2002 Alive DLBCL 45 
2 M 04/01/1924 01/02/2005 30/10/2005 
RAEB 
AML 81 
3 F 18/06/1941 01/09/1999 Alive  MCL 58 
4 M 12/08/1943 2000 Alive  **WM 57 
5 M 03/06/1906 01/05/1981 06/08/1981 **AML NOS 75 
6 M 06/07/1909 01/02/1951 02/02/1987 **HL 42 
47 F 30/08/1920 01/01/1955 16/06/1955 **HL 34 
*are defined in the abbreviation section 
** confirmed cases 
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3.3.11. Leukaemia Family 537 (LK537) 
This family consists of a brother and sister who both have CLL (Figure 3.3.11.1). 
There is no history of consanguinity in this family. Both cases were reconfirmed. The 
median age at diagnosis was 61.5 years (range 57-66 years). 
Figure 3.3.11.1 Pedigree of LK537 
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
 
Table 3.3.11.1: The disease characteristics of LK537 
ID Gender DOB Date of 
Diagnosis 
Date of 
Death 
Diagnosis* Age at 
diagnosis 
2 M 28/02/1928 01/11/1985 Alive CLL 57 
1 F 24/06/1937 01/11/2003 Alive CLL 66 
*are defined in the abbreviation section 
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3.3.12. Leukaemia Family 836 (LK836) 
There are 5 cases in this family. A pedigree for this family is given in Figure 
3.2.12.1.  The disease characteristics are given in Table 3.3.12.1. Three cases in this 
family could be reconfirmed. Two cases were from the original study(33, 112, 113). 
All the cases in this family were male and had lymphoid malignancies. The median 
age at diagnosis was 54 years (range 2 to 70 years). It is interesting to note that 3 of 
the affected individuals had first cousins as parents.  
 
Figure 3.3.12.1 Pedigree of LK836 
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Table 3.3.12.1: The disease characteristics of LK836 
ID Gender DOB Date of 
Diagnosis 
Date of 
Death 
Diagnosis* Age at 
diagnosis 
001 M 12/04/1930 01/05/1995 Alive CLL 65 
002 M 29/08/1933 01/01/1987 Alive HCL 54 
003 M 01/02/1930 01/05/1997 21/11/2000 DLBCL 67 
005 M 00/00/1955 1957 08/06/1957 **ALL 2 
004 M 07/10/1905 01/02/1957 11/03/1957 **NHL 52 
*are defined in the abbreviation section 
** confirmed cases 
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3.3.13. Leukaemia Family 2042 (LK2042) 
There are 27 cases in this family.  A pedigree is given in Figure 3.3.13.1. The disease 
characteristics are given in Table 3.3.13.1. Twenty-three cases could be reconfirmed. 
Only 5 cases were from the original study(33, 112, 113). This is the largest family 
with 27 affected; the male to female ratio was 21 to 6.  The median age at diagnosis 
was 55 years (range 2 to 86 years). This family contains a range of both myeloid and 
lymphoid malignancies. One unusual clinical feature is a 40 year old male who was 
diagnosed with CLL, and then developed CNS involvement 6 years after diagnosis. 
This family also has four cases of childhood leukaemia; two with B lymphoblastic 
leukaemia and two with T lymphoblastic leukaemia. The median age at diagnosis for 
these four childhood cases was 8.5 (range 2-13 years of age). 
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Figure 3.3.13.1 Pedigree of LK2042 
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Table 3.3.13.1: The patient characteristic of LK2042. 
ID Gender DOB 
Date of 
Diagnosis  
Date Of 
Death Diagnosis* 
Age at 
diagnosis 
1 M 24/08/1943 01/04/1983 31/01/1993 SLL 40 
2 M 11/04/1918 01/02/1992 12/03/1992  **NHL 74 
3 M 27/05/1981 04/05/1989 Alive  PT ALL 8 
4 M 8 /07/1927 01/04/1982 21/02/1988 NHL 55 
5 M 3 /12/1991 01/03/1994 Alive  PBALL 2 
6 M 24/02/1970 01/02/2000 Alive  HL NS 30 
7 M 23/03/1930 01/09/2000 11/05/2003 MM 70 
8 F 30/07/1970 01/09/1979 27/04/1980 PT ALL 9 
9 M 11/10/1924 01/04/1999 31/07/2002 ET 75 
10 M 18/03/1944 01/01/1994 2 /09/1994 MCL 50 
11 F 20/05/1916 01/10/1980 11/10/1980 WM  64 
12 F 29/08/1942 01/03/2002 25/02/2004 DLBCL 60 
13 M 30/07/1916 01/02/1989 21/03/1989 CLL 73 
14 M 13/06/1899 01/01/1976 10/09/1976 FCL  77 
16 M 21/12/1911 01/01/1980 10/01/1981 PV**  68 
41 M 03/06/1952 01/09/2003 21/10/2008 MDS 51 
129 F 11/02/1919 12/10/2004 Alive  MM 86 
133 M 19/12/1932 01/04/1988 20/04/1988 CML 55 
134 F 19/03/1898 01/01/1978 27/02/1981 MM**  79 
200 M 27/08/1946 01/04/1978 28/12/1995 PV** 32 
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207 M 7 /12/1978 01/12/1991 19/06/1994 PBALL 13 
220 M 03/09/1951 01/11/1983 27/04/1984 NHL 32 
231 M 06/07/1941 01/08/1999 24/05/2008 DLBCL 58 
245 M 26/02/1940 01/08/2002 29/01/2006 MM 62 
257 M 30/12/1939 01/10/2006 Alive HL 67 
266 M 25/07/1995 01/07/2000 Alive HL 5 
270 F 1943 1976 02/08/1976 AML 33 
*are defined in the abbreviation section 
** confirmed cases  
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3.4. Current Tasmanian patients with a family history 
In June 2006, approximately 560 subjects were registered with the TCR as having a 
confirmed HM and were alive. A total of 400 subjects from this list were traced, 
current addresses found, and permission obtained from their treating doctor to 
contact them. This was done to try to identify new families with HMs in Tasmania. 
One hundred subjects responded to the letter, but only 76 gave information about 
their family history. Of the 76 who provided information about their relatives with a 
HM, 15 reported having affected relatives (19.7%; number of affected relatives 1-3). 
Table 3.4.1 outlines how many were aware of a family history of a HM. There were 
no cases of parent-offspring affected pairs. 
Table 3.4.1: Shows the characteristics of the current patients who responded to 
our survey from the TCR and their affected relatives.  
Family number DOB Diagnosis* Relatives affected 
530 04/0719/41 FL 0 
558 27/06/1934 CLL 0 
560 02/11/1951 NHL 1 
589 27/08/1964 PBALL 0 
609 16/03/1903 HD 0 
612 08/01/1934 NHL 0 
614 24/07/1952 HD 0 
628 01/12/1930 DLBCL 0 
627 18/02/1925 NHL 1 
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633 02/12/1938 NHL 0 
647 24/10/1927 CLL 2 
658 31/01/1927 CLL 0 
660 13/05/1933 WM 1 
673 12/10/1953 NHL 0 
692 03/12/1948 CLL 2 
718 14/12/1942 MDS 0 
732 29/07/1950 TNHL 0 
737 20/11/1945 HCL 1 
739 14/05/1919 CLL 0 
740 12/11/1953 APML 0 
741 12/09/1923 MM 0 
823 06/03/1951 DLBCL 0 
853 25/9/1942 NHL 0 
855 11/12/1935 NHL 0 
908 08/12/1919 MM 0 
933 20/08/1936 HCL 0 
946 18/01/1928 CML 0 
948 14/03/1957 CML 1 
954 30/03/1925 ML 0 
958 15/10/1952 HCL 1 
1033 16/10/1934 NHL 0 
511 20/03/1932 HD 0 
 Page 83 
512 30/12/1941 NHL 0 
586 04/05/1932 MM 0 
569 04/07/1951 DLBCL 0 
585 06/07/1939 SLL 0 
595 24/10/1933 CLL 0 
589 05/02/1936 NHL 0 
600 10/04/1943 MM 0 
635 25/10/1934 NHL 0 
650 19/11/1935 CLL 0 
664 17/04/1957 FCCL 0 
684 13/03/1926 MPD 0 
689 16/07/1926 NHL 1 
715 25/04/1933 MM 0 
717 25/07/1940 NHL 0 
760 31/10/1936 NHL 0 
932 12/09/1942 MM 0 
952 13/09/1959 ALL 0 
981 04/12/1938 NHL 0 
1037 20/09/1935 NHL 0 
502 30/12/1963 MCL 0 
508 10/05/1982 AML M5 0 
509 28/07/1973 PRV 0 
546 09/08/1949 MM 1 
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561 18/01/1961 AML 1 
613 29/03/1930 NHL 2 
625 31/10/1946 MGUS 2 
629 31/03/1948 AML 1 
634 21/07/1969 HD 0 
661 01/01/1932 FCCL 0 
672 08/07/1977 PBALL 3 
693 24/10/1929 MPD 0 
756 21/07/1932 NHL 0 
811 08/03/1931 DLBCL 0 
818 01/10/1934 DLBCL 0 
838 06/11/1934 AML 0 
848 10/04/1938 NHL 0 
849 14/11/1940 NHL 0 
907 24/07/1960 MM 0 
956 14/07/1951 NHL 0 
984 19/04/1985 HD 0 
1035 18/10/1924 NHL 0 
1039 14/08/1959 AML 0 
1040 17/11/1947 NHL 0 
1045 21/07/1971 NHL 0 
*are defined in the abbreviation section 
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3.5. Results: Summary of the familial dataset 
In these 13 families there are 130 affected individuals with a male to female ratio of 
95 to 35. A total of 69 additional cases have occurred in these families since the 
original Tasmanian study(33, 112, 113). Reconfirmation of diagnosis was sought in 
all cases. A total of 105 could be reconfirmed and classified according to the current 
haematological classification system(1). The 25 that could not be reconfirmed 
consisted of 4 diagnosed outside of Tasmania and a further 21 who were in the 
original studies(33, 112, 113) but whose pathology records are now no longer 
available. Figure 3.5.1 shows the types of HMs present in these families according to 
the major subgroups in the WHO classification system(1). Pathology samples have 
been located for 90% of the affected cases.  
Figure 3.5.1 Types of HMs in the 13 families. 
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The age at diagnosis and the type of HM affecting those 25 persons was recorded in 
the original study(33, 112, 113).  The median age at diagnosis for all 130 affected 
individuals was 63 years (2-86 years). Figure 3.5.2 shows the age at diagnosis of all 
cases. The figure shows a tri-modal age distribution, with a peak in childhood (age 
<16) another peak between 16-36 years but with the majority of cases presenting in 
the sixth and seventh decades.  
 
Figure 3.5.2 Age at diagnosis for all cases (n=130). 
 
 
Eleven families out of the thirteen studied had multiple generations affected with a 
HM. The age at diagnosis was assessed for each generation (Table 3.5.1 and Figure 
3.5.3). In nine of the families, each affected generation after the first exhibits a 
reduction in age at diagnosis. Families LK16 and LK836 do not show this 
phenomenon.   
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Table 3.5.1: Mean age at diagnosis [years (number of subjects)] for each 
generation. 
 G1 G2 G3 G4 G5 
LK1 71.7 (4) 59.5 (4) 50.0 (1)   
LK2 73 (3) 66.0 (6) 50.3 (3)   
LK4 66.3 (1) 26.0 (2)    
LK16 63 (1) 66.1 (9) 54 (2)   
LK51 66.8 (5) 51.9 (7) 22.5 (2) 6.0 (1)  
LK65 66.3 (4) 34.5 (4)    
LK124 69.2 (7) 72.7 (7) 59.0 (1) 38.6 (3)  
LK132 72 (1) 58.3 (4)    
LK153 58.0 (4) 54.3 (3)    
LK836 52 (1) 64 (3) 2 (1)   
LK2042 86.0 (1) 74.8 (5) 54.5 (13) 42.6 (5) 5.3 (3) 
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Figure 3.5.3: Graph of the mean age at diagnosis (years) for each generation for 
all the families that have at least two generations affected. 
 
In the nine families where there was a reduction of the age at diagnosis, there were 
five direct parent-offspring cases in these nine families. The age at diagnosis for 
these cases is in Table 3.5.2. The mean age at diagnosis for the parents was 63.8 
years and for their offspring 44.8 years, this was a statistically significant decrease in 
the age at diagnosis by 19 years (p=0.0087). A log rank test for trend of the age at 
diagnosis by generation was statistically significant (see Figure 3.5.4; p<0.0001). 
The types of HMs in each generation was assessed (Figure 3.5.5), however no bias of 
subtypes such as ALL that have a younger age of onset was found, in particular 
MBCNs was diagnosed across four generations and ALL was also diagnosed across 
four generations. The age at diagnosis was assessed in one subtype of HM, MBCN. 
This was the largest type of diagnosis represented in these families and the subtypes 
of MBCN have a similar age of onset. Figure 3.5.6 demonstrates the age at diagnosis 
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for all cases of MBCN in families with at least two generations affected with this 
type of HM. This also shows a significant decrease in the age at diagnosis for each 
subsequent generation (P=0.0007). 
Table 3.5.2: Age at diagnosis (years) for direct parent-offspring affected pairs. 
Family LK1 LK1  LK2   LK4  LK51 Mean + 
SD 
Age of 
parent 
72 73  60   73  51 63.8 + 
9.1 
Age of 
offspring 
50 61 47 66 39 46 29 23 42 44.8 + 
13.7 
P value          0.0087 
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Figure 3.5.4: Test for trend of the age at diagnosis (years) for each generation 
 
 
Figure 3.5.5: Distribution of the type of haematological malignancy in each 
generation. 
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Figure 3.5.6: Age at diagnosis for each generation for subjects with a Mature B 
cell neoplasm 
 
 
3.6. Discussion and Conclusions 
The 13 Tasmanian families in this study are a unique research resource because of 
the number of cases of HM confirmed diagnosis and recording of their genealogy. In 
nine of the families there is a reduction in the age at diagnosis for each subsequent 
generation. This is confirmed in direct parent-offspring affected cases with a mean 
reduction of 19 years in the age at diagnosis between the generations. A decrease in 
age at diagnosis for each subsequent generation is often reported in familial disorders 
and is referred to as anticipation. It is said to be due to an autosomal dominant trait(7, 
22). Anticipation in CLL families with a reduction of 15 years in the age at diagnosis 
has been reported in the literature(7). It has also been observed in familial AML 
families, with the mean age at diagnosis in the first generation being 57 years, in the 
second generation 32 years, and in the third generation, 13 years(10). Anticipation 
 Page 92 
has also been observed in familial lymphoma families(23), in families with plasma 
cell dyscrasia(5) and in familial Hodgkin lymphoma(20). In fact, over 140 families 
with familial HMs which show anticipation have been documented(17). As different 
subtypes of HMs have different median age of onsets, the types of HM found in each 
generation of these families was assessed (Figure 3.5.5.), this showed no skewing of 
the subtypes of HMs in the younger generations. However, to confirm the 
anticipation, the analysis of the age at diagnosis was repeated for all cases of mature 
B cell neoplasm (including CLL), as they have a similar age of onset (Figure 3.5.6) 
(therefore, addressing the argument of young onset diseases only occurring in the 
younger generations) and there was still a significant decrease in the age at diagnosis 
for each subsequent generation (p=0.0007)(162). 
Anticipation is reported to be consistent with an autosomal dominant mutation. In 
instances where anticipation occurring in familial disorders has been reported, the 
mutation if known has been due to a triplet repeat mutation(139). However, the 
mutation in HMs has not been identified, although three genetic regions have been 
suggested to be involved in HMs; a locus on 21q22.1-22.2, a locus on 11q23.3 and a 
locus on 16q22 (10). It is interesting to note that the two families from the 13 
Tasmanian families that do not show a consistent decrease in age at diagnosis, were 
those families in which there was consanguinity involved (LK16 and LK836). Both 
of these families were selected because of a cluster of affected siblings whose parents 
were first cousins, suggesting that a different genetic mechanism (recessive 
mutation) is involved in these families (163). 
Consanguinity is a feature of some of the families in this study, in particular families 
LK16, LK836 and LK2. Consanguinity in these families consists of first cousin 
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marriages. There were six sets of consanguineous marriages, which resulted in 27 
children, of whom 11 were affected with a HM. A Japanese study from the 1970s 
found a significant increase in the number of consanguineous marriages in families 
with familial AML compared to the general population(12). It is known that 
consanguineous marriage leads to an increased prevalence of infants with recessive 
disorders(164). Therefore, a recessive mutation may be implicated in these families. 
It should be noted the LK2 family that does have consanguineous marriages also 
shows anticipation. This raises the possibility that the genetic predisposition in this 
family is not due to simple Mendel’s genetics, but rather due to a more complex 
genetic predisposition. 
The clinical features of the HMs in these 13 families studied were also reviewed. 
Three cases of primary CNS lymphoma were noted in the LK124 family. This is a 
rare site for lymphoma to present(165). The LK16 family consisted of 5 affected 
siblings with a HM, 4 with CLL and one with DLBCL. Houlston et al. 2003 has 
reported in the literature that “a family with three siblings affected by chance would 
be expected to occur once every 100 years in the UK”(11), thus making the LK16 
family in Tasmania with five affected siblings, where the population is significantly 
smaller than in the UK, is extremely rare. In fact, in these 13 Tasmanian families, 
there is 1 set of 5 siblings affected by a HM, 1 set of 3 siblings affected and 11 sets 
of affected sibling pairs.  
In the LK2042 family, CNS involvement is noted in a case of CLL, which according 
to the literature, is rare, as there are only 24 reported cases of this occurring(166). 
There was also an unexpectedly low number of CLL cases in these Tasmanian 
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families, as CLL is reported to be the most common leukaemia in western 
countries(6). In these families there were more cases of ALL or AML than CLL.  
The current Tasmanian survey of living affected people registered by the TCR 
revealed no new large families with HMs; however, approximately 20% of those 
who responded, had a positive family history of a HM. This is compared to 8% found 
by Chang et al. 2005(3), in the Swedish population. The higher positive rate in the 
Tasmanian population may reflect the low response rate to the survey (25%) and the 
response rate bias of people with a positive history being more inclined to respond to 
the survey than someone who has a negative family history. 
It is clearly recognised in the literature that there is a genetic basis for the familial 
risk of HMs(3-17, 19, 22-24, 130, 167, 168). However, although genome-wide 
studies have identified several genetic loci, these only account for approximately 3% 
of the inheritable risk(149). Additional loci for CLL and ALL have been recently 
published, but the SNPs identified so far for CLL are still reported to account for 
only 10% of the inheritable risk(144). There is evidence provided by other 
studies(169) of familial disease (Parkinsons disease) where application of high-
density genotyping and next generation sequencing to the study of familial disease 
will enable the identification of those rare alleles. These studies are likely to 
complement genome wide association studies, which are not designed to detect the 
rare alleles. Further study of these 13 Tasmanian families will be able to further 
explain the heritable risk in HMs. 
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4. Chapter 4: The LK16 family with 5 affected siblings from a consanguineous 
marriage 
4.1. Introduction 
Large families with multiple cases of HMs are rare(19). The vast majority of families 
that are reported in the literature have familial CLL(6, 8, 11, 15, 18, 170, 171). The 
largest reported pedigree was an Australian family(136). This family reported by 
Fuller et al. 2008, consists of 11 subjects with CLL over 3 generations, with several 
members of the fourth generation having monoclonal B cell lymphocytosis 
(MBL)(136). Another large CLL pedigree reported by Lynch et al. 2002, consists of 
a father and 4 sons affected with CLL(170), and more recently reported a third 
generation with CLL(25). This is the only family in the literature where a germline 
mutation has been identified and this mutation results in decreased expression of 
DAPK1(25). 
A genome-wide linkage study of 206 families with CLL (18) investigated the 
familial cause of CLL. This linkage study failed to find a definitive genetic cause, 
however it found that the region showing maximum nonparametric linkage was to 
chromosome 2q21.2; and two other regions also showed significant linkage  (6p22.1 
and 18q21.1)(18). The region on 6p22.1 was a recessively acting locus in contrast to 
a dominantly acting locus on 18q21.1(18).  
There are many types of SNP arrays available for use, such as oligonucleotide arrays 
(Agilent), Affymetrix SNP arrays and Illumina SNP arrays(172). The Affymetrix 
GeneChip® 250k Nsp SNP array was selected, as it was the most cost effective high 
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density SNP array available for use. It contains over 262,000 SNPs and uses 
established technology from the GeneChip® Mapping 10K array. 
The LK16 family was chosen to study first as there were 5 siblings affected with a 
HM whose parents were first cousins. Their mother was also affected with a HM and 
died as a result of CML in 1943 and six other members of this family are also 
affected with a HM. A pedigree is given in chapter 3.3.4. It is stated in the literature 
that “a family with three affected siblings would be expected to occur by chance 
approximately once every 100 years in the UK” (173), thus this represents a very rare 
family, even considering the purported selection bias that exists in the identification 
of families featuring a high aggregation of cases. There are a total of 12 subjects 
affected in this family across 3 generations.  
It is known that the offspring of consanguineous relationships are at an increased risk 
of recessive disorders(163, 164), as they inherit the same mutation from each parent. 
It is hypothesized in this family that the five siblings are homozygous for a region of 
the genome where the mutation is located. Therefore offspring of the affected 
siblings will be heterozygous for this region.  
 
4.2. Materials and Methods 
4.2.1. Sample Collection 
Living affected members and first-degree relatives of deceased affected members 
were contacted and asked to consent to participate in this study and to provide a 
blood or saliva sample for DNA extraction as described in Chapter 2.1. DNA from 
LK16-1, LK16-106, LK16-4, LK16-5, LK16-6, LK16-7, LK16-8, LK16-11, LK16-
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15, LK16-16 and LK16-3 were sent to the Australian Genome Research Facility for 
genome-wide Affymetrix GeneChip Human Mapping 250K Nsp SNP Array. 
4.2.2. Locating Pathology samples 
Formalin fixed paraffin embedded tissue (FFPET) was located at Bendigo hospital 
on LK16-14, who was diagnosed with melanoma from a skin biopsy in July 1978. 
FFPET from LK16-12 was located from Launceston Pathology and consisted of a 
skin biopsy and an ethmoid sinus biopsy. FFPET from LK16-9 was located from 
Launceston General Hospital and consisted of a gastrointestinal biopsy. Bone 
marrow biopsy samples from LK16-101, LK16-87, and LK16-50 were located from 
the RHH and peripheral blood from LK16-108 who was diagnosed with multiple 
myeloma in January 2008. DNA was extracted as per Chapter 2.2. 
4.2.3. Statistical analysis 
Affymetrix GeneChip® Human Mapping 250k Nsp SNP Array data was analysed by 
Dr Devindra Perera using Merlin (Gonalo Abecasis) analysing the genotypes of the 
genome where LK16-1 was homozygous and the children of the other affected 
siblings were heterozygous (IBD sharing). Haplotype analysis was performed using 
Merlin (Gonalo Abecasis) and HaploPainter. Pedigrees were drawn with Smartdraw 
version 5.0. 
4.2.4. PCR primers 
Primers for microsatellite markers and genes were designed and optimised as per 
Chapter 2.6. Sequencing of genes was on an ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems) as described in Chapter 2.8. 
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4.2.5. Conventional Cytogenetics and FISH 
Lithium heparin peripheral blood samples were obtained from LK16-4, LK16-15 and 
LK16-16. Chromosome preparations were obtained as described in Chapter 2.9.  
FISH probes for IGH@, 13q14, 13q34, CEP(12), TP53 and ATM were obtained from 
Vysis (Abbott Molecular, Australia) and used as described in Chapter 2.10. 
4.2.6. Laser Microdissection of the region of interest 
Chromosome preparations from LK16-15, LK16-16 and LK16-4 were obtained. The 
region of interest on chromosome 15 was dissected (as described in chapter 2.12), 
DNA isolated (as described in Chapter 2.2) and whole genome amplified using 
GenomePlex® (Sigma-Aldrich) (as described in Chapter 2.4). 
 
4.3. Results 
4.3.1. Statistical analysis of the Affymetrix GeneChip®  Human Mapping 250k 
Nsp SNP Array  
At the time of this study only one of the affected siblings (LK16-1) was alive, and he 
died of his disease shortly after consenting for this study. His child and children of 
his deceased affected siblings (LK16-9, LK16-12 and LK16-2) and his sole surviving 
sibling (LK16-4) consented to participate in this study. The other affected sibling 
LK16-14, had no children.  Figure 4.3.1.1 highlights the sub-pedigree structure of 
those who participated in the study. The genotypes were analysed using a SPLITPED 
analysis by Merlin (Gonalo Abecasis) analysing for areas of the genome where 
LK16-1 was homozygous and his nieces and nephews were heterozygous for that 
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region (IBD). Therefore implying that their parents (LK16-1’s siblings) were at least 
heterozygous for that region. 
Figure 4.3.1.1: A pedigree of LK16 family used in the initial analysis. 






 

 









  

 
 
This analysis identified two regions, one on chromosome 4 and the other on 
chromosome 15, as shown in Figure 4.3.1.2. DNA extracted from FFPET from the 
affected siblings was used to confirm which of these two regions of homozygosity in 
LK16-1 his siblings shared.  
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Figure 4.3.1.2: Regions of IBD sharing on chromosome 4 and chromosome 15. 
 
The combined regions where LK16-1 is homozygous and nieces and nephews’ are 
heterozygous are the regions within the red box (chromosome 15: 30000000-
38000000 and chromosome 4: 150000000-171000000). 
 
4.3.2. Confirming the region of homozygosity in the other affected siblings 
4.3.2.1. Microsatellites 
Chromosome 4 region 
Six microsatellites were chosen across this region (D4S2962, D4S3049, D4S2980, 
D4S2918, D4S2952, D4S1597).  Not all primers would hybridise with the low 
quality DNA obtained from the FFPET. Table 4.3.2.1 shows the allele sizes for these 
microsatellites for the siblings. It was concluded that the other siblings are not 
homozygous for this region on chromosome 4.  
 
 
 
 
Combined 
 
 
LK16-106 
 
LK16-5,6,7 & 8 
 
 
LK16-15 & 16 
 
LK16-1 
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Table 4.3.2.1: Microsatellite results for the chromosome 4 region 
Microsatellite Position LK16-
1* 
LK16-
12 
LK16-9 LK16-
14 
LK16-4 
D4S2962  Chr4:150583446-
150583787 
132/132 132/132 132/132 132/142 132/142 
D4S3049  chr4:154993900-
154994255 
231/231  231/226 231/244 231/221 
D4S2980  chr4:160827646-
160827989 
146/146  146/144 146/148 146/148 
D4S2918  chr4:160548592-
160548915 
160/160  160/162 160/162 160/162 
D4S2952  chr4:166675026-
166675407 
186/186 186/186 186/186 186/188 186/186 
D4S1597  chr4:170079690-
170080082 
274/274  274/274 274/274 274/274 
*LK16-1 is homozygous for this region 
 Chromosome 15 region 
Ten microsatellites were chosen across this region (D15S144, D15S995, D15S1040, 
ACTC, D15S971, D15S118, D15S102, D15S194, D15S1044, D15S214). Table 
4.3.2.2 shows the results for this region for the siblings.  
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Table 4.3.2.2: Microsatellite results for the chromosome 15 region 
Microsatell
ite 
Position LK16-1 LK16-12 LK16-9 LK16-
14 
LK16
-4 
D15S144  chr15:313881
79-31388405 
158/158 158/152 158/158 158/158 158/1
58 
D15S995 chr15:314537
71-31454043 
192/192  192/192 192/192 192/1
92 
D15S1040  chr15:319136
62-31913895 
203/203  203/203 203/203 203/2
03 
ACTC chr15:328706
97-32870925 
232/232 232/232 232/232 232/232 232/2
32 
D15S971  chr15:331711
20-33171439 
214/214  214/214 214/214 214/2
14 
D15S118  chr15:340240
22-34024377 
218/218 218/218 218/218 218/218 218/2
18 
D15S102  chr15:357628
75-35763087 
210/210 210/210 210/210 210/210 210/2
10 
D15S194 chr15:361363
29-36136718 
251/251  251/251 251/251 251/2
51 
D15S1044  chr15:374562
54-37456576 
180/180  180/180 180/180 180/1
80 
D15S214 chr15:381875
26-38187868 
264/264 264/264 264/264 264/264 264/2
64 
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The microsatellite sizes were also assessed on the offspring of the affected siblings 
(LK16-106, LK16-11, LK16-5, LK16-6, LK16-7, LK16-8, LK16-15 and LK16-16) 
and they all shared the haplotype in the heterozygous state. This helped to confirm 
the reliability of the microsatellite results form the DNA extracted from the FFPET. 
The microsatellite data confirmed that this was a region shared in a homozygous 
state by the affected siblings and therefore indicated that the chr15: 30000000-
38000000 is the region of interest in this family.  
4.3.2.2. Affymetrix GeneChip® Human Mapping 250k Nsp SNP Array 
using DNA from FFPET 
DNA was extracted from FFPET from LK16-14, LK16-9 (affected siblings of LK16-
1) and LK16-87 (distant relative with CLL). This was sent to the AGRF for the same 
genome-wide Affymetrix GeneChip Human Mapping 250k Nsp SNP Array. 
Assessing Mendelian errors using Merlin (Gonalo Abecasis) between offspring and 
parent pairs enabled the quality of the SNP array results on the FFPET samples to be 
compared. There were two parent offspring pairs (LK16-1, LK16-106 and LK16-9, 
LK16-11). There were 782 SNPs in the region of interest on chromosome 15 from 
the Affymetrix GeneChip® Human Mapping 250k Nsp SNP Array. There was a 
12.5% Mendelian error rate between LK16-11 and LK16-9, compared to an error 
rate of 0.02% between LK16-1 and LK16-106. There was also a very high no-call 
rate on the samples that were from FFPET (LK16-9 was 26.9%: LK16-14 was 
27.9%) compared to 2.5% for the peripheral blood sample from LK16-1.  Both the 
no-call rate and Mendelian error rate were considered too high and therefore the 
Affymetrix GeneChip® Human Mapping 250k Nsp SNP Array results from the 
FFPET were not reliable and could not be used.  
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4.3.3. Genes 
In the area of interest on chromosome 15, there are 33 genes, many of which have 
many isoforms. The functions of genes were reviewed in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), however there was no obvious candidate. 
Several genes that had been implicated in carcinogenesis were sequenced first. The 
following genes have been sequenced: AVEN, GPR176, MEIS2, PGBD4 and 
C15orf41.  No mutations were found in the coding regions, 5’UTR, 3’UTR or 500bp 
either side of the gene.  
 
4.3.4. Haplotype in distant affected relatives in the LK16 family 
There are a total of 12 people affected with a HM in this family. An abbreviated 
pedigree of this family is shown in Figure 4.3.4.1. This shows the other affected in 
this family and who was alive and consented to participate in this study. 18 children 
of affected deceased members agreed to participate in this study. 
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Figure 4.3.4.1: Extended pedigree of LK16 including all who have consented to 
participate in this study. 
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Microsatellite analysis for the full region of homozygosity was assessed on all 
available people in this family. The other affected people in this family are LK16-50 
(DLBCL), LK16-87 (CLL), LK16-101 (DLBCL and AML), LK16-77 (AML) and 
LK16-108 (MM) as shown in Figure 4.3.4.1. As the siblings were homozygous for 
the region on chromosome 15, by default their parents LK16-18 and LK16-17 must 
also be heterozygous carriers of this region. Thereby implying that their fathers 
(LK16-40 and LK16-44 respectively, whom are brothers) are also heterozygous 
carriers and either inherited this from their mother (LK16-61) or father (LK16-60). 
As the grandfather (LK16-46) of LK16-50 and the great-grandfather (LK16-19) of 
LK16-28 are also brothers of LK16-40 and LK16-44, there is a 50% chance that 
these two people (LK16-19 and LK16-46) were also carriers of this haplotype. If 
they did in fact inherit this haplotype as well, then there is a 12.5% chance that 
LK16-28 is also a carrier of this haplotype and 25% chance that LK50 is a carrier. 
From microsatellite and SNP analysis across the larger chromosome 15 region, they 
did not share this haplotype  
4.3.5. Chromosome analysis 
Conventional cytogenetic analysis was undertaken in the family to exclude a 
structural chromosome abnormality segregating in this family, especially at the site 
of the region of interest on chromosome 15. The chromosome analysis revealed a 
normal male karyotype for LK16-4 (Figure 4.3.5.1) and LK16-16 (Figure 4.3.5.2). 
However LK16-15 (Figure 4.3.5.3 normal) showed a translocation between the long 
arm of chromosome 12 and the long arm of chromosome 14 and a deletion of the 
long arm of chromosome 13 (Figure 4.3.5.4) in approximately 5% of cells. This was 
further investigated by FISH with a Vysis IGH@ dual colour break-apart probe. This 
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confirmed an IgH rearrangement (Figure 4.3.5.5) and deletion of the long arm of 
chromosome 13 in approximately 5% of cells. 
 
Figure 4.3.5.1: LK16-4 normal male karyogram. 
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Figure 4.3.5.2: LK16-16, showing a normal male karyogram. 
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Figure 4.3.5.3: LK6-15, showing a normal male karyogram. 
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Figure 4.3.5.4 : LK16-15 abnormal cell 46,XY,t(12;14)( q23;q32),del(13)(q12q25). 
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Figure 4.3.5.5: LK16-15 FISH result for IGH@ dual colour break-apart probe. 
 
 
Two interphase cells are shown. The cell on the right shows two intact IGH@ probes 
(normal), however the cell on the left shows one intact IGH@ probe and one IGH@ 
probe that has split into its individual probes (3’IGH@ and 5’IGH@) confirming a 
rearrangement of this gene. 
4.3.6. Laser microdissection of the region of interest on chromosome 15. 
To enable next generation sequencing of the entire region of interest on chromosome 
15 in this family, laser microdissection using the PALM laser microdissector (Zeiss, 
Germany) was undertaken on chromosomes from LK16-4 (homozygous for the 
region of interest), LK16-15 (partial heterozygous) and LK16-16 (full heterozygous). 
This enabled purification of the region of interest for DNA extraction and 
amplification using GenomePlex® (Sigma-Aldrich). The amplified DNA was sent to 
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the Australian Genome Research Facility for next generation sequencing. Figure 
4.3.6.1 shows the region that was dissected and Figure 4.3.6.2 shows a before and 
after photo of the dissection process.  
Figure 4.3.6.1: Region dissected 15q14 to 15q22.2 
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Figure 4.3.6.2: A typical metaphase showing two chromosomes 15 
(red arrow) free from cross-overs with other chromosomes prior to dissection 
(before and after). 
 
The red arrows point to the two chromosomes 15 in this metaphase.  
 
The red dots highlight both chromsomes 15 and show the region under the dot that 
was dissected off the slide by the laser.  
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4.4. Discussion and Conclusions 
The sub-pedigree structure of the LK16 family with five affected siblings from a 
consanguineous marriage is highly suggestive of a recessively acting mutation with 
incomplete penetrance. One region in the genome was found where all the affected 
siblings were homozygous. However it is known that at least one additional mutation 
has occurred in LK16-1s’ genome for the CLL to develop (deletion identified on 
chromosome 13q14) and that LK16-4 is also a homozygous carrier for the region of 
interest but is unaffected; he at the age of 83 years has not currently developed a HM.  
During the course of this study, a reciprocal translocation and a chromosome deletion 
was discovered in LK16-15, who is the child of LK16-12. The translocation was 
between the long arm of chromosome 12 and the long arm of chromosome 14 
involving the IGH@ locus, which was confirmed with a fluorescently labelled locus 
specific identifier break apart probe for the IGH@.  This translocation has been 
previously reported to occur in CLL(174). The deletion of the long arm of 
chromosome 13 is the most common cytogenetic abnormality seen in CLL(175), and 
this was also present in LK16-1. Further diagnostic testing of LK16-15 confirmed a 
population of lymphocytes that were co-expressing CD5, CD19, CD20, CD23 and 
showed an excess of lambda light chains. With the lymphocyte count in this person, 
this was consistent with MBL. It was intriguing to note that in this person (LK16-
15), these cells showed lambda light chain expression as it has been reported in the 
literature, for MBLs to preferentially express lambda light chains, when there should 
be more cases of kappa light chain restriction(176) as there are more lymphocytes 
that express kappa then lambda in a normal person. 
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MBL is an abnormal monoclonal B lymphocyte population that is considered pre-
malignant(1). It is found in approximately 0.3%-3.5% of the general population (176, 
177); but in families with CLL the incidence is reported to be increased at 
13.5%(177) to 16%(176). Currently, with MBL it is unknown how many of these 
patients who will subsequently develop CLL(176).  
LK16-15 was the person who critically defined the lower limit of the region of 
interest to 37872929bp. Both LK16-1 and LK16-4 are homozygous on chromosome 
15 from 30301633 to 57481797bp. All the other offspring of the siblings (LK16-106, 
LK16-5, LK16-6, LK16-7, LK16-8, LK16-11 and LK16-16) are heterozygous from 
30301633 to 57481797bp.  
A genome-wide association study identified 6 risk alleles for CLL(18), and a study 
by Crowther-Swanepoel et al. 2010 identified and additional 4 risk alleles(130). The 
risk increases for each risk allele a person carries. LK16-1 carries 4 of these risk 
alleles and therefore has an odds ratio of 2.23. LK16-4 (the unaffected brother of 
LK16-1, who is homozygous for the chromosome 15 region) carries 5 risk alleles. 
Interestingly LK16-15, who is the son of LK16-12 and the person whom has MBL 
and critically defines the lower limit of the region of interest, carries 5 risk alleles; 
whereas his brother (LK16-16) only carries 3 risk alleles. However it must be noted 
that that the authors of this paper, Di Bernardo et al. 2008(18), estimate that “the six 
loci we have identified to date through our GWAS account for ~3% of the excess 
familial risk of CLL”. The ten risk alleles identified account for approximately 10% 
of the heritable risk in CLL(130). Therefore this is a complex disease with many 
variants involved and it is unlikely that these six loci account for the increased risk in 
the LK16 family. 
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DNA extracted from FFPET is prone to degrade and results in fragmentation of the 
DNA. A recent study found that high-molecular weight DNA can be extracted from 
FFPET only if it has been stored for less than 6 months(178); and using DNA from 
FFPET samples older than 6 months greatly decreases the chances of detecting point 
mutations, deletions and triplet repeat expansions in these samples(178).  It has also 
been reported that assessing microsatellite size in FFPET from tumour samples 
requires caution as microsatellites can be unstable in tumour tissue and loss of 
heterozygosity in the tumour tissue may cause false homozygous results(179). The 
age of the FFPET samples from some of the subjects in my study ranged from 
several years to decades. The DNA was highly fragmented and was found not to be 
suitable for SNP array. It was also found that some of the PCR primers for the 
microsatellite analysis would not hybridise to the fragmented DNA, and the DNA 
from LK16-12 was the most highly fragmented compared to the other samples. 
However as the results from the FFPETs could be confirmed by checking for 
Mendelian errors with siblings and offspring, they could be confidently called in 
these samples. However DNA from FFPET was crucial to confirm the initial SNP 
analysis by using DNA extracted from LK16-14, as he was not represented in this 
initial analysis, as he had no children. The results from the microsatellite analysis of 
LK16-14 independently helped to confirm the region on chromosome 15 in this 
family. 
From the combined microsatellite and SNP data on both the siblings and offspring it 
was concluded that the region of interest in this family was chromosome 15q14 
(30919517 to 37872929) and that genes in this region should be sequenced. Although 
it was recognised that LK16-1 and LK16-4 were actually homozygous from 
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30919517 to 57481797 on chromosome 15. There were 33 genes in the smaller 
region of homozygosity. There were no obvious candidate gene and no other reports 
in the literature that implicated this region. Several genes in this region were 
sequenced, but no mutations found. 
It is always possible that one of the siblings developed a sporadic HM, therefore it 
was decided to dissect the larger region of homozygosity (30919517 to 57481797) on 
chromosome 15 from chromosomes from LK16-4, LK16-15 and LK16-16, as the 
region was narrowed to only one nephew (LK16-15).  The laser dissection approach 
was chosen as the method for isolating the target segment of DNA. Next generation 
sequencing requires enrichment of the target DNA prior to sequencing(180). 
Currently most studies are doing this by capture-based enrichment methods(155, 
181, 182).  However, these methods have some limitations: they require the prior 
knowledge of the sequence that is to be sequenced, they are not suitable for when 
rare sequence rearrangements are present; they do not include regions that were not 
sequenced by the Human Genome Project, such as peri centric heterochromatin, 
regions where there are no known genes (most are exon capture methods); and they 
are not suitable for when there are mutations corresponding to capture sites (180). 
Chromosomal dissection of the region of interest avoids all of these problems (180) 
and was undertaken in this family.  
However, the next generation sequencing of the microdissected chromosomes was 
unsuccessful, and the reads were non-specific. It was thought that this was probably 
due to the whole genome amplification process, as several microsatellite analysis of 
DNA from the dissected chromosomes prior to amplification was successful for 
microsatellites located on the chromosome 15 region and negative for other regions 
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in the genome. Previously, whole genome amplification has been found to cause 
artefact nucleotide sequence alterations(183) and fragmentation from the laser 
dissection.  
The study of the LK16 family identified a region of interest where the five affected 
siblings were homozygous on chromosome 15. 
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5. Chapter 5: Genome-wide Illumina 610 Quad Array of the 13 families. 
5.1. Introduction 
Using families with multiple cases of a particular disease is a proven method (linkage 
analysis) of discovering causative genetic mutations. Mutations in BRCA1, TP53, 
RB1, were originally found by linkage studies using families enriched for their 
respective disorders(28, 93, 120).  Although there are hundreds of families with HMs 
in the literature (17), only one mutation in one family has been found (25). However, 
most of the families with HMs in the literature are relatively small (with only 2-3 
affected members)(18).  
Many of the families reported in the literature are being revisited (184) and linkage 
analysis is being carried out with new high-density SNP arrays (18). There has been 
several genome-wide linkage analysis studies reported in the literature in families 
with HMs(18, 136-138). The largest of these was by Sellick et al. 2007, who studied 
206 families with CLL(18).  This study was performed in two parts: phase 1 
consisted of a genome-wide linkage scan using the GeneChip® Mapping 10Kv131 
Xba array containing 11555 SNP markers (Affymetrix); and phase 2 consisted of 
samples genotyped with over 10204 SNP markers on version 2.0 of the Affymetrix 
10K array(18). There were 105 families in phase 1 and 101 families in phase 2, 
comprising a total of 155 families with CLL and 51 families with CLL and other B 
lymphoproliferative disorders(18). In total there were 550 people with CLL, NHL or 
HL(18). This equates to a mean of 2.66 affected subjects per family (550/206). This 
is in contrast to the 13 Tasmanian families in which there are 130 subjects affected; 
which equate to a mean of 10 affected per family. Sellick et al. 2007, found evidence 
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of linkage to 2q21.2, 6p22.1 and 18q21.1(18). Fuller et al. 2007, found evidence in 
one family with CLL of linkage to 2q37, 4q35, 11p15 and 14q24(136); whereas Ng 
et al. 2007, found evidence of linkage in 6 families to 13q21.33-22.2(137). 
There have been several genome-wide association studies (GWAS) in HMs that have 
been reported in the literature(144, 145, 147-149, 185, 186); three of these were in 
CLL(144, 147, 149, 185), two were in childhood ALL(145, 148) and one was in 
NHL(186). These genome-wide association and linkage studies have identified many 
genetic regions of interest in HMs, however these loci account for a low percentage 
of the heritable risk of HMs(130). 
The structure of the human genome is more complicated than was first 
predicted(187-191). It is now realised that immense variation exists and that this 
ranges from SNPs to large chromosomal abnormalities(191). There are now studies 
discovering copy number variation (CNV) that range in size from kilobases to 
megabases(191). These studies have shown that CNVs are heterogenous throughout 
the genome and that no part of the genome is exempt(191). It has also been found 
that CNVs can predispose to disease(187); and that most new genome-wide SNP 
arrays include markers that can be used for CNV analysis.  
There are many types of SNP arrays available for use; oligonucleotide arrays 
(Agilent), Affymetrix SNP arrays and Illumina SNP arrays (172). The Illumina 610 
Quad array was chosen for the current study as it can be used for both SNP and CNV 
analysis and it is cost efficient.  
Kidd et al. 2008, identified 255 loci across the genome that are sites of CNVs in 39 
unrelated individuals(187). They found that CNVs are common to unrelated subjects; 
and that the CNVs can be in regions where genes are present; and that many CNVs 
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coincide with segmental duplications in the human genome(187). The CNVs in this 
paper are shown in Figure 5.1.1.  
Genome-wide SNP arrays have also been used on tumour samples to assess CNV 
and for loss of heterozygosity (82, 154, 172, 192). One study using both a 10K and 
50K SNP array on CLL samples found acquired chromosomal abnormalities in 74% 
of patients, a higher abnormality rate was present on the 50K SNP array compared to 
the 10K SNP array (192). The most common abnormality found was a deletion of 
chromosome 13q14 in 53% of patients(192).  
The aim of the SNP array in the 13 Tasmanian families was to identify regions of the 
genome that the affected individuals share in families and across families. This will 
allow for further investigations of genes that are located in these regions. 
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Figure 5.1.1: Reported regions of copy number variation 
 
Gains in blue, deletions in red, green circles to the left indicate known 
genome sequence gaps or known segmental duplications)(187). 
 
5.2. Materials and Methods 
5.2.1. DNA from alive affected and first-degree relatives of deceased affected 
family members 
Living affected members of the 13 families (as described in Chapter 3) were 
contacted and asked to provide a blood or saliva sample for DNA extraction (as 
described in Chapter 2.1). First-degree relatives of deceased affected members were 
also contacted and asked to participate and to provide blood or saliva for DNA 
extraction. DNA was extracted as described in Chapter 2.2.  
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5.2.2. Statistical analysis 
Several types of statistical analysis were undertaken on the genotyping data 
generated using the Illumina 610 Quad array. Due to the large size of these families 
and the number of consanguineous marriages, alternative approaches to traditional 
linkage analysis had to be implemented. These were an identity-by-descent (IBD) 
sharing approach to identify regions of the genome shared by pairs of cases; a novel 
family based association analysis; and a standard copy number variation analysis. 
 
IBD Analysis: 
This was inferred by Dr Russell Thomson. Identity-by-descent (IBD) between all 
pairs of cases across all families was inferred.  PLINK(193) stripped down the set of 
SNPs to 51,043 SNPs that are not in linkage disequilibrium (LD) with each other.  
Allele frequencies and LD were estimated using a sample of 373 Tasmanian 
unrelated controls.   Therefore the number of pairs of cases that shared an allele IBD 
across the genome (similar to the Spairs statistic(194)) could be generated for each 
SNP. These statistics followed a Poisson distribution. This property was then used to 
convert the statistics into p-values.   
Family based SNP association: 
This association was done by Dr Jac Charlesworth. This tested for significant 
differences between the allele frequencies of cases and controls, taking into account 
the relationships between cases. Genotypes for deceased cases were imputed using 
Merlin-based imputation procedure implemented in PEDSYS(195). Genotypes were 
not directly imputed; rather genotype covariates were calculated, ranging between 0 
and 2, representing the observed or expected number of minor alleles. These 
numbers were translated back into actual genotypes for integral values of the 
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covariate (±0.1). These inferred genotypes for the cases were combined with the 
genotypes of a dataset comprising unaffected Tasmanian controls (n=373). Then 
tested for association at each SNP by calculating three log likelihoods: firstly the log 
likelihood of the observed cases genotypes alone; secondly of the observed controls 
genotypes alone; and thirdly of the combined genotypes. The difference between the 
combined log likelihood and the sum of the other two log likelihoods is 
asymptotically distributed as a chi-square variate with 1 degree of freedom.   
Copy Number Variation analysis: 
This was analysed by Dr Patrick Danoy with PennCNV software. PennCNV 
implements a hidden Markov model that integrates multiple sources of information 
(considers SNP allelic ratio distribution as well as signal intensity) to infer CNV calls 
for individual genotypes samples(196).  
5.2.3. Fluorescence in situ hybridisation (FISH) 
Fosmid probes were ordered from The Hospital for Sick Children in Canada to cover 
the regions of the genome identified by the CNV analysis in order confirm the 
number of disease associated alleles in the family members. FISH was performed as 
described in Chapter 2.10. 
5.3. Results 
5.3.1. Patient recruitment 
A total of 258 people from these 13 families consented to participate in this study. 
An Illumina 610 Quad SNP array was carried out on 117 subjects from the 13 
Tasmanian families. Of these 117 people, 18 previously were affected with a HM, 3 
currently had circulating disease cells from a HM, 89 were offspring of a deceased 
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affected, 2 were a related spouse of an affected and 5 were siblings or parents of a 
deceased affected. In total, 78 out of 130 affected cases were represented in the 
genome-wide SNP array (Table 5.3.1). The HMs represented by these 78 is shown in 
Table 5.3.2. 
Table 5.3.1: Subjects submitted for the 610 Illumina SNP array 
 Affected Offspring of Disease 
LK1-1 Yes  MALT 
LK1-5  LK1-3 HLMC 
LK1-62  LK1-58 RAEB 
LK1-64  LK1-58  
LK1-91  LK1-80 MM 
LK1-94  LK1-80  
LK1-103  LK1-100 RAEBII 
LK2-11  LK2-9 NHL 
LK2-14  LK2-9  
LK2-22  LK2-21 MDS 
LK2-24  LK2-21  
LK2-35   LK2-33 (spouse and relative) CMML 
LK2-95  LK2-33  
LK2-97  LK2-1 NHL 
LK2-99 Yes  NHL 
LK2-131  LK2-30 HCL 
LK4-7  LK4-21 DLBCL 
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LK4-8  LK4-21  
LK4-12 Yes  HL 
LK4-37  LK4-39 HL 
LK16-1 Yes  CLL 
LK16-4  LK16-18 CML 
LK16-5  LK16-2 CLL 
LK16-11  LK16-9 DLBCL 
LK16-15  LK16-12 CLL 
LK16-16  LK16-12  
LK16-30  LK16-28 ALL 
LK16-31  LK16-28  
LK16-55  LK16-50 DLBCL 
LK16-59  LK16-50  
LK16-80  LK16-77 AML M1 
LK16-91  LK16-87 CLL 
LK16-92  LK16-87  
LK16-104  LK16-101 DLBCL/AML 
LK16-105  LK16-101  
LK16-108 Yes  MM 
LK26-3  LK26-1 PV 
LK26-9  LK26-8 PV 
LK26-10  LK26-8  
LK26-19  LK26-18 DLBCL 
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LK26-20  LK26-18  
LK26-23  LK26-6 FL 
LK26-24  LK26-6  
LK51-1 Yes  TNHL 
LK51-66  LK51-63 AML 
LK51-67  LK51-63  
LK51-73  LK51-70 HL 
LK51-74  LK51-70  
LK51-75  LK51-70  
LK51-79  LK51-78  AML 
LK51-93  LK51-90 HL 
LK51-94  LK51-90  
LK51-99  LK51-97 NHL 
LK51-110  LK51-106 NHL 
LK51-139  LK51-135 CML 
LK51-140  LK51-135  
LK51-158  LK51-065 DLBCL 
LK51-159 Yes  DLBCL 
LK65-28  LK65-22 DLBCL 
LK65-33  LK65-21 MM 
LK65-34  LK65-21  
LK124-15  Spouse LK124-14 (3rd cousins) AML 
LK124-16  LK124-14  
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LK124-17  LK124-14  
LK124-18 
 LK124-14 (different mother, not 
15) 
 
LK124-19 
 LK124-14 (different mother, not 
15) 
 
LK124-37  LK124-35 CMML 
LK124-43  LK124-35  
LK124-86  LK124-82 DLBCL 
LK124-87  LK124-82  
LK124-95  LK124-93 AML 
LK124-117 Yes  AML 
LK124-140  LK124-145 DLBCL 
LK124-141  LK124-145  
LK124-165  LK124-161 DLBCL 
LK124-179 Yes  DLBCL 
LK124-202 Yes  APML 
LK124-209  LK124-187 DLBCL 
LK132-16  LK132-14 CLL 
LK132-17  LK132-14  
LK132-35  LK132-31 MM 
LK132-37  LK132-31  
LK153-1 Yes  DLBCL 
LK153-3 Yes  MCL 
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LK537-1 Yes  CLL 
LK537-2 Yes  CLL 
LK836-1 Yes  CLL 
LK836-2 Yes  HCL 
LK836-6  LK836-4 NHL 
LK836-8  LK836-5 (mother) ALL 
LK836-30  LK836-4  
LK836-31  LK836-4  
LK836-53  LK836-50 (sister) ALL 
LK836-54  LK836-5 (brother)  
LK2042-3 Yes  PTALL 
LK2042-5 Yes  PBALL 
LK2042-6 Yes  HLNS 
LK2042-18  LK2042-16 PV 
LK2042-19  LK2042-16  
LK2042-20  LK2042-16  
LK2042-29  LK2042-11 WM 
LK2042-30  LK2042-11  
LK2042-50  LK2042-8 (father of) PTALL 
LK2042-56  LK2042-2 NHL 
LK2042-57  LK2042-2  
LK2042-162  LK2042-7 MM 
LK2042-163  LK2042-7  
 Page 130 
LK2042-129 Yes  MM 
LK2042-180  LK2042-134 MM 
LK2042-186  LK2042-9 ET 
LK2042-187  LK2042-9  
LK2042-197  LK2042-12 DLBCL 
LK2042-198  LK2042-12  
LK2042-203  LK2042-200 (mother of) PV 
LK2042-212  LK2042-207 PBALL 
LK2042-231 Yes  DLBCL 
LK2042-273  LK2042-270 AML 
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Table 5.3.2: Distribution of the HM subtypes genotyped in each family. 
 MPN MPN/MDS MDS AML ALL MBCN CLL MTCN HL 
LK1   2   2   1 
LK2  1 1   4    
LK4      1   2 
LK16 1   1 1 4 4   
LK26 2     2    
LK51 1   2  4  1 2 
LK65      2    
LK124  1  4  5    
LK132      1 1   
LK153      2    
LK537       2   
LK836     2 2 1   
LK2042 3  1 1 4 6   1 
Total 7 2 4 8 7 35 8 1 6 
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5.3.2. Quality review of the genotyping data. 
Missingness 
This was assessed with PLINK, and represents the number of SNPs that are not 
assessable. Ideally a missingness rate should be less than 5%(197). All the samples 
were under this limit (Figure 5.3.2.1). 
Homozygosity 
Samples LK16-4, LK16-1, LK836-1, LK836-2 and LK836-54 all had an increased 
proportion of homozygous calls (Figure 5.3.2.1). There are three explanations for 
this: firstly that there may be a region of uniparental disomy; secondly that there may 
be an acquired deletion in the tumour cells; or thirdly that the parents of the 
individuals are related. All of these subjects were products of consanguineous 
marriages and represented two families only. 
 
Figure 5.3.2.1: Missingness and homozygosity assessment of the data  
(Provided by Russell Thomson) 
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5.3.3. Copy number variants (CNVs) 
Figure 5.3.3.1a,b,c demonstrates the total number of CNVs present in each persons 
genome. There was a total of 4276 CNVs detected in these 117 subjects, of which 
695 were unique. The median number of CNVs detected in each person’s genome 
was 36.53 (range 17-92). Figure 5.3.3.2 shows all the 4276 CNVs and their type and 
location in the genome. Each row on the Y-axis on this graph represents an 
individual persons’ genome and along the X-axis is each chromosome (1 to 22) 
represented from p arm to q arm along the axis. A copy number change of 0 
(homozygous deletion) is represented by a red line at its location, a CNV of 1 
(heterozygous deletion) is represented by a green line at its location, a CNV of 3 
(heterozygous duplication) is represented by a dark blue line at t’s location, a CNV 
of 4 (homozygous duplication) is represented by a aqua line at its location and where 
there is no coloured lines the CNV is two (normal number). The specific CNVs by 
chromosome position are given in Appendix C for all 117 people. It can be seen that 
there are certain regions in the genome that are very polymorphic, especially a region 
on chromosome 4, chromosome 6 and chromosome 11; where virtually every sample 
in this analysis is polymorphic at these sites.  Figure 5.3.3.3 shows the CNVs for all 
the affected individuals, although not one is shared by all affected.  
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Figure 5.3.3.1a: Total number of CNVs present in each person in the LK1, LK2, 
LK4, LK16 and LK26 Families. 
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Figure 5.3.3.1b: Total number of CNVs present in each person in the LK51, 
LK124 and LK132 Families.
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Figure 5.3.3.1c: Total number of CNVs present in each person in the, LK153, 
LK537, LK836 and LK2042 Families. 
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Figure 5.3.3.2: Shows the location and type of CNV for all individuals. 
! !
!
! !
!
! ! !
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Figure 5.3.3.3: Shows the location and type of CNV for individuals who have been 
diagnosed with a HM. 
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5.3.3.1. CNVs in the LK1 family 
Seven subjects from this family were included in this study. One person (LK1-1) was 
affected with a HM, the other six were offspring of another four affected members 
(see Table 5.3.1). The CNVs in this family are shown in Figure 5.3.3.1.1. 
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Figure 5.3.3.1.1: Shows the location and type of CNV in the LK1 family. 
!
!
!
!
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5.3.3.2. CNVs in the LK2 family 
Nine subjects from this family were included in this study. One person (LK2-99) was 
affected with a HM, the other eight were offspring of another six affected members 
(see Table 5.3.1). The CNVs in this family are shown in Figure 5.3.3.2.1. 
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Figure 5.3.3.2.1: Shows the location and type of CNV in the LK2 family. 
!
!
!
!
! ! ! ! !
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5.3.3.3. CNVs in the LK4 family 
Four subjects from this family were included in this study. One person (LK4-12) was 
affected with a HM, the other three were offspring of another two affected members 
(see Table 5.3.1). The CNVs in this family are shown in Figure 5.3.3.3.1. 
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Figure 5.3.3.3.1: Shows the location and type of CNV in the LK4 family. 
!
!
!
!
! ! ! ! !
 
 Page 145 
5.3.3.4. CNVs in the LK16 family 
Sixteen subjects from this family were included in this study. Two subjects (LK16-1 
and LK16-108) were affected with a HM, the other fourteen were offspring of 
another nine affected members (see Table 5.3.1). The CNVs in this family are shown 
in Figure 5.3.3.4.1. 
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Figure 5.3.3.4.1: Shows the location and type of CNV for the LK16 family. 
!
! !
!
! ! ! ! !
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5.3.3.5. CNVs in the LK26 family 
Seven subjects from this family were included in this study. All seven were offspring 
of four affected members (see Table 5.3.1). The CNVs in this family are shown in 
Figure 5.3.3.5.1. 
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Figure 5.3.3.5.1: Shows the location and type of CNV for the LK26 family. 
!
! !
!
! ! ! ! !
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5.3.3.6. CNVs in the LK51 family 
Fifteen subjects from this family were included in this study. Two subjects (LK51-1 
and LK51-159) were affected with a HM, the other thirteen were offspring of another 
eight affected members (see Table 5.3.1). The CNVs in this family are shown in 
Figure 5.3.3.6.1. 
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Figure 5.3.3.6.1: Shows the location and type of CNV for the LK51 family. 
!
! !
!
! ! ! ! !
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5.3.3.7. CNVs in the LK65 family 
Three subjects from this family were included in this study. All were offspring of 
two affected members (see Table 5.3.1). The CNVs in this family are shown in 
Figure 5.3.3.7.1. 
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Figure 5.3.3.7.1: Shows the location and type of CNV for the LK65 family. 
!
!
! !
!
! ! ! ! !
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5.3.3.8. CNVs in the LK124 family 
Seventeen subjects from this family were included in this study. Three subjects 
(LK124-117, LK124-179 and LK124-202) were affected with a HM, the other 
fourteen were first-degree relatives of another seven affected members (see Table 
5.3.1). The CNVs in this family are shown in Figure 5.3.3.8.1. 
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Figure 5.3.3.8.1: Shows the location and type of CNV for the LK124 family. 
!
! !
!
! ! ! ! !
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5.3.3.9. CNVs in the LK132 family 
Four subjects from this family were included in this study. All were offspring of two 
affected members (see Table 5.3.1). The CNVs in this family are shown in Figure 
5.3.3.9.1. 
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Figure 5.3.3.9.1. Shows the location and type of CNV for the LK132 family. 
!
!
!
! ! ! ! !
 
 
 Page 157 
5.3.3.10. CNVs in the LK153 family 
Two subjects from this family were included in this study. All (LK153-1 and LK153-
3) were affected with a HM (see Table 5.3.1). The CNVs in this family are shown in 
figure 5.3.3.10.1. 
 Page 158 
Figure 5.3.3.10.1: Shows the location and type of CNV for the LK153 family. 
!
!
!
!
! ! ! ! !
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5.3.3.11. CNVs in the LK537 family 
Two subjects from this family were included in this study. Both  (LK537-1 and 
LK537-2) were affected with a HM (see Table 5.3.1). The CNVs in this family are 
shown in Figure 5.3.3.11.1. 
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Figure 5.3.3.11.1: Shows the location and type of CNV for the LK537 family. 
!
!
!
!
! ! ! ! !
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5.3.3.12. CNVs in the LK836 family 
Eight subjects from this family were included in this study. Two (LK836-1 and 
LK836-2) were affected with a HM and the remaining six were all first-degree 
relatives of 3 affected members (see Table 5.3.1). The CNVs in this family are 
shown in Figure 5.3.3.12.1. 
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Figure 5.3.3.12.1: Shows the location and type of CNV for the LK836 family. 
!
!
!
!
! ! ! ! !
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5.3.3.13. CNVs in the LK2042 family 
Twenty-three subjects from this family were included in this study. Five subjects 
(LK2042-3, LK2042-5, LK2042-6, LK2042-129 and LK2042-231) were affected 
with a HM, the other eighteen were first-degrees of another ten affected members 
(see Table 5.3.1). The CNVs in this family are shown in Figure 5.3.3.13.1. 
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Figure 5.3.3.13.1: Shows the location and type of CNV for the LK2042 family. 
!
!
!
!
! ! ! !
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5.3.3.14. CNVs shared in the tumour samples 
LK16-1, LK537-1 and LK537-2 all had CLL and all had circulating disease when 
their DNA was extracted for this study. LK16-1, LK537-1 and LK537-2 have 3 
CNVs in common; one on chromosome 13q14, a second on chromosome 12p13.31 
and a third on chromosome 4q13. All three have a deletion of chromosome 13q14 
(Figure 5.3.3.14.1) of different size, but they overlap. Chromosomal abnormalities at 
12p13 are seen in about 1.4% of cases of CLL(198); however the CNV is not shared 
in the same number by all 3 (LK16-1 has 1 copy, LK537-1 has 3 copies and LK537-
2 has 1 copy) and this region of 12p13 is a known CNV region. The third CNV that 
they share is shown in Figure 5.3.3.14.2(blue arrows). Table 5.3.3.14.1 lists all the 
people who share this duplication; This duplication has been confirmed by FISH 
(Figure 5.3.3.14.3) in LK16-15, with 3 regions for the G248P89388D9 fosmid probe 
(maps to chr4:69067720-69102943) and 2 signals for the G248P87131E4 fosmid 
probe (maps to Chr4: 69105512-69141702).  
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Figure 5.3.3.14.1: Copy number variations on chromosome 13.  
The arrow on the right points to the large deletion on LK537-1 and the two arrows on 
the left point to LK16-1 and LK537-2. 
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Figure 5.3.3.14.2: Shows the CNV on chromosome 4q13 in all 117 people.  
 
 
Each row on the y-axis is an individual samples result, they are in numerical order 
from bottom to top (LK1-1, LK1-5…LK2042-231,LK2042-273).  Blue is a CNV of 3 
(duplication), green is a CNV of 1(heterozygous deletion), red is a CNV of 0 
(homozygous deletion) and no colour is a CNV of 2 (normal).   
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Table 5.3.3.14.1: All the people who have 3 copies of the chromosome 4q13 
segment. 
Position ID HM Representing 
HM 
chr4:69047457-69087412 LK0051-140  CML 
chr4:69047457-69087412 LK2042-005 PBALL  
chr4:69064675-69087412 LK0002-022  MDS 
chr4:69064675-69087412 LK2042-231 DLBCL  
chr4:69064675-69087412 LK0124-179 DLBCL  
chr4:69064675-69087412 LK0016-015 MBL*  
chr4:69064675-69087412 LK0051-075  HL 
chr4:69064675-69087412 LK0002-011  NHL 
chr4:69064675-69087412 LK0537-002 CLL  
chr4:69064675-69087412 LK0836-053  ALL 
chr4:69064675-69097539 LK0065-034  MM 
chr4:69064675-69097539 LK0124-117  AML 
chr4:69064675-69097539 LK0016-016  CLL 
chr4:69064675-69097539 LK2042-273  AML 
chr4:69064675-69097539 LK2042-180  MM 
chr4:69064675-69115543 LK2042-030  WM 
chr4:69064675-69115543 LK2042-212  PBALL 
chr4:69064675-69117090 LK2042-029  WM 
chr4:69064675-69117090 LK2042-057  NHL 
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chr4:69064675-69126660 LK0001-062  RAEB 
chr4:69064675-69135491 LK0537-001 CLL  
chr4:69064675-69163188 LK0004-007  DLBCL 
chr4:69066337-69087412 LK0004-012 HL  
chr4:69066337-69097539 LK0026-009  PV 
chr4:69066337-69115543 LK2042-129  MM 
chr4:69066337-69117090 LK0016-005  CLL 
chr4:69066337-69117090 LK0002-131  HCL 
chr4:69066337-69117090 LK0132-016  MM 
chr4:69066337-69135491 LK0016-001 CLL  
chr4:69066337-69163188 LK0026-010  PV 
chr4:69066337-69163188 LK0004-008  DLBCL 
chr4:69076097-69117090 LK2042-162  MM 
chr4:69076097-69144894 LK0124-141  DLBCL 
chr4:69076346-69117090 LK2042-187  ET 
chr4:69085989-69117090 LK0836-001 DLBCL  
chr4:69047457-69087412 LK2042-005 PBALL  
chr4:69064675-69087412 LK2042-231 DLBCL  
*Developed MBL during the course of this study. 
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Figure 5.3.3.14.3: Two interphase cells from LK16-15, showing 3 red signals 
(duplication) and two green signals (normal) per cell. 
 
 
 
5.3.4. PLINK analysis of IBD 
The results of the analysis of the 13 families identifying regions of genotype sharing 
are shown in Figure 5.3.4.1. This paired analysis showed that the region where the 
most number of pairs are shared is on chromosome 9; the second highest region of 
sharing was on chromosome 3 and the third highest region was on chromosome 7.  
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Figure 5.3.4.1 Regions of chromosome sharing among all the families (black) 
compared to un-related Tasmanian controls (red). 
 
 
5.3.5. Results of Sequencing of genes in these regions 
5.3.5.1. Chromosome 9 peak (DAPK1) 
The primers used in sequencing this gene are given in Appendix B. No mutation was 
found in this gene. 
5.3.5.2. Chromosome 7 peak (NDUF4) 
The primers used in sequencing this gene are given in Appendix B. No mutation was 
found in this gene. 
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5.3.6. The family based SNP association analysis 
The top 5 SNPs that showed the most significant association in the families 
compared to a control dataset are listed in Table 5.3.6.1; and the reference allele 
frequencies of these 5 SNPs in Table 5.3.6.2. One of these top 5 SNPs (rs4314718) is 
near the region identified by the PLINK analysis on chromosome 9.  
Table 5.3.6.1: Highest ranking SNPs. 
SNP Chr 
Position 
(bp) Consequence Gene p-value 
rs1011313 6 15633432 INTRONIC DTNBP1 0.000007743 
rs978846 12 33128833 Gene desert  - closest: (PKP2) 0.000024000 
rs156109 5 131626611 INTRONIC SLC22A4 0.000034400 
rs4314718 9 112013469 UPSTREAM (C9orf152) 0.000041600 
rs11489600 7 102735276 
SPLICE_SITE,INTR
ONIC PMPCB 0.000046300 
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Table 5.3.6.2: Top 5 SNP hits reference allele frequency based upon HapMap 
data. 
SNP Ref Allele CEU JPT YRI 
rs1011313 T 8.4% 13.4% 0.4% 
rs978846 T 78.3% 25.6% 83.3% 
rs156109 C 31.9% 15.7% 42.5% 
rs4314718 A 67.3% 23.3% 71.7% 
rs11489600 T 33.1% 65.1% 91.8% 
 
5.4. Discussion and Conclusions 
A genome-wide SNP array in 206 families by Sellick et al. 2007, identified three 
regions in which genetic mutations were located; but no specific disease causative 
mutation was identified. This study involved 206 families representing 550 affected 
people in those families(18). This results in a mean of 2.66 affected people per 
family. This is a relatively low number of affected in each family, compared to the 
13 Tasmanian families where there is a mean of 10 people affected (2-27 people) and 
a mean of 6 (2-16) people per family represented in this SNP array. The likelihood of 
finding a mutation is increased with more densely affected families. The other 
difference between these families and the 13 Tasmanian families is that the affected 
people in the families studied by Sellick et al. 2007, all had CLL, whereas there is a 
range of different HMs in the 13 Tasmanian families. This difference, and hence the 
use of families that have different types of HMs has been postulated by Shpilberg et 
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al. 1994, as supportive evidence of the mutation being present in the pluripotent stem 
cell(19). 
Three people had circulating tumour cells at the time of their DNA collection in this 
study. Therefore, the CNVs in these 3 patients might represent acquired CNVs in 
their tumour cells. A recent study found that acquired CNVs could be detected when 
as little as 30% of the starting material is from the tumour(172). All three people 
with circulating tumour cells (LK16-1, LK537-1, LK537-2) had CLL.  
One person (LK537-1) had significantly more CNVs than anyone else genotyped (92 
compared to a mean of 35 CNVs). The increased CNVs in this subject were all due 
to a large heterozygous deletion on chromosome 13q14. Figure 5.3.3.14.1 shows the 
CNVs on chromosome 13. LK537-2 and LK16-1 also show a heterozygous deletion 
within the region that LK537-1 has deleted. A deletion of chromosome 13q14 is a 
commonly seen acquired deletion in CLL (172) and this results in the deletion of two 
microRNA genes (miR15 and 16)(199). This was the most common deletion that was 
found in a study of acquired CNVs in CLL(192). 
The CNV that these three people share on chromosome 4q13 is interesting. There is a 
gene in this region, UDP-glucuronosyltransferase (UGT2B17). UGT2B17 encodes an 
enzyme that catalyses the transfer of glucuronic acid from uridine 
diphosphoglucuronic acid to a variety of substrates including steroid hormones. This 
process, known as glucuronidation, is an intermediate step in the metabolism of 
steroids(200). 
CNVs of UGT2B17 have been reported to be associated with disease, in particular 
osteoporosis and prostate cancer (201, 202). Homozygous deletions of UGT2B17 (a 
CNV of zero) have also been implicated in causing donor-recipient mismatch in graft 
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versus host disease(203). This gene has only ever been reported in the literature to 
have 0,1 or 2 copy numbers per person (201); however, in the 117 people in this 
study, several members had 3 copies of this region. In fact 32% of people had 3 
copies of this region. This CNV analysis was repeated in another dataset of 
Australian subjects with uveitis and found that approximately 30% of these patients 
have 3 copies of this region (This analysis was done by Dr Patrick Danoy). FISH 
with fosmid probes mapped to this region were also used to confirm this duplication 
(Figure 5.3.3.14.3). It is interesting to note that in Caucasian populations this CNV 
seems to be commonly duplicated, while in Asian populations it is commonly 
deleted; which correlates with the incidence of CLL in these populations. Houlston et 
al. 2002, previously reported a CLL predisposition allele located at 4q11-q21(204); 
4q13 is in the middle of this predisposition region. Therefore, an increased copy 
number of this region may be associated with an increased risk of CLL. It would be 
interesting to assess this in a larger number of CLL patients. There were 8 CLL 
affected individuals genotyped and at least 5 of them had 3 copies of this region 
(62.5%).  
During the course of this study, LK16-15 developed MBL; therefore the CNVs that 
LK16-1 and LK16-15 had were compared to assess for a germline CNV segregating 
in this family. As they are related, it is not unexpected that they should share some 
CNVs as these are inheritable traits. It was found that they shared CNVs on 
chromosome 4 (64381774-64398956 & 69064675-69082412), chromosome 6 
(56040470-56140734), chromosome 9 (43613173-43616717), chromosome 12 
(9535285-9607393) and chromosome 13 (63231043-63277373).  It is intriguing that 
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they share the duplication on chromosome 4q13 and this would support this being a 
predisposition allele. 
PLINK analysis of IBD sharing across all the 13 Tasmanian families showed that the 
region of greatest sharing was on chromosome 9. It was interesting that this 
corresponded to a region seen in another CLL family(25), in which the only 
causative familial HM mutation (affecting the expression of DAPK1) was found. 
However this mutation and any other mutation in DAPK1 was not found in the 13 
Tasmanian families.  
As only one gene (NDUFA4) was located in the chromosome 7 region of sharing, 
this was sequenced and no mutations were identified. The region of sharing on 
chromosome 3 contains many genes, several of which have been implicated in HMs. 
The results of their sequencing in the present study are shown in Chapter 7. Formal 
linkage analysis is also underway to confirm the PLINK analysis. 
Analysis of SNPs that showed an increased association in these 13 Tasmanian 
families compared to controls identified several SNPS with a significant association 
in these 13 Tasmanian families. One region that has previously been identified in the 
literature as harbouring a predisposition allele (6p22.1)(18) is located very close to a 
SNP (rs1011313 6p22.3) identified in these 13 Tasmanian families. It is becoming 
clear in the literature that multiple genes and multiple mutations are going to be 
responsible for the heritable risk of HMs (18, 149). 
In conclusion, the genome-wide SNP array has identified several different types of 
genetic loci (SNPs, CNVs and genetic loci) that require further follow up in another 
dataset of patients with HMs. It would be very interesting to follow up these results 
in patients from different ethnic backgrounds.  
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6. Chapter 6: Cell lines and gene expression 
6.1. Introduction 
Another approach used to identify mutations in families has been to assess the 
differential gene expression in affected individuals compared to normal controls(205, 
206). In one CLL family, decreased expression of DAPK1 was found in affected 
members compared to unaffected family members(25); and subsequent sequencing 
of this gene found a SNP up-stream of DAPK1 (c.1-6531A>G) which resulted in 
increased binding of HOXB7 causing decreased expression of DAPK1(25).  
The first report of a gene expression array was published in 1996 (207).  This first 
array was based on hybridization to small, high-density arrays containing thousands 
of synthetic oligonucleotides, which in turn are based upon sequence information and 
synthesized in situ using both photolithography and oligonucleotide chemistry(207). 
There are a variety of expression microarray platforms that are available for use 
today (spotted cDNA arrays, Affymetrix GeneChip® arrays, Agilent ink-jet arrays 
and Illumina long-oligonucleotide bead-based arrays)(208). 
The Affymetrix GeneChip® Human Exon 1.0 ST array has been available for 
commercial use since 2006, and contains over six million probes targeting all 
annotated and predicted exons in the human genome(209). This array was chosen for 
this experiment because its new design allows gene expression profiling at both the 
exon level and gene level using a single array, with at least 30 distinct probes 
representing most genes(210). 
Epstein Barr Virus (EBV) transformation of peripheral blood lymphocytes can be 
used to establish permanent lymphoblastic cell lines(211). This is an established 
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method and has the following advantages: firstly peripheral blood lymphocytes are 
easy to obtain from patients; secondly EBV transformed cell lines have been shown 
to exhibit chromosomal stability; thirdly RNA/DNA can be readily extracted from 
the cell lines; and finally they are a continuous/permanent resource (211).  
EBV infects peripheral blood B lymphocytes and transforms them by altering 
cellular gene expression through the expression of viral EBNA2, EBNALP, EBNA3A, 
EBNA3C, EBNA1, and LMP1(212). When a person is infected with EBV, a 
significant percentage of their B lymphocytes are latently infected and express virus-
encoded proteins; a process called latency III infection(212). The gene expression 
profile of latency III lymphocytes is also characteristic of the gene expression in 
EBV transformed lymphoblastoid cell lines(212).  The genes that show an altered 
expression in latency III EBV infection are listed in Figure 6.1.1(212).  Whilst EBV 
transformation will affect the gene expression profile, in this analysis gene 
expression differences between the homozygous, compared to the heterozygous, 
compared to normal controls; will be assessed and EBV transformation should affect 
all samples equally.   
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Figure 6.1.1: The reported effect of changes in gene expression in latency III EBV 
infection (212). 
 
(B) Intersection of genes induced by EBV twofold or greater in both BL41EBV 
and IB4 
(C) Intersection of genes repressed by EBV twofold or greater in both BL41EBV 
and IB4 
The hypothesis in the LK16 family is that a homozygous incompletely penetrant 
gene mutation is segregating in this family. It is proposed that examination of the 
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differential gene expression in the family may provide altered gene expression data 
that could be compared with the linkage analysis. The LK16 family is described in 
Chapter 3 and Chapter 4. A region on chromosome 15 between 30919517 and 
37872929 base positions was found in this family where the affected siblings (LK16-
1, LK16-9, LK16-12, LK16-14 and LK16-2) were homozygous, with four of them 
being homozygous from 30919517 to 57481797 base positions.  
Ideally, the differential gene expression was to be assessed in the LK16 family 
(Figure 6.1.2): in multiple affected members who are homozygous for the 
chromosome 15 region; a member heterozygous for the chromosome 15 region; and 
in unrelated controls. However, this proved impossible because the last remaining 
affected sibling (LK16-1) was now deceased. However his last surviving sibling 
(LK16-4) was still alive and homozygous for the whole region on chromosome 15. A 
nephew (LK16-11) was used as the heterozygous carrier. 
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Figure 6.1.2: Pedigree of the LK16 family showing members represented in the 
gene expression and their relationship to the index case (LK16-1). 
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
 
6.2. Materials and Methods 
6.2.1. Cell lines 
Blood was collected in Ethylenediaminetetraacetic acid (EDTA) from LK16-4, 
LK16-11 and 2 unrelated males matched for age. Cell lines were made by standard 
methods using EBV to transform B lymphocytes in combination with cyclosporine 
(Sigma, Australia) to suppress a T lymphocyte response as described in chapter 2.11. 
All samples were treated in the same manner.  
 Page 182 
6.2.2. Molecular Cytogenetics  
Lithium heparin peripheral blood samples were obtained form LK16-4. Chromosome 
preparations were obtained as described in Chapter 2.9 and results reported as per 
ISCN(161).  FISH probes from Vysis (Abbott Molecular, Australia) for IGH@, 
13q14, 13q34, CEP(12), TP53 and ATM were used as described in Chapter 2.10. 
6.2.3. Statistical analysis 
RNA from LK16-4, LK16-11, and two normal controls matched for age and gender 
were sent to the Australian Genome Research Facility for genome-wide Affymetrix 
GeneChip Human Exon 1.0 ST array. The analysis of the gene expression data was 
performed by Professor Gordan Smyth and Yifang Hu of the Walter and Eliza Hall 
Institute using R (The R Foundation for Statistical Computing). The analysis was 
undertaken in 3 parts: firstly, analysis at the gene level for genes located on 
chromosome 15:30919517 to 37872929; secondly, analysis at the exon level for all 
exons located on chromosome 15:30919517 to 37872929; and thirdly, for all genes 
on a genome-wide analysis. The levels of gene expression were compared in the 
homozygous to the heterozygous compared to normal controls. 
6.2.4. PCR primers 
Primers for genes and differentially expressed exons were designed and optimised as 
per Chapter 2.8. Sequencing of genes was done on an ABI PRISM 310 Genetic 
Analyzer (Applied Biosystems) as described in Chapter 2.8. 
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6.3. Results  
6.3.1. Molecular cytogenetics 
This was undertaken to confirm that LK16-4 did not have the known common 
acquired mutations that occur in CLL. Deletions of chromosome 13q14, ATM, TP53 
and trisomy 12 are common cytogenetic abnormalities seen in CLL(213). FISH using 
the commercially available probes from Vysis (Abbott Molecular, Australia) for the 
common abnormalities found in CLL (Probe set 1:LSI D13S319/13q34/CEP 12: 
Probe set 2: LSI ATM/TP53) were normal in 200 metaphase and interphase cells 
examined. The FISH images are provided in Figure 6.3.1.1 for probe set 1 and Figure 
6.3.1.2 for probe set 2.  
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Figure 6.3.1.1: FISH image of LK16-4, using the Vysis probe set 1 for CLL, 
showing a normal metaphase cell (2 signals for 13q14 (red), 2 signals for 
13q34(aqua) and 2 signals for centromeric region of chromosome 12(green)). 
 
Figure 6.3.1.2: FISH image of LK16-4 using Vysis probe set 2 for CLL, showing 
normal interphase and metaphase cell (2 signals for ATM(green) and 2 signals for 
TP53(red)). 
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6.3.2. Statistical analysis of differential expression of individual exons and 
genes on chromosome 15:30919517-37872929 and of the all genes. 
When the region of interest on chromosome 15 (Chr15: 30919517-37872929) was 
analysed at the gene level, the most differentially expressed gene was PGBD4 
Statistical analysis of the differential individual exon expression for this same region 
found that several exons were differentially expressed. These exons and how they 
were differentially expressed are listed in Table 6.3.2.1. 
Table 6.3.2.1: Exons within the region of interest that were differentially 
expressed 
Gene Position Expression P value 
C15orf24  32175402-32175490  Increased  p=0.0269 
PGBD4  32182228-32183724  Decreased  p=0.0286 
TMEM85  32309295-32309320  Increased  p=0.0077 
LPCAT4  32441777-32441814  Decreased  p=0.0447 
GOLGA8A  32460866-32460901 Increased  p=0.0026 
GOLGA8A  32466152-32466181 Increased   p=0.0155 
GOLGA8A  32467345-32467400  Increased  p=0.0433 
ACTC1  32871902-32871926  Increased  p=0.0217 
AQR  32969743-32969809  Increased  p=0.0140 
AQR  32997799-32997871  Increased p=0.0182 
C15orf41  34771623-34771668  Increased  p=0.0570 
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TMCO5 36022837-36022861 Increased p=0.0121 
FAM98B 36553005-36553029 Increased p=0.0270 
RASGRP1 36579596-36579630 Increased p=0.0291 
RASGRP1 36595690-36595764 Increased p=0.0136 
 
Analysis at a genome-wide level found that the most differentially expressed gene 
was RNF111 (this showed decreased expression, p=1.9 x 10-5). This gene is located 
on chromosome 15: 57067157 to 57176545.  
6.3.3. Sequencing of genes and exons identified 
Exons differentially expressed 
The exons that were identified were sequenced as well as 100 base pairs on either 
side of the exon. The primers used to sequence these regions are listed in Appendix 
B. No mutations were identified in the coding regions or any splice site variations. 
PGBD4 
This gene is located on chromosome 15 at 32181566 to 32183883 base positions. 
PGBD4 stands for piggBac transposable element derived 4. It has only one coding 
exon. The primers used in the sequencing of this gene are given in Appendix B. No 
known or novel mutations were found in the sequencing of this gene or 500bp 
upstream or downstream of this gene in the LK16 family. Interestingly LK16-1 was 
AA for a SNP (RS1436923), which is located 1 base pair position upstream of this 
gene, the reference base for this position is C. However, the allele frequency for the 
A allele is 92% in the CEU population. 
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RNF111 
The ring finger protein III (RNFIII) gene is located on chromosome 15 at base 
position 57067157 to 57176545. According to UCSC genes, it has 8 isoforms and a 
total of 15 coding exons. The primers used in sequencing this gene are given in 
Appendix B. Sequencing of RNF111 found a coding mutation in exon 2 that results 
in an amino acid change at the 9th position, asparagine to lysine. LK16-1 was 
homozygous for this mutation. The allele frequency of the “GG” genotype for this 
SNP (RS289964) is 18.3% in the CEU population. The GG genotype is not seen in 
African-American or Asian populations. The results of the genotype for this SNP in 
12 unrelated CLL patients and 22 normal controls are provided in Table 6.3.3.1. 
There were an increased number of CLL patients with a homozygous “GG” at this 
SNP compared to unaffected controls (15.3% compared to 9.1%, however this is not 
statistically significant increase). 
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Table 6.3.3.1: Genotype frequency data for RS2899642 SNP in sporadic CLL 
patients and normal controls 
Genotype CLL patients Controls 
CC 38.5% 50% 
CG 46.2% 40.9% 
GG 15.3% 9.1% 
 
6.4. Discussion and Conclusions 
Gene expression profiling has been used in many types of HMs. This has mainly 
been used for assessing the gene expression profile of the HM cells: which can then 
be used to classify and predict outcome in ALL(214); MLL positive 
leukaemias(215); and mature B cell neoplasms(216). Gene expression differences 
have been used successfully in one other CLL family(25) reported by Raval et al. 
2007, and this information helped to identify a causative predisposition mutation. 
This family, when first published, consisted of a father and four sons affected with 
CLL(170). Interestingly the people affected with CLL in this family also had an 
acquired deletion of 13q14 in their CLL cells(170), just like LK16-1. This pedigree 
has been extended and a third generation is now affected with CLL(25). Linkage 
analysis in this family was to chromosome 9 between markers D9S175 to D9S1776. 
This region included 11 predicted genes and 3 known genes, one of which was 
DAPK1(25). Another study had shown an increased methylation of the DAPK1 
promoter in CLL cells(217), resulting in decreased expression of this gene. 
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Therefore, they assessed DAPK1 expression by RT-PCR and this was found to be 
decreased in this family(25). Sequencing of this gene region found a SNP (c.1-6531 
A>G) in the CLL samples, but not in normal controls. This SNP is located at a 
HOXB7 binding site and this SNP increases the affinity of HOXB7 binding which 
results in a decreased expression of DAPK1(25).  
DAPK1 expression was reduced by approximately 25% in family members who are 
carriers of this SNP; however, a further reduction in the DAPK1 expression levels 
occurred in the CLL cells due to acquired promoter methylation(25),  these patients 
also had an acquired deletion of chromosome 13q14 in their CLL cells. This finding 
supports the hypothesis that further mutations have to occur in addition to the 
germline mutation in these families for a HM to develop. Interestingly LK16-1 also 
had a deletion of chromosome 13q14 in his CLL cells; however this is a common 
deletion in CLL(175) and results in down-regulation of two micro-RNA genes 
(miR15a and miR16-1). No conventional or molecular cytogenetic abnormality was 
found in LK16-4, the homozygous surrogate for LK16-1, in particular FISH did not 
identify a deletion of chromosome 13q14. In mice RNF111 has been reported to have 
a target site for miR15a(218). 
EBV transformation of lymphocytes to make lymphoblastoid cell lines has been a 
standard technique employed for several decades(211). The gene expression changes 
of the EBV transformation process have been studied, and it has been found to result 
in similar changes to gene expression to that seen in cells that have a latent III EBV 
infection(212). It has been reported that only 38 genes have significantly altered 
expression as a result of EBV infection(212). None of these genes were identified in 
the LK16 family. None the less, it is a possibility that one of these genes was the 
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responsible gene in the LK16 family, and that the EBV process “normalised” the 
expression. However none of these 38 genes were located in the chromosome 15 
region of interest. 
The most differentially expressed gene (p=0.031) in the region of interest was 
piggyBac transposable element derived 4 (PGBD4). PGBD4 belongs to the piggyBac 
transposon family of genes(219) and there are 5 in the human genome(219).  PGBD4 
comprises a single exon and appears to be derived from the MER75 transposon(220). 
Transposons are segments of DNA that can move around to different positions in the 
genome of a single cell, and by doing so, they may cause mutations or 
increase/decrease the amount of DNA in the genome and are sometimes referred to 
as “jumping genes”(219). A SNP (RS1436923) that is 1 base pair upstream of 
PGBD4 was found to be the non-reference allele in the LK16 family; however the 
non-reference allele frequency is 92.5% in people of European ancestry and of a 
similar frequency in other ethnic groups. 
The most differentially expressed gene in the whole genome was RNFIII. RNFIII is 
located on chromosome 15 at base pair position 57067157 to 57176545. This is 
outside the region of interest; however LK16-1 (index case) and his brother (LK16-
4), whose RNA was used in the gene expression array are homozygous from base 
pair position 30301633 to 57481797 on chromosome 15; which includes RNF111. 
The region of interest is narrowed from 30919517 to 37872929 because of LK16-15 
whom only carries the haplotype to chr15: 37872929. This means that his mother 
(LK16-12), who is one of the affected siblings can only be homozygous from 
chromosome 15 base position 30919517 to 37872929 and is heterozygous from base 
 Page 191 
position 37872930 to 57481797 as her other son (LK16-16) is a heterozygous carrier 
of the full region of interest (30919517 to 57481797). 
It has been reported that the leukaemic cells in CLL accumulate from deficiencies in 
apoptosis rather than by acute proliferation(221). RNFIII encodes for a protein that 
contains a RING finger domain, which is known to be involved in protein-protein 
and protein-DNA interactions(222). The mouse version of this gene (arkadia) has 
been shown to interact with transforming growth factor beta-like factor nodal and act 
as a modulator of the nodal signalling cascade(222). Transforming growth factor-
Beta (TGF-ß) and TGF-ß related factors induce apoptosis in a many tissue 
types(223). It is known that TGF-ß appears to function in CLL as a negative 
regulator of B lymphocytes(224), and that TGF-ß induces the expression of death-
associated protein kinase (DAP-kinase) as an immediate response in cells that 
undergo apoptosis in response to TGF-ß (223). It has been found in CLL that loss of 
responsiveness to TGF-ß and a decrease in TGF-ß receptor expression in CLL cells 
might provide a selective advantage to CLL cells(224, 225). It is also known that 
DAPK1 expression is down regulated in CLL(25). Therefore it is plausible that 
RNFIII may play a role in CLL in this family, especially as it has been reported that 
genetic variants in apoptosis related genes are associated with the risk of CLL(221).  
DNA sequencing of RNF111 led to the finding of a mutation in exon 2. This is a 
known mutation of the gene (RS2899642) and results in an amino acid change from 
asparagine to lysine at the 9th amino acid position. LK16-1 was homozygous for GG 
at this SNP. This missense mutation is considered a normal variant. The reference 
allele for this SNP is C. The interesting anomaly about this SNP is its allele 
frequency in different populations. According to HapMap data the G allele frequency 
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in the CEU population is 45%, but in Japanese or African populations its frequency 
is only 10% and 0% respectively (http://hapmap.ncbi.nlm.nih.gov/cgi-
perl/gbrowse/hapmap28_B36/#search). This G allele frequency also correlates with 
the incidence of CLL in different populations; as it is the most common leukaemia in 
western countries, but rare in Africa and Asia(35). It is also known that people of an 
Asian background keep their low risk of CLL if they move to a western country(35). 
This SNP was assessed in 12 unrelated people with CLL from Tasmania and the 
frequency of the G allele was 38.5%, which is the expected allele frequency.  The 
allele frequency of this SNP was also assessed in 22 unrelated Tasmanians who did 
not have a HM, the G allele frequency was 29.5%. It would be intriguing to assess 
this SNP in people who have CLL and who are of Asian ethnicity. 
In the literature, it has been suggested “that common genetic variants with modest 
effects on disease susceptibility may be related to risk”(221). Therefore, the genetic 
causes for familial CLL and other HMs may arise as a result of the complex 
interactions of multiple genetic loci. Many of the common loci identified as 
significantly associated with CLL are common. Therefore RS2899642 may 
additionally contribute to the risk of CLL. However, this needs to be validated in 
another dataset. Due to its different allele frequency in different populations, it would 
be very interesting to assess the G allele in CLL patients who are of Asian descent.  
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7.  Chapter 7: Whole genome sequencing 
7.1. Introduction 
The technical ability to be able to do a whole genome sequence (WGS) of an 
individual person has dramatically advanced in recent years(226). The existence of 
chromosomes has been known since Karl Wilhelm von Nageli observed them under 
a microscope in 1842. Mitosis was discovered by Walther Flemming in 1882 and in 
1912 Hans von Winiwarter declared the diploid number of chromosomes in humans 
to be 48(227). However this was revised to 46 in 1956 by Tjio and Leven(228). The 
molecular structure of DNA was first reported by Watson and Crick in 1953(229). 
Sequencing of DNA was achieved in 1977(230) and became known as Sanger 
sequencing after the author of this paper. Soon after this, the first gene sequence was 
published(231). The next major advancement in sequencing was the use of 
fluorescent dyes attached to the nucleotides, which then lead to the first automated 
DNA sequencer.  
The sequence of the human genome was first published in October 2000(232). This 
was actually a combination of five people’s genomes and took 3 to 4 years to 
complete and it cost approximately $300 million(157). In 2007 a single person’s 
genome (J. Craig Venter’s) was sequenced using Sanger dideoxy technology(226). 
Also in 2007, James Watson’s genome sequence was published; however this 
genome was sequenced by next generation technology and was completed in 2 
months(159).  
With this new technology, originally called next generation sequencing, but now 
often referred to as second generation sequencing(156), it is possible to sequence all 
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the known exons (exomes), expressed genes (transcriptomes) or the complete 
genomes of people or their tumour cells. This allows for a comprehensive genome-
based classification of cancer which should ultimately lead to better therapy for 
specific mutations(156); as well as aiding in the diagnosis of constitutional genetic 
disorders. 
A paper by Ley et al. 2008 reported the whole genome sequencing of a 
cytogenetically normal AML genome(107). Approximately 40 to 50% of cases of 
AML have normal cytogenetics at diagnosis(233); however this does not imply that 
genetic mutations have not occurred, but are instead below the resolution of 
conventional cytogenetics(233). Many of these normal cytogenetic AML are known 
to have specific genetic mutations and this is reflected in the current WHO 
classification system of AML, which now includes a specific sub-type that have 
recurrent gene mutations(1). The sequencing of the cytogenetically normal AML 
genome identified two mutations in genes known to be commonly mutated in AML 
and an additional eight mutations in eight genes that were previously not thought to 
be involved in AML(107). The functionality of these mutations is still being 
assessed, however they would not have been found by any other approach. In the 
literature there are nine key whole genome sequencing studies to date(156); two of 
which are on HMs, both AML genomes. 
The 1000 genome project aims to characterise the variation in the human genome so 
that correlation between phenotype and genotype can be made(234). To date they 
have published a pilot study comparing different types of platforms for WGS. They 
undertook 3 projects; firstly low coverage WGS of 179 individuals from four 
different populations, secondly high coverage WGS of two parent offspring trios, and 
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thirdly exon sequencing of 697 individuals from seven different populations(234). 
This project claims to have catalogued over 95% of the variants found in any 
individual’s WGS(234). They have found that on average each person’s WGS shows 
250-300 loss of function variants and 50-100 variants previously implicated in 
inherited disorders(234). 
LK16-1 was selected for WGS as he was the index case in a seminal family and a 
region of interest had been narrowed down to chromosome 15 (Chapter 4). The DNA 
obtained from LK16-1 was from peripheral blood lymphocytes; however at the time 
of the DNA collection his white cell count (WCC) was 60 x 109/L and comprised 
mainly lymphocytes, in keeping with his diagnosis of CLL. Therefore the WGS 
would be of tumour cells and some of the mutations would represent acquired 
changes in his CLL cells rather than a germline mutation. However as the hypothesis 
in this family is that the affected siblings inherited one mutation from each parent, a 
homozygous mutation is implicated. WGS study of cytogenetically normal AML 
cells had found that the acquired mutations were all heterozygous(160). 
 
7.1. Methods and Materials 
DNA from LK16-1 was chosen for whole genome sequencing. The DNA was 
extracted as described in Chapter 2.2. Sequencing was performed by Knome 
(Cambridge, MA, USA) on Illumina platform using pair end reads. The sequence 
reads were aligned to their reference genomes and to version Mar. 2006 
(NCBI36/hg18) of the human genome and this was also undertaken by Knome 
(Cambridge, MA, USA). 
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7.2. Results 
7.2.1. Whole Genome Sequence quality 
WGS was undertaken on LK16-1 using DNA derived from his CLL cells. The mean 
sequencing depth was 37.45 reads per base with an average read length of 107.91 
(See Table 7.2.1.1). Sequencing of the X and Y chromosomes showed no 
heterozygous calls, consistent with a male gender for LK16-1. 
Table 7.2.1.1: Summary of sequence coverage and quality 
Sequence coverage/quality measures  Number 
Effective read length (bp) 107.91 
Mean sequencing depth  37.45 
Mismatches per site per read 0.008 
Sites covered (of 3080436051) 2776947377 
Sites called heterozygous 2217344 
X-Specific sites call 154913754 
X-Specific sites call heterozygous 0 
Y-Specific sites call 25652954 
Y-Specific sites call heterozygous 0 
Autosomal sites call 2677446101 
Autosomal sites call heterozygous 1975513 
7.2.2. Mutations found in the genome of LK16-1 
A summary of the type and number of mutations/polymorphisms found in the 
genome is shown in Table 7.2.2.1. There were a total of 2776947377 base pair 
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positions sequenced in this WGS, with 3616955 base pairs that were different to the 
reference genome (0.13%); of these 38.69% were homozygous changes and 10.61% 
novel changes (1.56% novel homozygous changes). However novel homozygous 
changes (56297) represent 0.00202% of bases sequenced in the whole genome. There 
were a total of 3414278 same-length substitution changes and 40% of these were 
homozygous. There were a total of 202677 insertion-deletion (indel) changes present 
(0.007%), of which 57.47% were homozygous. The number of 
mutations/polymorphisms that were actually located within a gene was 1326149, 
which represents 0.04% of the WGS. The types of mutations found in gene regions 
consisted of 8017 synonymous mutations (40.66% homozygous), 7174 missense 
mutations (40.66% homozygous), 49 nonsense mutations (20.4% homozygous), 5 
read-through mutations (40% homozygous), 97 frameshift mutations (77.32% 
homozygous) and 3 splice site mutations (66.67% homozygous).  
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Table 7.2.2.1: The non-reference allele (polymorphism/mutations) results 
Type of mutation Number Percentage 
Total sites mismatching reference  3616955 0.13% 
Homozygous total 1399611 38.69% 
Novel total 383887 10.61% 
Novel homozygous 56297 1.56% 
Same-length substitution total 3414278 0.12% 
Same-length substitution homozygous 1366503 40.00% 
Indel total 202677 0.007% 
Indel homozygous 116489 57.47% 
Gene regions mismatching reference (includes novel) 1326149 0.04% 
Synonymous total 8017  
Synonymous homozygous 3260 40.66% 
Missense total 7174  
Missense homozygous 2917 40.66% 
Nonsense total 49  
Nonsense homozygous 10 20.4% 
Read-through total 5  
Read-through homozygous 2 40% 
Frameshift 97  
Frameshift homozygous 75 77.32% 
Splice region 3  
Splice region homozygous 2 66.67% 
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7.2.2.1. Mutations/Polymorphisms associated with known phenotypes 
There were 372938 non-reference alleles (polymorphisms/mutations) in genes that 
have been reported to be associated with a disease. A total of 5110 of these were in 
genes that had previously been reported in the literature to be implicated in 
predisposing to the development of CLL. These 5110 SNPs were in 36 genes (listed 
in Table 7.2.2.1.1).  Table 7.2.2.1.2 lists the genotypes of LK16-1 to specific SNPs 
known to be associated with an increased predisposition to CLL. 
Table 7.2.2.1.1: Summary of genes known to be associated with CLL where non-
reference genotypes were identified in LK16-1. 
Gene Location 
AKR7A3 Chr1 
APC Chr5 
APOC4 Chr19 
ATM Chr11 
BRCA2 Chr13 
BUB1B Chr15 
CAPN13 Chr2 
CFTR Chr7 
CHEK2 Chr22 
CLCA2 Chr1 
CRY2 Chr11 
DKK3 Chr11 
DPYD Chr1 
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EXOC2 Chr6 
FBL1M1 Chr1 
FGF2 Chr4 
GGT5 Chr22 
IL1ORA Chr11 
LPL Chr8 
MCM3AP Chr21 
MIR1302 Chr22 
MTR Chr1 
MYO18B Chr22 
NUDT6 Chr4 
PDLIM5 Chr4 
POLB Chr8 
PPIG Chr2 
RBICC1 Chr8 
ROS1 Chr6 
SEC14L4 Chr22 
SHROOM3 Chr4 
TLR4 Chr9 
TOP1M1 Chr8 
ZC3H3 Chr8 
ZNF233 Chr19 
ZNF24 Chr18 
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Table 7.2.2.1.2: Previously identified SNPs known to be associated with an 
increased risk of CLL where LK16-1 carries the risk allele. 
SNP Gene Substitution* Genotype of LK16-1 OR* 
Rs10927851 FBLP-1 F191S TT 1.18  
Rs997558 MCM3AP S102L AG 0.86 
Rs1048201 NUDT6 R209Q CT 1.20 
Rs2250889 MMP9 R574P CC 1.41 
Rs1801265 DPYD C29R AG 0.84 
Rs17409304 CLCA2 Q306E CG 0.87 
Rs3206824 DKK3 G335R CC 1.16 
Rs619203 ROS1 S2229C CG 0.87 
Rs459552 APC V1822D AA 1.15 
Rs508405 CAPN13 T280A TT 1.13 
Rs1738023 AKR7A3 D215N CC 1.16 
Rs1805087 MTR D919G AG 1.15 
Rs2278106 EPHA7 P278S CT 1.34 
Rs1211554 HUS1B Y268D AA 0.79 
Rs2032729 ZNF24 S220N CC 1.21 
Rs17738527 SEC14L4 E211K CT 0.67 
Rs17337252 RB1CC1 M234T AG 1.19 
Rs8207 PPIG N699D AG 0.65 
*From Rudd et al. 2006(150) 
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7.2.2.2. Predicted functional mutations identified in LK16-1 
There were 154 predicted functional mutations that were detected by the WGS. 
These are listed in table 7.2.2.2.1. There were a total of 49 nonsense, 97 frameshift, 5 
read-through and 3 splice site mutations. 57.79% were homozygous mutations. Four 
mutations were identified on chromosome 15; two of which were homozygous, only 
one was located within the region of homozygosity. This was a splice site variation 
in C15orf48.  
Table 7.2.2.2.1: Summary of genetic mutations in protein coding regions 
 
Chr. Start Position  Ref 
Allele 
LK16-1 
Allele 1 
LK16-1 
Allele 2 
Gene(s) mutation 
 1 12776676 T A T PRAMEF nonsense  
1 35352095 T A T ZMYM1 nonsense  
1 46853265 G A G MOBKL2C nonsense  
1 47053333 AT - AT CYP4B1 Frameshift  
1 120138307 C T T REG4 nonsense  
1 143787039 C C T PDE4DIP nonsense  
1 150462352 T - - HRNR Frameshift  
1 154831674 - AC AC GPATCH4 Frameshift  
1 156816115 C T T OR10X1 nonsense  
1 159593234 G A G 
LOC642502 nonsense;  
SDHC nonsense  
1 159742827 C C T FCGR2A nonsense  
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1 169823507 - C C BAT2L2 Frameshift  
1 246179648 T A A 
OR2L8 nonsense 
OR2L13 nonsense  
2 24240683 - C C 
LOC375190 
Frameshift  
2 70916342 - C C CD207 Frameshift  
2 112330899 G A G ANAPC1 nonsense 
2 113710768 - C C 
LOC654433 
Frameshift 
PAX8 Frameshift 
2 171889016 A G G 
METTL8 read-through 
 
2 179170548 - G G TTN Frameshift 
2 228184383 C C T C2orf83 nonsense 
3 14172876 G - - XPC Frameshift 
3 99556281 A - - OR5K4 Frameshift  
3 99593097 - A A OR5K3 Frameshift  
3 155440980 CAGT - - SGEF Frameshift 
3 161501501 - A - IFT80 Frameshift 
4 75996 - A A 
ZNF718 Frameshift 
ZNF595 Frameshift 
4 76102 - C C 
ZNF718 Frameshift 
ZNF595 Frameshift 
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4 77314 - A A 
ZNF718 Frameshift 
ZNF595 Frameshift 
4 22429601 A A T GBA3 read-through 
4 47633340 G A G CNGA1 nonsense 
4 70547375 A A T UGT2A1 nonsense 
4 104052059 G A G NHEDC1 nonsense 
4 129061252 A A C MFSD8 nonsense 
4 152420469 - CAGGT CAGGT PRSS48 Frameshift 
4 155463851 TTTG - - DCHS2 Frameshift 
4 185787625 TTGAA - TTGAA CASP3 Frameshift 
5 1293756 C G G SLC6A18 nonsense 
5 61911470 - G G 
LRRC70 Frameshift 
IPO11 Frameshift 
5 101625533 G G T SLCO4C1 nonsense 
5 135540985 - C C SMAD5 Frameshift  
5 140548219 - A A PCDHB9 Frameshift 
5 149355072 T - - TIGD6 Frameshift 
5 156654442 - C C CYFIP2 Frameshift  
6 56589492 AT - AT DST Frameshift 
6 65074936 GA - - 
EYS Splice site 
variation 
6 117256700 G A G GPRC6A nonsense 
6 167629691 G A G UNC93A nonsense 
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7 12357794 - A - VWDE Frameshift 
7 47921711 - A A PKD1L1 Frameshift 
7 93378079 C C T GNGT1 nonsense 
8 3254411 C - - CSMD1 Frameshift 
8 6660787 A - - XKR5 Frameshift 
8 24866981 G - - NEFL Frameshift 
8 30740383 - T T UBXN8 Frameshift 
8 37913463 - T T GOT1L1 Frameshift 
8 38946342 C - - PLEKHA2 Frameshift  
8 48968370 - G G PRKDC Frameshift 
8 64261284 - G G YTHDF3 Frameshift 
8 126088870 G - - SQLE Frameshift 
9 106400589 T - - OR13C5 Frameshift 
9 106407485 GC - - OR13C2 Frameshift 
9 124431592 - A A OR1B1  Frameshift 
9 131631329 A A G C9orf78 read-through 
9 138754315 G A G LCN10 nonsense 
10 7645083 C - - ITIH5 Frameshift 
10 27727230 A G G PTCHD3 read-through 
10 50360764 C A C ERCC6 nonsense 
10 97910090 - C C ZNF518A Frameshift 
10 118373454 - G G PNLIPRP2 Frameshift 
10 126717591 T A T CTBP2 nonsense 
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11 4345980 G - - OR52B4 Frameshift 
11 4747449 G - - OR51F1 Frameshift 
11 5129372 - C C OR52A1 Frameshift 
11 5733059 A T T OR52N4 nonsense 
11 14058070 - C C SPON1 Frameshift 
11 46298836 - G - CREB3L1 Frameshift 
11 48242806 T A A OR4X1 nonsense 
11 48303589 G A G OR4C3 nonsense 
11 55096227 C C T OR4C16 nonsense 
11 56187791 C T T 
OR5AR1 nonsense 
OR8U8 nonsense 
11 59921928 TT - - MS4A14 Frameshift 
11 60021577 C T T MS4A12 nonsense 
11 60922308 - A A TMEM216 Frameshift 
11 62814500 G A G SLC22A10 nonsense 
11 67542641 - C C ALDH3B1 Frameshift 
11 94339156 - T T CWC15 Frameshift 
11 94440551 - C C SFRS2B Frameshift 
11 99195585 C C T CNTN5 nonsense 
11 111358317 - C C DIXDC1 Frameshift 
11 118403645 C - - SLC37A4 Frameshift 
11 118445150 - C C VPS11 Frameshift 
11 124957511 - C C EI24 Frameshift 
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12 892829 A A C RAD52 nonsense 
12 10162353 A A C CLEC7A nonsense 
12 46883143 - A - OR10AD1 Frameshift 
12 53809853 T - T OR9K2 Frameshift 
12 53927521 C C T OR6C74 nonsense 
12 54107225 A - - OR6C76 Frameshift 
12 84162776 A - - LRRIQ1 Frameshift 
12 100943940 - G G CCDC53 Frameshift 
12 111376815 T G T PTPN11 nonsense 
14 19736016 - A - OR11G2 Frameshift 
14 62854161 - G G GPHB5 Frameshift 
15 39792871 C C T MGA nonsense 
15 43510320 AAGT - - 
C15orf48 Splice site 
variation 
15 63704669 C - C SLC24A1 Frameshift 
15 81145551 - C C AP3B2 Frameshift 
16 3542228 G - - NLRC3 Frameshift 
16 31678198 - A - ZNF720 Frameshift 
16 57134816 A - A CNOT1 Frameshift 
16 70538916 - TTTG - PKD1L3 Frameshift 
16 74869104 - T T CNTNAP4 Frameshift 
16 79799698 G A G PKD1L2 nonsense 
16 80591310 G A G SDR42E1 nonsense 
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17 3541025 G - G P2RX5 Frameshift 
17 6496271 - G - C17orf100 Frameshift 
17 7411009 A - - SENP3 Frameshift 
17 7435886 C - - FXR2 Frameshift 
17 8665940 - G G PIK3R6 Frameshift 
17 21144802 C C T MAP2K3 nonsense 
17 23716352 - G - SEBOX Frameshift 
17 23751848 A - - 
SLC46A1 Frameshift 
SARM1 Frameshift 
17 24110580 - G - C17orf63 Frameshift 
17 31124464 - C - MMP28 Frameshift 
17 40720077 - G - MAP3K14 Frameshift 
17 42602360 G A G CDC27 nonsense 
17 57022734 G A G NACA2 nonsense 
17 59014621 G - - DCAF7 Frameshift 
17 71589391 C C T 
ZACN nonsense 
EXOC7 nonsense 
17 77225337 TAAC - TAAC 
TSPAN10 Splice site 
variation 
18 31980332 A - A ELP2 Frameshift 
18 50134886 G A G STARD6 nonsense 
19 15591499 - C - CYP4F8 Frameshift 
19 40410859 C T T FAM187B nonsense 
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19 40906473 - G G MLL4 Frameshift 
19 45814934 - G G LTBP4 Frameshift 
19 49708830 T - - 
CEACAM20 
Frameshift 
19 56420915 CCGG - - CD33 Frameshift 
19 56527705 - G G VSIG10L Frameshift 
19 56696714 G A G SIGLEC12 nonsense 
19 57495481 TG - - ZNF480 Frameshift 
19 61191090 G C G NLRP8 read-through 
19 62334593 C A A USP29 nonsense 
20 74310 CC - - DEFB126 Frameshift 
20 21134162 - G G PLK1S1 Frameshift 
21 30835852 G - - KRTAP19 Frameshift 
21 31123840 A - - KRTAP7 Frameshift 
21 33088058 - T T 
C21orf62 Frameshift 
C21orf49 Frameshift 
21 33088060 A A T 
C21orf62 nonsense 
C21orf49 nonsense 
22 34917792 - CT CT APOL4 Frameshift 
22 44188943 - C C RIBC2 Frameshift 
X  50137887 - G  DGKK Frameshift 
X  69395896 C T  P2RY4 nonsense 
X  151659500 C G  CSAG1 nonsense 
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7.2.2.3. Mutations identified within the regions of IBD identified 
in Chapter 5 
The top 3 regions where the most number of pairs share genotypes were on 
chromosome 3 (Figure 7.2.2.3.1), chromosome 7 (Figure 7.2.2.3.2) and chromosome 
9 (Figure 7.2.2.3.3). These regions were identified by the PLINK analysis as 
potentially harbouring predisposition alleles in the 13 Tasmanian families. 
 
 
 
 
 
Figure 7.2.2.3.1: Number of pairs sharing genotypes on chromosome 3 
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Figure 7.2.2.3.2: Number of pairs sharing genotypes on chromosome 7 
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Figure 7.2.2.3.3: Number of pairs sharing genotypes on chromosome 9 
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There are two predicted functional mutations within the region on chromosome 3 and 
one mutation within the region on chromosome 7 (Table 7.2.2.3.1). No predicted 
functional mutations were identified within the chromosome 9 region. Confirming 
that no mutation was present anywhere near or in the coding regions of DAPK1. 
Table 7.2.2.3.1: Predicted functional mutations in these regions in LK16-1 
 
Chr. Start 
Position  
Ref Allele 1 Allele 2 Gene 
3 99556281 A - - OR5K4 Frameshift  
3 99593097 - A A OR5K3 Frameshift  
7 12357794 - A - VWDE Frameshift 
 
 
 
7.2.2.4. Novel mutations identified 
There were 33 novel predicted functional mutations identified in this WGS of LK16-
1, of which 10 were homozygous mutations (Table 7.2.2.4.1). 
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Table 7.2.2.4.1: List of the novel predicted functional mutations identified in 
LK16-1 
Chr. start end ref allele allele Gene(s) 
1 35352095 35352096 T A T ZMYM1 
1 150462352 150462353 T - - HRNR† 
1 159593234 159593235 G A G LOC642502/SDHC 
3 99593097 99593097 - A A OR5K3* 
3 161501501 161501501 - A - IFT80 
4 75996 75996 - A A ZNF718/ZNF595* 
4 47633340 47633341 G A G CNGA1 
4 70547375 70547376 A A T UGT2A1 
4 104052059 104052060 G A G NHEDC1 
4 129061252 129061253 A A C MFSD8 
4 155463851 155463855 TTTG - - DCHS2* 
4 185787625 185787630 TTGAA - TTGAA CASP3 
5 101625533 101625534 G G T SLCO4C1 
6 56589492 56589494 AT - AT DST 
7 47921711 47921711 - A A PKD1L1* 
7 93378079 93378080 C C T GNGT1 
9 124431592 124431592 - A A OR1B1* 
10 50360764 50360765 C A C ERCC6 
10 126717591 126717592 T A T CTBP2† 
11 4345980 4345981 G - - OR52B4* 
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11 5129372 5129372 - C C OR52A1* 
11 124957511 124957511 - C C EI24* 
12 53809853 53809854 T - T OR9K2† 
12 111376815 111376816 T G T PTPN11† 
15 39792871 39792872 C C T MGA 
15 43510320 43510324 AAGT - - C15ORF48* 
16 3542228 3542229 G - - NLRC3* † 
16 31678198 31678198 - A - ZNF720 
17 6496271 6496271 - G - C17ORF100 
19 15591499 15591499 - C - CYP4F8† 
19 56420915 56420919 CCGG - - CD33 
21 33088060 33088061 A A T C21ORF62/C21ORF49 
X  69395896 69395897 C T  P2RY4 
* novel homozygous mutations 
† mutation has been reported in the 1000 genomes project 
 
 
7.3. Discussion and Conclusion 
One of the limitations of familial studies has been that the ability to find the 
causative genetic mutations depends upon having a minimum of 10 affected 
individuals to identify a LOD score (is the decimal log likelihood ratio) greater than 
3. Now with next generation sequencing this requirement is no longer necessary and 
WGS has been used in Miller syndrome to identify the causative gene(235). WGS 
has also been used in 10 unrelated Kabuki syndrome patients to explain the variation 
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in the clinical symptoms of these patients and a common mutation in MLL2 was 
discovered(236).  
Ley et al. 2008 identified 14 variants in their WGS of cytogenetically normal AML 
cells, 4 were inherited variants and 10 were acquired variants in coding regions(160). 
Two acquired mutations were in genes commonly mutated in AML (FLT3 and 
NPM1), the other genes were PTPRT, CDH24, PCLKC, SLC15A1, KNDC1, 
GPR123, EBI2 and GRINL1B. Four of these genes (PTPRT, CDH24, PCLKC and 
SLC15A1) belong to gene families that are strongly associated with cancer 
pathogenesis and the remaining four have not been previously implicated in 
leukaemia(160).  The WGS has been reanalysed and another mutation was identified 
in DNMT3A, this has subsequently been identified as a commonly mutated gene in 
cytogenetically normal AML and is associated with a poor prognosis(237). They also 
reported that all the acquired mutations, except the FLT3 mutations were 
heterozygous and present in virtually all the tumour cells(160).  
As the DNA that was used in the sequencing of LK16-1 represented tumour cells, 
therefore some of the mutations identified would be acquired mutations in his CLL 
cells, rather than germline mutations. However, due to the family structure of the 
LK16 family with his parents being first cousins, a homozygous mutation is 
implicated in this family. There were a total of 89 predicted homozygous predicted 
functional mutations identified. All mutations present in LK16-1 will be assessed in 
the remaining family members to confirm whether they are a false positive, germline 
or an acquired mutation. Knowledge of the genome-wide SNP array results in the 
LK16 family, especially from LK16-106 (child of LK16-1) and LK16-4 (brother of 
LK16-1), allows assessment of whether the mutations are germline (if homozygous 
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in LK16-1, LK16-106 is an obligate carrier; if heterozygous there is a 50% chance 
that LK16-4 or LK16-106 is a carrier; and it is known which regions of the genome 
these people share with LK16-1). The germline mutations should be present in the 
other family members, where as acquired mutations in LK16-1’s CLL cells should 
not be.  
The confirmed acquired mutations will also be assessed in other patients who have 
CLL, both in their CLL cells (peripheral blood DNA) and their germline DNA 
(extracted from saliva samples). These acquired mutations have the potential to 
provide knowledge on the mutations required for the development of CLL and 
therefore may provide targets for novel therapies. 
The WGS identified 372938 non-reference alleles present in gene regions in LK16-1. 
5110 were in 36 genes that have been reported in the literature to predispose to the 
development of CLL(150). Rudd et al. 2006, reported 49 germline SNPs in the ATM-
BRCA2-CHEK2 axis that are significantly associated with the risk of developing 
CLL(150). It was found that LK16-1 carries the risk allele for 18 of these SNPs, of 
which 8 are in the homozygous state. 
Of the genes where a predicted functional mutation was identified, 20 are involved in 
DNA repair (PRKDC, ERCC6 and RAD52), cell cycle (MOBKL2C, PDE4DIP, 
ANAPC1, MGA, CDC27 and PLKIS1), tumourogenesis (MMP28, DIXDC1, CSMD1, 
PAX8, MLL4, ITIH5 and C15orf48) or apoptosis pathways (CASP3, CYFIP2, EI24 
and CD33). Ten of these were heterozygous mutations and 11 were homozygous 
mutations. Intriguingly the homozygous mutations were mostly in genes involved in 
the apoptosis or tumourogenesis pathways, suggesting that genes in these pathways 
act as tumour suppresser genes. 
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The WGS has identified 154 predicted functional mutations in LK16-1’s CLL cells, 
89 of these were homozygous mutations. Only one homozygous mutation was 
identified within the larger region of interest on chromosome 15, this was a splice 
site variation in C15orf48. Very little information is known about C15orf48, but it 
was first identified in a study of oesophageal carcinomas(238). In this study it was 
proposed that C15orf48 was a tumour suppressor gene(238). This would fit with the 
hypothesis in the LK16 family. 
The regions of the genome identified in chapter 5 that showed the most sharing in the 
IBD analysis were on chromosome 9 (8247948-97581865), chromosome 3 
(188583591-199322659; 73482376-105281251; 39653716-58867074) and 
chromosome 7 (9945064-10945597).  Two homozygous frameshift mutations in two 
genes (OR5K3 and OR5K4) were identified in the chromosome 3 region, both 
belonging to the olfactory receptors family of genes. A heterozygous frameshift 
mutation was present in the VWDE gene located within the chromosome 7 region. 
No predicted functional mutations were identified in genes within the chromosome 9 
region. None of these genes (VWDE, OR5K3 or ORK4) have been implicated 
previously as having a role in leukaemogenesis. 
According to the 1000 genomes browser 
(http://browser.1000genomes.org/Homo_sapiens/Gene/Variation_Gene/Table?db=co
re;g=ENSG00000166920;r=15:43510055-43512937), which claims to provide over 
95% of the novel variants in the human genome(234), the splice site variant 
identified in C15orf48 has not been found in their dataset. This supports the 
possibility that this is a very rare mutation and may be the causative mutation in this 
family. The 1000 genome project has in fact identified six of the novel mutations that 
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were identified in LK16-1. Many of the novel mutations identified in LK16-1 may be 
due to the fact that some of the novel mutations in LK16-1 are acquired mutations in 
his CLL cells. However, these mutations were also assessed in the publically 
available data from the cancer genome project 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) and they were also not present 
there either, although this project does not include CLL as one of the specific cancers 
that they are sequencing, they are sequencing AML genomes.  
WGS of LK16-1 has potentially identified a novel mutation in C15orf48. This, as 
well as the remaining predicted functional mutations is in the process of being 
confirmed in the remaining members of LK16 family, the other 12 Tasmanian 
families and a sporadic dataset of 100 patients with haematological malignancies.   
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8. Chapter 8: Summary and Conclusions 
8.1. Current aims 
The aim of this study was to identify the genetic mutation(s) in these 13 Tasmanian 
families. These families have been expanded to include the current generations and 
all those affected have had their disease verified and reclassified into the current 
haematological classification system(1). The hypothesis is that there is a 
predisposition allele in these families; and due to the structure of some of the 
families some of the affected have inherited two copies of the predisposition allele. 
More families are still being referred to the study and are being consented to 
participate. These families are being systematically cross referenced with individuals 
on the TCR to identify new cases in these families.  
 
8.2. Familial Haematological Malignancy pedigree collection.  
Thirteen families were selected for the study, due to their high number of affected 
individuals. A total of 130 affected individuals were identified in these 13 Tasmanian 
families. Nine families show a statistically significant reduction in the age at 
diagnosis for subsequent generations (anticipation), and two show a pattern of 
inheritance that would be in keeping with a recessive mutation(162). Another family 
(LK124) also shows a cluster of a rare subtype of DLBCL, with three people having 
primary CNS lymphoma. These Tasmanian families have a denser aggregation of 
affected members than families in the literature. DNA from three members of the 
LK124 family from different generations is being used in a whole genome sequence 
to assess the size of repeats (dynamic mutations) across generations. 
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8.3. Investigation of previously identified predisposing mutations 
Only one causative mutation has been found in one family with familial CLL in the 
literature(25).  This was a mutation upstream of DAPK1. This mutation, 3’UTR, 
5’UTR, cDNA, splices site variants and 500bp upstream and downstream of DAPK1 
were sequenced in these 13 Tasmanian families and found to be normal.  
 
8.4. High density SNP array of LK16 CLL family. 
This identified a region on chromosome 15 where the 5 affected siblings are 
homozygous.  
 
8.5. High density SNP array of all 13 Tasmanian families 
This used DNA from 117 people in these 13 families, representing 78 affected 
individuals. CNV analysis revealed how polymorphic the human genome is. One 
CNV on chromosome 4q13 was shared in the samples from tumour DNA (CLL 
samples), were they all had 3 copies of this region. This CNV has a marked 
difference is allele frequency in different ethnic populations correlating with the 
incidence of CLL. PLINK IBD analysis of the regions of sharing by individuals 
showed the regions with the most sharing are on chromosome 7, chromosome 3 and 
chromosome 9. It was interesting that DAPK1 is located in the region on 
chromosome 9, however no mutation was found in this gene. Two predicted 
functional novel mutations were identified in genes in the chromosome 3 region and 
one in the chromosome 7 region. SNP analysis looking for increased association of 
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SNPs in the affected compared too non-affected controls highlighted several SNPs of 
significance. Formal linkage analysis of these 13 families in currently also being 
completed. 
 
8.6. Cell lines and gene expression 
This identified RNF111 as the most differentially expressed gene and sequencing 
identified a missense mutation in exon 2 of this gene. The genotype of this missense 
mutation that the LK16 family carry is common in western countries, but rare in 
Asia, correlating with the incidence of CLL in these two geographical regions. 
However this missense mutation is considered a normal variant, due to its high allele 
frequency. This missense mutation is being followed up in Asian CLL patients. 
 
8.7. Whole genome sequencing of LK16-1 
Whole genome sequencing was undertaken on LK16-1. This was done on an 
Illumina platform with greater than 30 times coverage of the genome. A total of 154 
predicted functional mutations were identified. Only one of these was within the 
larger region of homozygosity on chromosome 15. This was a homozygous splice 
site variation (4 base pair deletion) in C15orf48. This splice site mutation has not 
been reported in any other databases of human variation. This gene was first 
identified in oesophageal carcinoma as a potential tumour suppressor gene(238). 
These 154 predicted functional mutations are being confirmed in the all the familial 
dataset (250 people) and 100 sporadic HM controls to assess whether they are a false 
positive (error), acquired mutation or a germline mutation. 
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Importantly this is the first WGS of a CLL genome. Many of the mutations identified 
also represent acquired changes in the CLL cells and provide insight into the genetic 
changes that occur for this disease to develop. These may potentially provide new 
targets for therapy.  
 
8.8. Conclusion 
This study has identified and documented 13 Tasmanian families with a dense 
aggregation of people with familial HMs. A putative predisposition haplotype was 
identified in the LK16 family on chromosome 15 and the potential predisposition 
mutation in this family identified in C15orf48. The WGS also identified many 
acquired mutations that occur in the development of CLL. These are currently being 
confirmed in the familial and sporadic dataset of HMs. This study has identified 
several novel and known alleles for the genetic basis of HMs and is consistent with 
the literature in that this is a complex genetic disorder and many common genetic 
polymorphisms are responsible for the heritable predisposition in HMs. 
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